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Global, regional, and national incidence, prevalence, and 
years lived with disability for 301 acute and chronic diseases 
and injuries in 188 countries, 1990–2013: a systematic 
analysis for the Global Burden of Disease Study 2013
Global Burden of Disease Study 2013 Collaborators*
Summary
Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived 
with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of 
Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 
188 countries between 1990 and 2013.
Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods 
with some important reﬁ nements. Results for incidence of acute disorders and prevalence of chronic disorders are new 
additions to the analysis. Key improvements include expansion to the cause and sequelae list, updated systematic 
reviews, use of detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and use of 
severity splits for various causes. An index of data representativeness, showing data availability, was calculated for each 
cause and impairment during three periods globally and at the country level for 2013. In total, 35 620 distinct sources of 
data were used and documented to calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity 
simulation provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, and sex. 
Disability weights were updated with the addition of new population-based survey data from four countries.
Findings Disease and injury were highly prevalent; only a small fraction of individuals had no sequelae. Comorbidity 
rose substantially with age and in absolute terms from 1990 to 2013. Incidence of acute sequelae were predominantly 
infectious diseases and short-term injuries, with over 2 billion cases of upper respiratory infections and diarrhoeal 
disease episodes in 2013, with the notable exception of tooth pain due to permanent caries with more than 200 million 
incident cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-communicable diseases, 
with prevalence estimates for asymptomatic permanent caries and tension-type headache of 2∙4 billion and 1∙6 billion, 
respectively. The distribution of the number of sequelae in populations varied widely across regions, with an expected 
relation between age and disease prevalence. YLDs for both sexes increased from 537∙6 million in 1990 to 
764∙8 million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased little from 
114∙87 per 1000 people to 110∙31 per 1000 people between 1990 and 2013. Leading causes of YLDs included low back 
pain and major depressive disorder among the top ten causes of YLDs in every country. YLD rates per person, by 
major cause groups, indicated the main drivers of increases were due to musculoskeletal, mental, and substance use 
disorders, neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver of 
increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years due to YLDs increased 
globally from 21·1% in 1990 to 31·2% in 2013.
Interpretation Ageing of the world’s population is leading to a substantial increase in the numbers of individuals with 
sequelae of diseases and injuries. Rates of YLDs are declining much more slowly than mortality rates. The non-fatal 
dimensions of disease and injury will require more and more attention from health systems. The transition to non-
fatal outcomes as the dominant source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our 
results can guide future health initiatives through examination of epidemiological trends and a better understanding 
of variation across countries.
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Introduction
The Global Burden of Disease Study 2013 (GBD 2013) is 
the ﬁ rst of a series of yearly updates for the GBD studies 
that began with estimates for 1990 and were most 
recently updated to 2010. The 2010 update (GBD 2010) 
systematically quantiﬁ ed prevalence of 1160 sequelae of 
289 diseases and injuries across 21 regions.1 National 
estimates for 187 countries were also derived on the basis 
of global and regional statistical analyses.1 The metrics of 
years lived with disability (YLDs), equal to the sum of 
prevalence multiplied by the general public’s assessment 
of the severity of health loss, was used to explore patterns 
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over time, age, sex, and geography.1 Results for speciﬁ c 
diseases and impairments have been extensively 
reported.2–46 These results drew attention to the 
importance of disability from musculoskeletal disorders, 
mental and substance use disorders, and various other 
non-communicable diseases.1 In developing countries, 
disorders such as anaemia and neglected tropical 
diseases remained important contributors to health 
loss.18,43,47 More generally, the analysis showed the global 
transition towards a rapid increase in YLDs due to global 
population growth and ageing, combined with little 
progress in reduction of age-speciﬁ c YLD rates.
In view of the ambitious goal of the GBD 2010, to 
synthesise the global evidence for the country–age–sex–
year prevalence of all major disorders, several speciﬁ c 
estimates were critiqued. Speciﬁ c data sources, modelling 
assumptions, and aspects of the general approach were 
challenged and there was widespread recognition that 
more and higher quality data could improve the 
estimates.48–52 Disability weights that were used to 
calculate YLDs were based on surveys of the general 
public in ﬁ ve countries (Bangladesh, Indonesia, Peru, 
Tanzania, and the USA) and an open internet survey. The 
validity of disability weights was questioned for selected 
states including hearing loss, vision loss, drug use, spinal 
cord lesion, intellectual disability, and musculoskeletal 
disorders.53,54 Some investigators questioned whether 
disability weights should be used to measure health or 
the loss of wellbeing associated with health states.53,55 
Additionally, the YLD uncertainty intervals were large for 
several disorders because of scarce data, hence there was 
a need to statistically adjust for diﬀ erent case deﬁ nitions, 
measurement methods, and wide uncertainty intervals 
for disability weights. Wide uncertainty intervals reduced 
the number of signiﬁ cant diﬀ erences for some disorders 
reported across time and countries. Broad interest and 
crucial discourse about GBD also drew attention to many 
unpublished data sources in speciﬁ c countries that could 
be used to strengthen the analysis.
With the prominent role attached to quantiﬁ cation of 
disease burden for health research and policy nationally 
and globally, up-to-date estimates based on the latest 
evidence for descriptive epidemiology constituted an 
essential global public good.22–27,32,56–60 The GBD 2013 
provides an opportunity to incorporate constructive 
criticism about GBD 2010 data sources, model 
development, methods, and interpretation. Additionally, 
the GBD 2013 shows methodological advances and 
includes new data for disability weights, capturing 
many new published or unpublished data sources for 
the disorders included in the GBD. Here, we report 
data, methods, and results from the analysis of 
188 countries for 1990 to 2013 for 301 diseases and 
injuries and their 2337 sequelae. We report incidence 
for acute sequelae, prevalence for chronic sequelae, 
total prevalence by cause, in addition to YLDs for all 
causes. Because prevalence and YLDs for the entire 
period from 1990 to 2013 were reanalysed using 
consistent data and methods, these results supersede 
any previous publications about GBD.
Methods
Overview
Our general approach was similar to that for GBD 2010. 
The analysis of incidence and prevalence for HIV/AIDS, 
tuberculosis, and malaria for GBD 2013 have already 
been reported in detail.61 Key changes from GBD 2010 
were the inclusion of new data through updated 
systematic reviews and the contribution of unpublished 
data sources from many collaborators; elaboration of the 
sequelae list to include asymptomatic states, such as 
Plasmodium falciparum parasitaemia (without 
symptoms); use of more detailed nature-of-injury codes; 
improve ments to the Bayesian meta-regression method; 
increased simulation size for comorbidity; estimation of 
the prevalence of injuries by cohort; and use of a novel 
method to estimate the distribution of mild, moderate, 
and severe anaemia by cause.
Cause and sequelae list changes
Based on feedback about GBD 2010, and input from the 
GBD 2013 collaborators, we expanded the cause and 
sequelae list (appendix pp 60–89). There were several key 
changes. First, we included asymptomatic states as 
explicit sequelae so that overall disease prevalence 
estimates were available, which might be useful for 
disease targeting, health service planning, or mass 
treatment strategies. Asymptomatic sequelae, by 
deﬁ nition, were not associated with ill health and 
therefore were not assigned disability weights. Second, to 
deal with the challenge that some of the nature-of-injury 
categories used in the GBD 2010 were highly 
heterogeneous, these categories were expanded from 
23 to 47. Third, we added several new causes and sequelae. 
All these additions to the cause list were done to either 
reduce the size of the large residual categories, such as 
other injuries, or recognition of substantial 
epidemiological heterogeneity within a disease category 
(appendix pp 60–89). With these changes, the cause list 
was expanded from 289 to 301 causes and from 1160 to 
2337 sequelae. Most of the increase in sequelae was due 
to the expansion of the nature-of-injury sequelae, which 
applied to each of the external causes of injuries. The 
appendix pp 90–96 provides a list of the International 
Statistical Classiﬁ cation of Diseases and Related Health 
Problems, Tenth Revision (ICD-10) and International 
Classiﬁ cation of Diseases, Ninth Revision (ICD-9) codes 
for all GBD causes and the nature-of-injury categories.
Data sources
GBD 2010 collaborators undertook systematic reviews 
for most of the causes and sequelae. For some sequelae, 
the majority of the data came from household survey 
microdata reanalysis and administrative data such as 
See Online for appendix
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hospital discharges. For others, most of the data were 
extracted from publications. Documentation of the GBD 
2010 systematic reviews, however, was not centralised 
and only some of these reviews have been published. For 
this study, we updated systematic reviews through 
Aug 31, 2013. In some cases, studies published after 
Aug 31, 2013, were identiﬁ ed and included on the basis of 
GBD collaborator input; no data or studies were extracted 
after Nov 30, 2014. Household surveys including the 
demographic and health surveys, multiple indicator 
cluster surveys, living standards measurement surveys, 
reproductive health surveys, and various national health 
surveys included in the Global Health Data Exchange 
were systematically screened for data relevant to 
sequelae. For some diseases, case notiﬁ cations reported 
to WHO were used as inputs and updated until the end 
of 2013. The appendix pp 97–653 provides a full list of 
citations for sources organised by country that were used 
for this analysis.
We computed an index of the geographical and 
temporal representativeness of the data sources available 
for non-fatal health outcomes for each cause or 
impairment—the data representativeness index (DRI). 
The overall DRI simply counts the fraction of countries 
that have any incidence, prevalence, remission, or excess 
mortality data available for causes that are prevalent in 
that country. We did not count cause of death data in this 
measure, even if it was used in the estimation of 
incidence or prevalence. We computed the same measure 
for three periods: before 1998, 1998–2005, and 2006 
onwards. Table 1 provides the overall DRI and period-
speciﬁ c DRI measures for each cause and table 2 provides 
the same information for estimation of total impairment 
prevalence. The DRI was also computed for level 1 and 
level 2 causes (aggregate causes; see appendix pp 60–89) 
by counting data availability for any cause within that 
aggregate. This metric represents the availability of data 
and does not incorporate any assessment of data quality. 
The all-cause DRI was 100% overall and for each period, 
indicating that there was at least data for one cause for all 
188 countries in each period. At more detailed levels, 
however, there was wide variation in the DRI across 
causes and time. DRI ranged from less than 2% for eight 
causes, including glucose-6-phosphate dehydrogenase 
deﬁ ciency trait and other mental and substance use 
disorders, to 100% for Chagas disease, African 
trypanosomiasis, and food-borne trematodiases. Causes 
with required infectious disease case reporting had high 
DRI values. Other disorders, such as cancers, had DRI 
values above 70% due to the network of population-based 
cancer registries. Although the time trend varied by 
disease, many of the highest DRI values were from 1998 
to 2005. The lag in data analyses and publications might 
explain lower DRI values for 2006 to present.
Data representativeness can also be assessed at the 
country level. Figure 1 shows a map of the percentages of 
causes for which there were data available in each of the 
188 countries between 1990 and 2013. The DRI values 
ranged from 6% in South Sudan to 92% in the USA. 
Many developed countries had data for more than 65% of 
causes; Brazil, India, and China have similar levels. Low 
levels of data availability were noted in several 
sub-Saharan African countries, central Asia, the 
Caribbean, and the Balkans. There was substantial 
Before 1998 1998–2005 2006–13 Total
All causes 100·0% 100·0% 100·0% 100·0%
Communicable, maternal, neonatal, and 
nutritional diseases
99·5% 100·0% 100·0% 100·0%
HIV/AIDS and tuberculosis 91·0% 96·8% 98·9% 99·5%
Tuberculosis 56·9% 91·5% 98·4% 99·5%
HIV/AIDS 79·8% 80·3% 79·8% 80·3%
HIV/AIDS resulting in mycobacterial infection 3·3% 1·1% 0·5% 3·3%
HIV/AIDS resulting in other diseases 79·8% 80·3% 79·8% 80·3%
Diarrhoea, lower respiratory, and other 
common infectious diseases
97·9% 99·5% 100·0% 100·0%
Diarrhoeal diseases 31·9% 58·5% 38·3% 67·0%
Intestinal infectious diseases 18·1% 25·0% 10·6% 34·6%
Typhoid fever 16·5% 10·6% 6·4% 20·2%
Paratyphoid fever 4·8% 8·0% 4·8% 9·0%
Other intestinal infectious diseases ·· ·· ·· ··
Lower respiratory infections 30·9% 61·2% 48·9% 73·4%
Upper respiratory infections 30·9% 28·2% 25·0% 44·7%
Otitis media 18·1% 11·7% 5·9% 23·4%
Meningitis 30·3% 36·7% 22·3% 47·9%
Pneumococcal meningitis 26·1% 21·3% 8·5% 36·7%
Haemophilus inﬂ uenzae type B meningitis 26·1% 21·8% 8·0% 37·2%
Meningococcal meningitis 25·5% 20·2% 8·5% 35·6%
Other meningitis 25·5% 20·2% 8·0% 34·6%
Encephalitis 19·7% 20·7% 15·4% 30·3%
Diphtheria 57·4% 61·2% 59·6% 71·3%
Whooping cough 97·3% 96·3% 93·6% 98·4%
Tetanus 64·4% 65·4% 61·2% 75·0%
Measles 97·3% 97·9% 98·9% 98·9%
Varicella and herpes zoster 14·4% 17·6% 2·7% 21·3%
Neglected tropical diseases and malaria 97·3% 98·9% 97·9% 99·5%
Malaria 37·8% 31·9% 23·4% 42·6%
Chagas disease 42·1% 100·0% 57·9% 100·0%
Leishmaniasis 41·4% 44·1% 44·1% 52·6%
Visceral leishmaniasis 27·6% 32·2% 33·6% 40·1%
Cutaneous and mucocutaneous leishmaniasis 29·6% 33·6% 34·2% 40·8%
African trypanosomiasis 94·4% 100·0% 100·0% 100·0%
Schistosomiasis 50·0% 21·2% 4·5% 50·0%
Cysticercosis 4·3% 1·6% 0·5% 6·4%
Cystic echinococcosis 6·9% 18·1% 14·4% 20·2%
Lymphatic ﬁ lariasis 37·9% 37·9% 19·7% 50·0%
Onchocerciasis ·· ·· ·· ··
Trachoma 34·5% 27·6% 25·9% 44·8%
Dengue 50·4% 54·8% 54·8% 60·0%
Yellow fever 90·9% 95·5% 88·6% 95·5%
Rabies 49·5% 61·2% 59·6% 67·6%
(Table 1 continues on next page)
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
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variation within regions; for example, Kenya had 49%, 
whereas Djibouti had less than 10%, Laos had 14%, and 
Thailand had 54%.
Sequelae incidence and prevalence
The appendix pp 654–84 provides a brief description of 
the modelling strategy used for each sequela and cause. 
The most extensively used estimation method was the 
Bayesian meta-regression method DisMod-MR 2.0. For 
some causes such as HIV or hepatitis B and C, disease-
speciﬁ c natural history models were used in which the 
underlying three state model in DisMod-MR 2.0 
(susceptible, cases, or dead) was insuﬃ  cient to capture 
the complexity of the disease process. For some diseases 
with a range of sequelae diﬀ erentiated by severity, such 
as chronic obstructive pulmonary disease (COPD) or 
diabetes mellitus, DisMod-MR 2.0 was used to meta-
analyse the data for overall prevalence. Separate DisMod-
MR 2.0 models were then used to analyse data for the 
proportion of cases with diﬀ erent severity levels or 
sequelae. Likewise, DisMod-MR 2.0 was used to 
meta-analyse data for the proportions of liver cancer and 
cirrhosis due to underlying causes such as hepatitis B, 
hepatitis C, and alcohol use. For acute sequelae, we 
report incidence (deﬁ ned as a duration of 3 months or 
less) at the cause level in table 3, because incidence is the 
preferred measure for disorders of short duration.
DisMod-MR 2.0 represents a major advance in the 
computational speed, geographical disaggregation of 
full internally consistent posterior estimation, and 
display of data results compared with DisMod-MR 1.0, 
which was used in GBD 2010. Through cross-validation 
tests, Flaxman and colleagues reported62 that the log-
rates speciﬁ cation of models worked as well or better 
than the negative binomial speciﬁ cation used in 
DisMod-MR 1.0. Based on these ﬁ ndings, and the 
substantial improvements in computational speed for 
log-rate models, this speciﬁ cation was the default 
method for DisMod-MR 2.0. The appendix pp 3–6 
provides details of the DisMod-MR 2.0 likelihood 
estimation. The DisMod-MR 1.0 sequence of global 
estimation, regional estimation, and country prediction, 
which we call an analytical cascade, is illustrated in the 
appendix p 734. DisMod-MR 2.0 uses a more complete 
cascade (appendix p 735). At the global level, a mixed-
eﬀ ects non-linear regression with all available country 
data was used to generate initial global estimates that 
are passed to the next level of the DisMod cascade to 
inform the model for each super region. In turn, a 
super-region speciﬁ c mixed-eﬀ ects non-linear 
regression was used to estimate for regions. The same 
regression method was used for estimation of further 
geographical dis aggregation. The analyst could choose, 
depending on data density, to branch the cascade in 
terms of time and sex at diﬀ erent levels. In GBD 2010, 
DisMod-MR 1.0 was used to generate ﬁ ts for three 
periods only: 1990, 2005, and 2010 because of long 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Intestinal nematode infections 92·7% 88·3% 70·1% 99·3%
Ascariasis 92·7% 88·3% 70·1% 99·3%
Trichuriasis 92·7% 88·3% 70·1% 99·3%
Hookworm disease 92·0% 88·3% 69·3% 98·5%
Food-borne trematodiases 100·0% 35·3% 5·9% 100·0%
Other neglected tropical diseases ·· ·· ·· ··
Maternal disorders 33·0% 51·6% 47·3% 60·6%
Maternal haemorrhage 10·1% 27·7% 22·3% 33·5%
Maternal sepsis and other infections 4·8% 15·4% 15·4% 18·6%
Maternal hypertensive disorders 12·8% 34·0% 36·7% 46·8%
Obstructed labour 10·1% 23·4% 23·9% 29·3%
Complications of abortion 3·2% 13·3% 13·8% 16·0%
Other maternal disorders ·· ·· ·· ··
Neonatal disorders 68·1% 70·2% 58·5% 81·9%
Preterm birth complications 36·2% 45·2% 31·4% 55·3%
Neonatal encephalopathy due to birth asphyxia 
and trauma
12·2% 14·4% 5·9% 20·2%
Neonatal sepsis and other infections 4·8% 3·2% 0·5% 6·9%
Haemolytic disease and other neonatal jaundice 42·6% 40·4% 35·1% 55·3%
Other neonatal disorders ·· ·· ·· ··
Nutritional deﬁ ciencies 93·6% 95·7% 91·0% 98·9%
Protein-energy malnutrition 92·6% 95·7% 91·0% 98·9%
Iodine deﬁ ciency 37·8% 22·3% 2·7% 45·2%
Vitamin A deﬁ ciency 20·8% 5·0% 0·8% 22·5%
Iron-deﬁ ciency anaemia ·· ·· ·· ··
Other nutritional deﬁ ciencies ·· ·· ·· ··
Other communicable, maternal, neonatal, and 
nutritional diseases
82·4% 83·0% 77·1% 92·6%
Sexually transmitted diseases excluding HIV 37·2% 43·1% 19·7% 56·4%
Syphilis 1·1% 3·7% 0·0% 3·7%
Chlamydial infection 16·5% 26·6% 13·8% 40·4%
Gonococcal infection 15·4% 23·9% 8·0% 31·9%
Trichomoniasis 8·0% 18·1% 9·6% 26·6%
Genital herpes 24·5% 24·5% 3·2% 31·9%
Other sexually transmitted diseases 4·3% 1·1% 0·5% 4·8%
Hepatitis 56·9% 45·7% 19·7% 68·1%
Hepatitis A 46·8% 27·7% 12·2% 56·4%
Hepatitis B 36·2% 27·7% 5·3% 43·6%
Hepatitis C 26·6% 28·2% 8·5% 38·3%
Hepatitis E 20·7% 12·2% 5·9% 25·5%
Leprosy 88·1% 77·6% 85·3% 99·3%
Other infectious diseases 3·7% 2·1% 0·0% 4·3%
Non-communicable diseases 98·4% 99·5% 98·4% 99·5%
Neoplasms 73·9% 74·5% 69·1% 82·4%
Oesophageal cancer 65·4% 68·1% 61·2% 76·1%
Stomach cancer 65·4% 69·1% 61·7% 76·6%
Liver cancer 66·5% 71·3% 63·8% 78·7%
Liver cancer due to hepatitis B 17·0% 17·6% 9·6% 24·5%
Liver cancer due to hepatitis C 17·6% 17·6% 10·1% 24·5%
Liver cancer due to alcohol use 6·9% 9·6% 6·4% 11·2%
Liver cancer due to other causes 3·7% 5·3% 4·3% 5·9%
(Table 1 continues on next page)
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computational time. For GBD 2013, we generated ﬁ ts 
for 1990, 1995, 2000, 2005, 2010, and 2013.
DisMod-MR 2.0 internal validity was assessed by use of 
R² for adjusted data. Results for all DisMod-MR 2.0 models 
are provided in the appendix pp 654–84. Adjusted data 
were the original study data transformed to the reference 
case deﬁ nition and measurement method, using the meta-
regression component of DisMod-MR 2.0 to make the data 
from diﬀ erent studies with varying methods comparable. 
External validity was also evaluated through cross-
validation on a small number of sequelae due to the 
computational time and complexity for this analysis. We 
selected ten DisMod-MR 2.0 models representing a range 
of data densities to evaluate. We held out 30% of datapoints 
for incidence and prevalence at random, reﬁ t the model, 
and compared predictions to the held-out data. We 
assessed model performance using two metrics: the root-
mean squared error of the predictions compared with the 
data held out, and the coverage of the data prediction with 
95% uncertainty intervals. The appendix pp 736–37 
provides these metrics for the ten models tested. In all 
cases, external validity was equal to or only slightly worse 
than the internal validity.
As in GBD 2010, DisMod-MR was not used to model 
estimates for a shortlist of causes; custom models were 
created for many of these. For some of these causes, 
important improvements in the modelling strategy were 
implemented. Changes for HIV and malaria have been 
described elsewhere.61 For dengue, the model was 
modiﬁ ed to use the ﬁ rst component of a principal 
components’ analysis of Bhatt and colleagues’ dengue 
transmission probability to improve estimation of case 
rates.63 For lymphatic ﬁ lariasis, precontrol levels were 
estimated from data reported in the lymphatic ﬁ lariasis 
atlas.64 Last, based on crucial input from GBD 
collaborators, we chose to model rheumatic heart disease 
in low-income and middle-income countries separately 
from high-income countries in view of potential 
diﬀ erences in long-term cohort eﬀ ects of treatment.
Estimation for cancer in GBD 2013 largely followed a 
similar analytical strategy to GBD 2010, which used a 
combination of incidence data, survival data, and 
sequelae durations to estimate cancer prevalence and 
YLDs.65,66 The analysis beneﬁ ted from the inclusion of 
both the latest edition of Cancer Incidence in Five 
Continents and a larger number of other cancer registries 
particularly in China. In GBD 2013, we also incorporated 
new data from the US National Cancer Institute’s 
Surveillance, Epidemiology, and End Results Program 
(SEER)67 and WHO’s International Agency for Research 
on Cancer’s Cancer Survival in Africa, Asia, the 
Caribbean, and Central America to update best and worst 
case survival, yearly survival trends, and sequelae 
durations for all cancers.68 Based on evidence that 
individuals with most cancers continue to have higher 
mortality beyond 5 years than do the general population, 
we estimated the burden of cancer for up to 10 years after 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Larynx cancer 65·4% 68·1% 61·2% 75·5%
Tracheal, bronchus, and lung cancer 65·4% 69·1% 61·7% 76·6%
Breast cancer 66·0% 69·1% 61·7% 76·6%
Cervical cancer 65·4% 69·1% 61·2% 76·6%
Uterine cancer 65·4% 68·6% 61·7% 76·6%
Prostate cancer 65·4% 69·1% 61·7% 76·6%
Colon and rectum cancer 65·4% 69·1% 61·2% 76·1%
Lip and oral cavity cancer 60·1% 66·5% 60·1% 75·0%
Nasopharynx cancer 60·1% 66·0% 60·1% 74·5%
Other pharynx cancer 60·1% 66·0% 60·1% 74·5%
Gallbladder and biliary tract cancer 60·1% 66·0% 60·1% 74·5%
Pancreatic cancer 60·6% 67·6% 60·6% 75·0%
Malignant skin melanoma 62·2% 67·0% 60·6% 75·0%
Non-melanoma skin cancer 60·1% 68·1% 62·2% 75·0%
Ovarian cancer 60·6% 66·5% 61·2% 74·5%
Testicular cancer 60·6% 66·5% 60·1% 74·5%
Kidney cancer 60·6% 66·5% 60·1% 74·5%
Bladder cancer 60·6% 67·0% 60·6% 74·5%
Brain and nervous system cancer 60·6% 67·6% 61·2% 75·0%
Thyroid cancer 60·6% 66·0% 60·1% 74·5%
Mesothelioma 53·7% 64·4% 58·0% 73·9%
Hodgkin’s lymphoma 60·6% 66·5% 60·1% 74·5%
Non-Hodgkin lymphoma 60·6% 67·6% 60·6% 75·5%
Multiple myeloma 60·6% 67·0% 60·6% 75·0%
Leukaemia 66·0% 69·1% 62·2% 77·1%
Other neoplasms 66·0% 69·1% 62·8% 77·7%
Cardiovascular diseases 71·3% 76·6% 69·1% 86·2%
Rheumatic heart disease 15·4% 19·1% 18·6% 34·0%
Ischaemic heart disease 21·8% 42·6% 13·8% 50·0%
Cerebrovascular disease 63·8% 64·9% 63·3% 75·5%
Ischaemic stroke 59·0% 64·4% 62·8% 73·9%
Haemorrhagic stroke 59·6% 64·4% 62·2% 73·4%
Hypertensive heart disease 11·7% 10·1% 8·5% 18·6%
Cardiomyopathy and myocarditis 12·8% 22·9% 19·1% 30·9%
Atrial ﬁ brillation and ﬂ utter 8·5% 10·6% 5·9% 13·3%
Peripheral vascular disease 3·7% 9·0% 4·3% 11·7%
Endocarditis 5·9% 16·0% 14·4% 17·6%
Other cardiovascular and circulatory diseases 0·0% 0·5% 0·5% 0·5%
Chronic respiratory diseases 38·3% 64·9% 32·4% 68·6%
Chronic obstructive pulmonary disease 11·7% 17·0% 9·0% 22·3%
Pneumoconiosis 2·7% 13·3% 13·3% 15·4%
Silicosis 2·7% 13·3% 13·3% 15·4%
Asbestosis 11·8% 17·6% 17·6% 23·5%
Coal workers’ pneumoconiosis 5·7% 20·0% 20·0% 22·9%
Other pneumoconiosis 1·6% 12·2% 11·7% 13·3%
Asthma 34·6% 64·9% 25·0% 68·6%
Interstitial lung disease and pulmonary sarcoidosis 8·0% 16·5% 13·8% 18·1%
Other chronic respiratory diseases ·· ·· ·· ··
Cirrhosis 15·4% 19·1% 18·1% 29·3%
Cirrhosis due to hepatitis B 10·6% 6·9% 4·3% 14·9%
Cirrhosis due to hepatitis C 12·8% 7·4% 4·3% 16·5%
(Table 1 continues on next page)
Articles
748 www.thelancet.com   Vol 386   August 22, 2015
incidence. Estimates for cancer sequelae now represent 
the burden for all cancer patients by contrast with 
estimation of the burden just for cancer survivors (see 
appendix pp 7–8 for more detail on aspects of estimating 
non-fatal cancer outcomes that were diﬀ erent from the 
methods used in GBD 2010).
Injuries
We followed a similar strategy to GBD 2010 for estimating 
the burden of injuries, except for an expanded list of 
26 external cause-of-injury categories (from 15) and 
47 nature-of-injury categories (from 23) for both short-
term outcomes and lasting disability (see appendix 
pp 90–96 for ICD codes). More detail was added to both 
external causes and nature-of-injury categories to reduce 
epidemiological heterogeneity within each combination 
of cause and nature-of-injury category. The key analytical 
steps are explained in greater detail in the appendix 
pp 9–14. Here we provide a summary of the methods.
First, for each external cause, DisMod-MR 2.0 was used 
to analyse incidence based on hospital, emergency 
department, and survey data. Second, we estimated the 
distribution of nature of injury for each external cause 
using data that had both types of code available. When 
individuals were coded with more than one nature-of-
injury code, we used the most severe. Third, we analysed 
seven studies that provided at least 1 year of follow-up for 
various natures of injury to estimate long-term disability.69–75 
Fourth, we estimated cohort prevalence of long-term 
disability from the incident cases of injury for each 
external cause and nature-of-injury combination while 
accounting for excess mortality for the more severe post-
injury sequelae. For some injuries, treatment modiﬁ es the 
disability weight. In these cases, we approximated the 
fraction of injuries receiving treatment as a function of an 
indicator of health system access.76
Short-term disability was estimated for all natures of 
injury by cause-of-injury categories as the product of 
prevalence (estimated by multiplying incidence by mean 
duration) and the appropriate disability weight. The 
duration for treated cases of injuries was determined by 
information in the Dutch Injury Surveillance System 
follow-up studies of 2001–04 and 2007–10.71,73 We used 
expert opinion to estimate a multiplier for the duration of 
short-term disability from untreated injuries and used 
the estimates of access to care by country and year as we 
have described for the long-term disability.
YLDs from 29 residual causes
Despite expanding our list of causes and sequelae in 
GBD 2013, many diseases remain for which we do not 
explicitly model disease prevalence and YLDs. The GBD 
cause list is collectively exhaustive such that all sequelae 
with an ICD code are mapped to a cause group (appendix 
pp 90–96). Many less common sequelae are included in 
29 of the residual categories. For 14 of these cause 
groupings, epidemiological data for incidence or 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Cirrhosis due to alcohol use 6·9% 5·3% 3·7% 9·6%
Cirrhosis due to other causes 5·3% 5·3% 4·3% 8·5%
Digestive diseases 19·7% 25·0% 18·6% 30·3%
Peptic ulcer disease 5·3% 14·4% 14·9% 17·0%
Gastritis and duodenitis 2·7% 13·8% 13·8% 15·4%
Appendicitis 2·1% 13·3% 13·8% 14·9%
Paralytic ileus and intestinal obstruction 3·2% 15·4% 13·8% 17·0%
Inguinal, femoral, and abdominal hernia 2·1% 13·3% 13·8% 14·9%
Inﬂ ammatory bowel disease 12·8% 14·4% 6·4% 19·1%
Vascular intestinal disorders 2·1% 13·3% 13·8% 14·9%
Gallbladder and biliary diseases 10·6% 16·5% 14·4% 22·3%
Pancreatitis 4·8% 14·9% 14·9% 16·0%
Other digestive diseases ·· ·· ·· ··
Neurological disorders 46·3% 37·2% 28·7% 55·3%
Alzheimer’s disease and other dementias 18·6% 15·4% 12·2% 22·3%
Parkinson’s disease 18·1% 14·9% 7·4% 23·4%
Epilepsy 21·3% 16·0% 3·7% 28·2%
Multiple sclerosis 21·3% 16·0% 7·4% 26·1%
Migraine 16·0% 13·3% 11·7% 25·0%
Tension-type headache 9·0% 6·4% 10·6% 19·1%
Medication overuse headache 3·2% 4·8% 9·0% 11·2%
Other neurological disorders 8·5% 3·2% 0·0% 9·0%
Mental and substance use disorders 37·8% 58·5% 35·6% 67·6%
Schizophrenia 17·0% 9·0% 3·7% 19·1%
Alcohol use disorders 19·7% 28·7% 14·9% 31·4%
Drug use disorders 20·7% 47·3% 26·1% 51·6%
Opioid use disorders 12·8% 17·6% 2·7% 19·7%
Cocaine use disorders 6·9% 31·9% 5·9% 34·6%
Amphetamine use disorders 6·4% 23·9% 8·0% 27·7%
Cannabis use disorders 16·0% 42·0% 20·7% 46·8%
Other drug use disorders ·· ·· ·· ··
Depressive disorders 19·7% 23·9% 11·2% 33·0%
Major depressive disorder 19·7% 23·9% 11·2% 33·0%
Dysthymia 9·0% 13·8% 5·3% 18·6%
Bipolar disorder 8·5% 16·0% 3·7% 18·6%
Anxiety disorders 12·8% 21·8% 5·3% 26·1%
Eating disorders 10·6% 12·2% 4·3% 14·9%
Anorexia nervosa 10·1% 12·2% 4·3% 14·4%
Bulimia nervosa 8·5% 11·7% 3·2% 14·9%
Autistic spectrum disorders 5·3% 5·9% 3·7% 9·6%
Autism 5·3% 5·3% 3·7% 9·6%
Asperger’s syndrome 1·6% 4·8% 1·6% 5·3%
Attention-deﬁ cit or hyperactivity disorder 10·6% 10·1% 4·8% 19·1%
Conduct disorder 5·9% 6·4% 1·6% 11·2%
Idiopathic intellectual disability 6·4% 3·2% 1·1% 7·4%
Other mental and substance use disorders 0·5% 0·5% 0·0% 1·1%
Diabetes, urogenital, blood, and endocrine 
diseases
97·9% 98·4% 92·0% 98·4%
Diabetes mellitus 36·7% 35·1% 33·5% 58·5%
Acute glomerulonephritis 5·3% 18·1% 5·9% 19·1%
Chronic kidney disease 79·8% 82·4% 75·5% 89·4%
(Table 1 continues on next page)
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prevalence are available so that they can be modelled as 
other causes have been modelled—this set includes 
meningitis, cirrhosis, liver cancer, pneumoconiosis, and 
chronic kidney disease due to other causes, other 
neoplasms, other cardiovascular and circulatory diseases, 
other drug use disorders, other mental and substance 
use disorders, other gynaecological diseases, other 
musculoskeletal disorders, other skin and subcutaneous 
diseases, age-related and other hearing loss, other vision 
loss, other sense organ diseases, and other oral disorders. 
For 12 residual categories (other intestinal infectious 
diseases, other neglected tropical diseases, other maternal 
disorders, other neonatal disorders, other nutritional 
deﬁ ciencies, other infectious diseases, other chronic 
respiratory diseases, other digestive diseases, other 
neurological disorders, other urinary diseases, other 
haemoglobinopathies and haemolytic anaemias, and 
other congenital anomalies), epidemiological data for 
incidence and prevalence were not available for the entire 
residual cause groupings but suﬃ  cient cause of death 
data allowed for cause of death estimates. For each 
category, we identiﬁ ed causes within the larger cause 
group that had both estimates of years of life lost (YLLs) 
and YLDs, which we expected to have similar ratios of 
mortality to morbidity. We then computed the ratio of 
YLLs to YLDs for these speciﬁ c causes (on a country–
sex–year basis) and applied them to the residual 
category’s YLLs to estimate its YLDs. This approach 
makes the simpliﬁ ed assumption that on average within 
a level 2 disease grouping the disability is proportionate 
to mortality within a country–sex–year. For an additional 
three residual categories (other sexually transmitted 
diseases, other drug use disorders, and other mental and 
substance use disorders), there were no overall 
epidemiological data or suﬃ  cient deaths to generate 
cause of death estimates. For the last two, we used US 
outpatient data or prevalence data from the Medical 
Expenditure Panel Survey (MEPS), National 
Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC), or the 1997 Australian mental health survey77 
and applied a severity distribution from these surveys in 
all countries and periods. These two causes for which US 
and Australian data were applied worldwide account for 
1·6% of global YLDs.
Impairments
As in GBD 2010, we estimated the country–age–sex–year 
prevalence of nine impairments: anaemia, epilepsy, 
hearing loss, heart failure, intellectual disability, 
infertility, vision loss, Guillain-Barré, and pelvic 
inﬂ ammatory disease. These impairments were selected 
because they are sequelae of more than one disease and 
data are available to estimate prevalence for the overall 
impairment. Generally, overall impairment prevalence 
was estimated using DisMod-MR 2.0. Cause-speciﬁ c 
estimates of impairments, such as the 19 causes of 
blindness, are required to provide the total prevalence 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Chronic kidney disease due to diabetes mellitus 6·9% 8·5% 19·1% 27·1%
Chronic kidney disease due to hypertension 6·9% 11·7% 19·1% 28·7%
Chronic kidney disease due to 
glomerulonephritis
5·9% 7·4% 19·1% 26·1%
Chronic kidney disease due to other causes 3·2% 5·9% 19·1% 24·5%
Urinary diseases and male infertility 15·4% 21·3% 17·6% 28·7%
Interstitial nephritis and urinary tract infections 2·1% 13·3% 13·8% 14·9%
Urolithiasis 8·5% 18·1% 16·0% 20·2%
Benign prostatic hyperplasia 6·9% 16·0% 14·4% 19·7%
Male infertility due to other causes 5·3% 3·2% 1·6% 8·0%
Other urinary diseases ·· ·· ·· ··
Gynaecological diseases 66·0% 95·2% 22·9% 95·2%
Uterine ﬁ broids 2·1% 3·2% 4·8% 6·9%
Polycystic ovarian syndrome 2·1% 4·8% 3·2% 8·0%
Female infertility due to other causes 5·3% 3·2% 1·6% 8·0%
Endometriosis 3·7% 3·7% 4·8% 6·4%
Genital prolapse 3·2% 3·7% 0·5% 8·0%
Premenstrual syndrome 64·4% 95·2% 6·9% 95·2%
Other gynaecological diseases 1·6% 13·3% 13·8% 14·9%
Haemoglobinopathies and haemolytic anaemias 97·9% 97·9% 60·1% 97·9%
Thalassaemias 87·2% 87·2% 38·8% 87·2%
Thalassaemia trait 1·1% 0·0% 0·0% 1·1%
Sickle cell disorders 96·3% 96·8% 52·1% 96·8%
Sickle cell trait 0·5% 0·0% 0·0% 0·5%
Glucose-6-phosphate dehydrogenase 
deﬁ ciency
39·9% 24·5% 5·3% 46·3%
Glucose-6-phosphate dehydrogenase 
deﬁ ciency trait
0·5% 0·5% 0·5% 1·6%
Other haemoglobinopathies and haemolytic 
anaemias
·· ·· ·· ··
Endocrine, metabolic, blood, and immune disorders 1·6% 13·3% 13·8% 14·9%
Musculoskeletal disorders 22·9% 44·1% 20·2% 51·1%
Rheumatoid arthritis 16·5% 13·8% 9·6% 24·5%
Osteoarthritis 10·6% 10·1% 7·4% 18·1%
Low back and neck pain 12·8% 41·5% 13·3% 46·3%
Low back pain 12·8% 40·4% 12·2% 46·3%
Neck pain 6·4% 12·8% 3·2% 15·4%
Gout 11·2% 9·6% 4·8% 18·1%
Other musculoskeletal disorders 6·4% 5·9% 2·1% 10·1%
Other non-communicable diseases 58·5% 61·2% 47·9% 75·0%
Congenital anomalies 26·6% 28·7% 21·3% 32·4%
Neural tube defects 14·4% 20·2% 20·7% 22·3%
Congenital heart anomalies 20·7% 22·9% 20·7% 25·5%
Orofacial clefts 21·8% 24·5% 20·7% 25·5%
Down’s syndrome 21·8% 23·9% 20·7% 25·5%
Turner’s syndrome 8·0% 10·1% 10·1% 10·6%
Klinefelter’s syndrome 8·5% 10·6% 10·6% 11·2%
Chromosomal unbalanced rearrangements 20·7% 23·4% 20·7% 25·5%
Other congenital anomalies 11·2% 9·6% 1·6% 16·5%
Skin and subcutaneous diseases 35·1% 46·8% 30·9% 51·1%
Dermatitis 32·4% 39·9% 20·2% 43·6%
Psoriasis 4·8% 9·0% 4·8% 13·8%
(Table 1 continues on next page)
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estimated for that impairment. Anaemia, epilepsy, 
hearing loss, heart failure, intellectual disability, and 
pelvic inﬂ ammatory disease are estimated for diﬀ erent 
levels of severity. Separate estimates were made for 
primary infertility (in couples who have not been able to 
conceive) and secondary infertility (in couples having 
trouble conceiving again) and, for each, if the impairment 
is aﬀ ecting men or women, or both. The severity 
distribution of cause-speciﬁ c prevalence of each 
impairment was estimated as explained above or, in the 
absence of severity-speciﬁ c data, assumed to be 
proportionate across all levels of severity. In the case of 
epilepsy, severity levels were determined by mixed-eﬀ ect 
models for the proportions of primary, severe, and 
treated epilepsy, and a meta-analysis for seizure-free 
treated epilepsy, and thus had values that were speciﬁ c 
for country, age, sex, and year. DisMod-MR 2.0 models 
produced country-speciﬁ c, age-speciﬁ c, sex-speciﬁ c, and 
year-speciﬁ c levels of hearing loss and vision loss. Due to 
little information about the severity levels of intellectual 
disability, we assumed a similar distribution of severity 
worldwide based on meta-analysis of intelligence 
quotient (IQ)-speciﬁ c data for the overall impairment. 
This was supplemented with cause-speciﬁ c distributions 
for chromosomal causes and iodine deﬁ ciency, whereas 
the severity of intellectual disability included in the long-
term sequelae of causes such as meningitis, neonatal 
tetanus, and malaria was combined with several 
impairments such as motor impairment, blindness, or 
seizures. The severity of heart failure is derived from our 
MEPS analysis and therefore is not speciﬁ c for country, 
year, age, or sex.
Our method for estimating overall anaemia was largely 
the same as in GBD 2010 but with the addition of new 
data sources, speciﬁ cally subnational data for the UK, 
China, and Mexico.43 We adopted diﬀ erent thresholds for 
deﬁ ning anaemia during the neonatal period, because 
the GBD 2010 thresholds did not account for 
haematological realities of early life. The GBD 2013 
thresholds match the WHO recommendations78 with the 
exception of thresholds of less than 1 month because 
there is no international cutoﬀ  for diagnosis at that 
age.43,79 To disaggregate marginal estimates of anaemia 
severity and cause into a complete set of prevalence 
estimates for cause and severity pairs, we developed a 
new method for GBD 2013 that used techniques from 
Bayesian contingency table modelling.80,81
In GBD 2010, hearing loss of more than or equal to 
35 dB in DisMod-MR 1.0 was estimated and then broken 
down into six severity levels based on a series of 
regressions on the proportionate distribution across 
categories. In GBD 2013, we ﬁ rst estimated the 
prevalence of normal hearing, hearing loss of 20–34 dB 
(mild), and greater than 35 dB (moderate and above); 
these three categories were ﬁ xed to add up to 100%. We 
then ran separate DisMod-MR 2.0 models for ﬁ ve severity 
levels (ie, moderate 35–49 dB, moderately severe 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Cellulitis 1·6% 12·8% 13·3% 14·4%
Bacterial skin diseases 3·7% 18·6% 15·4% 21·8%
Scabies 8·5% 9·0% 5·9% 16·5%
Fungal skin diseases 2·7% 8·5% 5·9% 12·2%
Viral skin diseases 6·4% 7·4% 5·3% 12·8%
Acne vulgaris 5·9% 6·9% 5·9% 13·8%
Alopecia areata 2·1% 2·7% 2·1% 4·8%
Pruritus 2·1% 3·7% 3·2% 6·9%
Urticaria 3·2% 4·3% 3·2% 8·5%
Decubitus ulcer 2·1% 12·8% 13·3% 14·4%
Other skin and subcutaneous diseases 0·5% 0·5% 0·5% 0·5%
Sense organ diseases 22·3% 27·7% 14·4% 45·7%
Glaucoma 14·9% 10·6% 6·9% 23·4%
Cataract 17·0% 19·1% 11·7% 36·7%
Macular degeneration 12·2% 12·2% 6·9% 23·9%
Uncorrected refractive error 0·0% 0·0% 3·2% 3·2%
Age-related and other hearing loss 12·2% 11·2% 2·1% 18·1%
Other vision loss 8·5% 7·4% 3·7% 16·0%
Other sense organ diseases 0·5% 0·5% 0·5% 0·5%
Oral disorders 39·4% 30·9% 25·0% 51·1%
Deciduous caries 28·7% 21·3% 17·6% 42·6%
Permanent caries 29·3% 21·3% 16·0% 41·0%
Periodontal diseases 18·6% 12·8% 5·3% 25·5%
Edentulism and severe tooth loss 9·6% 9·0% 9·0% 16·0%
Other oral disorders 0·5% 0·5% 0·5% 0·5%
Injuries 94·7% 94·7% 94·7% 96·3%
Transport injuries 2·7% 34·0% 17·0% 42·6%
Road injuries 2·7% 34·0% 16·5% 42·0%
Pedestrian road injuries 1·1% 4·3% 8·0% 8·0%
Cyclist road injuries 1·1% 4·8% 7·4% 8·0%
Motorcyclist road injuries 1·1% 4·3% 7·4% 7·4%
Motor vehicle road injuries 1·1% 4·8% 7·4% 8·0%
Other road injuries 1·1% 4·3% 7·4% 7·4%
Other transport injuries 1·1% 4·3% 8·5% 8·5%
Unintentional injuries 3·2% 12·2% 13·8% 20·2%
Falls 2·1% 10·6% 13·3% 18·1%
Drowning 1·1% 7·4% 9·6% 11·7%
Fire, heat, and hot substances 2·7% 9·0% 12·2% 16·0%
Poisonings 1·6% 8·5% 11·2% 14·9%
Exposure to mechanical forces 1·6% 8·5% 9·6% 13·8%
Unintentional ﬁ rearm injuries 1·1% 4·8% 8·5% 8·5%
Unintentional suﬀ ocation 0·5% 4·8% 8·5% 8·5%
Other exposure to mechanical forces 1·1% 4·8% 8·5% 8·5%
Adverse eﬀ ects of medical treatment 1·1% 4·8% 8·5% 8·5%
Animal contact 2·1% 8·5% 11·7% 15·4%
Venomous animal contact 1·1% 4·8% 8·5% 8·5%
Non-venomous animal contact 1·1% 4·8% 8·5% 8·5%
Foreign body 1·1% 4·8% 8·5% 8·5%
Foreign body in pulmonary aspiration and 
foreign body in airway
1·1% 4·8% 8·5% 8·5%
Foreign body in eyes 1·1% 2·7% 4·8% 4·8%
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50–64 dB, severe 65–79 dB, profound 80–94 dB, and 
complete ≥95 dB), which were then proportionally 
rescaled to ﬁ t in the 35 dB or greater envelope. In GBD 
2010, the same severity distribution was assumed for 
each cause of hearing loss. In GBD 2013, we customised 
the prevalence estimation for each cause. Hearing loss 
due to otitis media and age-related hearing loss were 
estimated by DisMod-MR 2.0 using prevalence data. 
Hearing loss due to meningitis was estimated as a 
proportion of meningitis cases from a meta-analysis.82 
Congenital hearing loss was estimated using birth 
prevalence data in DisMod-MR 2.0, assuming a constant 
prevalence for all ages because there was no evidence of 
an increased mortality risk. We assumed all hearing loss 
from otitis media was mild or moderate on the basis of 
reported distribution of hearing loss.83,84 To account for 
hearing aids, we assumed that the use of a hearing aid 
reduces the severity of hearing loss by one severity level. 
The other causes were assumed to cover the full range of 
severities. More details about impairments are provided 
in the appendix pp 15–32.
Severity distributions
For 213 causes, a range of sequelae are deﬁ ned in terms of 
severity. Important changes to the sequelae list with 
regards to severity include low back pain, alcohol and drug 
dependence categories, uterine prolapse, and epilepsy. 
Milder states for low back pain and alcohol and drug 
dependence categories were added because these 
disorders had a large gap between asymptomatic cases 
and the high value of the disability weight for the least 
severe symptomatic categories, whereas the epi-
demiological data for severity indicates a sizeable 
proportion of cases with milder disability. Stress 
incontinence was added as a sequela of uterine prolapse 
with a new disability weight that is distinct from full 
incontinence. Also, epilepsy health states are now better 
aligned with epidemiological data based on seizure 
frequency. In cases in which severity is related to a 
particular impairment, such as mild, moderate, and 
severe anaemia due to malaria, the analysis is driven by 
the impairment estimation described above. For some 
outcomes such as COPD or asthma, data have been 
gathered in diﬀ erent locations around the world and these 
have been modelled using DisMod-MR 2.0 (see appendix 
pp 694–733 for details). In other cases, published meta-
analyses have been used to estimate the allocation of cases 
by severity. For the remaining causes, we used the same 
approach for estimating the distribution of severity as in 
the GBD 2010; empirical analysis of this model was 
updated through the addition of 2 years from the US 
MEPS. The appendix pp 685–87 lists the GBD causes that 
can be identiﬁ ed in MEPS and the corresponding 
ICD-9 CM codes. In total, 203 960 observations, covering 
119 676 individuals, were used. In the cases of dementia, 
Parkinson’s disease, multiple sclerosis, osteoarthritis, 
schizophrenia, and bipolar disorder, data identiﬁ ed 
through literature reviews were used to inform the severity 
distribution. The introduction of a mild health state for 
four drug dependence categories required identiﬁ cation 
of epidemiological data to estimate the proportion of cases 
with mild versus more severe disability. For cannabis 
dependence, we used the NESARC survey in the USA and 
the Australian National Survey of Mental Health and 
Wellbeing. For the remaining three drug dependence 
categories, we only had access to one study on polydrug 
users in Australia, which led to about half of dependent 
cases being assigned to the more severe and mild health 
states. Although this information is derived from a non-
representative cohort of drug users, it was thought to be 
more appropriate than deriving a severity distribution 
from a household survey like NESARC in which only a 
small proportion of individuals dependent on opioids, 
cocaine, or amphetamines would be represented.
Revisions to disability weights
The GBD 2010 disability weights measurement study 
introduced a new method of pairwise comparisons as a 
means of eliciting weightings for health states in 
Before 1998 1998–2005 2006–13 Total
(Continued from previous page)
Foreign body in other body part 1·1% 4·8% 8·5% 8·5%
Other unintentional injuries 2·7% 10·6% 11·7% 18·1%
Self-harm and interpersonal violence 2·1% 9·0% 13·3% 16·5%
Self-harm 1·1% 7·4% 11·7% 12·8%
Interpersonal violence 2·1% 8·5% 12·2% 16·0%
Assault by ﬁ rearm 1·1% 4·8% 8·5% 8·5%
Assault by sharp object 1·1% 4·8% 8·5% 8·5%
Assault by other means 1·1% 2·1% 3·7% 3·7%
Forces of nature, war, and legal intervention 100·0% 98·3% 98·9% 100·0%
Exposure to forces of nature 100·0% 98·8% 99·4% 100·0%
Collective violence and legal intervention 100·0% 99·1% 99·1% 100·0%
GBD 2013=Global Burden of Diseases 2013 Study.
 Table 1: GBD 2013 data representativeness index by cause
Before 1998 1998–2005 2006–13 Total
Anaemia 61·2% 56·9% 22·3% 74·5%
Epilepsy 35·6% 23·4% 11·7% 44·1%
Guillain-Barré 
syndrome
12·2% 5·9% 0·0% 13·3%
Hearing loss 10·1% 15·4% 5·9% 23·4%
Heart failure 10·1% 17·6% 15·4% 21·3%
Infertility 49·5% 34·6% 27·1% 60·1%
Intellectual disability 12·2% 6·9% 3·2% 16·0%
Pelvic inﬂ ammatory 
disease
4·3% 12·2% 12·8% 14·9%
Vision loss 22·3% 46·8% 24·5% 60·1%
GBD 2013=Global Burden of Diseases 2013 Study.
 Table 2: GBD 2013 data representativeness index by impairment, calculated 
as fraction of countries with data for each impairment and period
For more on DisMod-MR 2.0 see 
http://ihmeuw.org/dismod-ode
For the Cancer Incidence in Five 
Continents see http://ci5.iarc.fr/
Default.aspx
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population surveys.85,86 Data were gathered in ﬁ ve countries 
(Bangladesh, Indonesia, Peru, Tanzania, and the USA) 
and supplemented with a web survey. In total, responses 
were gathered from 30 230 people in 167 countries. 
Respondents were presented with a series of randomly 
selected pairwise comparisons of lay descriptions of 
health states and asked to state which health state is 
healthier than the other. Salomon and colleagues85 
developed a statistical model that yields from these 
pairwise comparisons disability weights on a scale from 
0 (no health loss) to 1 (equivalent to death). 
Based on important commentary and review of the GBD 
2013 collaborators, we have revised the lay descriptions of 
32 states and added 16 new states. The revised lay 
descriptions were based on identifying inconsistency in 
the way progression across levels of severity had been 
handled for some outcomes and the addition of social 
isolation to the descriptions for complete, profound, and 
severe hearing loss. New states included ﬁ ve milder health 
states for alcohol and drug dependence; two health states 
for the alignment of epilepsy with the epidemiological data 
deﬁ ning severe epilepsy in individuals who had on average 
one or more ﬁ ts per month and less severe epilepsy in 
those with between one and 11 ﬁ ts in the past year; two 
milder health states for low back pain; and one each for 
stress incontinence, concussion, hypothyroidism, 
hyperthyroidism, thrombocytopenic purpura, vertigo, and 
amputation of one arm without treatment. The appendix 
pp 688–93 provides a complete list of the lay descriptions 
of all 235 GBD 2013 health states.
In 2013, we had the opportunity to collaborate with the 
European Centre for Disease Prevention and Control to 
gather new data for disability weights in four 
population-based national surveys (Hungary, Italy, 
Sweden, and the Netherlands) using the Salomon and 
colleagues’ protocol.85,87 Because of funding and 
questionnaire length, the surveys included 140 of 220 GBD 
2010 health states for which the lay descriptions had not 
been revised, 32 health states with revised lay descriptions, 
and 42 new health states, 16 of which were included in 
GBD 2013. These nationally representative samples were 
comprised of 30 660 respondents. For GBD 2013, the data 
of GBD 2010 disability weights measurement study and 
the European disability weights measurement study88 were 
pooled in a single analysis of individual responses, thus 
doubling the number of respondents to 60 890 in both 
studies. For states where the lay description was not 
previously included, revised, or new, only the European 
disability weights measurement study data were used. 
This means that all disability weights in GBD 2013 diﬀ er 
from the GBD 2010 disability weights. Most disability 
weights changed slightly, but some diﬀ er more widely 
(appendix pp 688–93). Some of the more substantial 
changes were due to the inclusion of incontinence in the 
Figure 1: Percentage of causes with data available between 1990 and 2013 for 188 countries
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. Isl=Islands.
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Cases in 1990 
(× 1000)
Cases in 2013 
(× 1000)
Percentage change Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage change
Upper respiratory 
infections
13 557 038
(13 317 034 to 
13 806 346)
18 770 589
(18 479 508 to 
19 048 703)
38·26*
(35·33 to 41·60)
243 621·2
(239 383·6 to 
248 019·3)
259 491·0
(255 547·1 to 
263 318·4)
6·48*
(4·20 to 8·95)
Diarrhoeal disease 
episodes
2 920 208
(2 866 614 to 
2 968 429)
2 711 253
(2 666 452 to 
2 761 161)
–7·29*
(–9·55 to –4·91)
46 265·7
(45 440·7 to 
47 003·5)
37 467·6
(36 858·2 to 
38 151·9)
–19·07*
(–20·98 to –17·09)
Other exposure to 
mechanical forces
349 533
(334 775 to 
367 702)
381 968
(364 953 to 
401 105)
9·28*
(6·86 to 11·52)
6049·4
(5797·0 to 
6369·6)
5092·8
(4866·9 to 5355·1)
–15·81*
(–17·57 to –14·16)
Acute otitis media 339 485
(332 992 to 
345 806)
324 720
(318 445 to 
330 958)
–4·44*
(–7·03 to –1·88)
5292·2
(5194·9 to 
5384·2)
4480·9
(4394·0 to 4566·7)
–15·34*
(–17·58 to –13·09)
Tooth pain due to 
permanent caries
164 255
(144 960 to 
184 155)
222 966
(194 054 to 
252 697)
35·63*
(32·63 to 38·69)
3028·4
(2676·9 to 3391·5)
3 070·6
(2672·3 to 3479·0)
1·41
(–0·94 to 3·58)
Bacterial skin diseases 148 035
(123 990 to 
172 137)
154 851
(132 130 to 
180 387)
4·81 
(–4·86 to 14·19)
2655·7
(2244·7 to 
3075·9)
2194·3
(1870·5 to 2572·9)
–17·21*
(–22·61 to –11·95)
Falls 107 951
(106 004 to 
109 801)
154 533
(151 535 to 
157 392)
43·16* 
(39·53 to 46·97)
2030·3
(1993·1 to 
2063·9)
2017·5
(1988·0 to 2048·0)
–0·62
(–2·90 to 1·69)
Lower respiratory 
infections
164 622
(162 190 to 
167 306)
150 087
(146 724 to 
152 859)
–8·85*
(–12·07 to –6·67)
2891·4
(2849·7 to 
2940·9)
2206·9
(2156·5 to 2246·2)
–23·58*
(–26·17 to –21·86)
Clinical episodes of 
malaria
172 741
(107 735 to 
279 197)
146 761
(85 673 to 
249 239)
–16·56 
(–34·66 to 12·48)
2853·7
(1741·1 to 4755·7)
2036·0
(1184·4 to 3465·6)
–29·81*
(–44·89 to –5·93)
Chlamydia infection 111 204
(108 362 to 
114 280)
141 437
(137 606 to 
144 793)
27·25* 
(22·27 to 31·31)
2001·8
(1952·0 to 
2055·9)
1885·4
(1834·3 to 1929·7)
–5·69*
(–9·36 to –2·73)
Chickenpox and herpes 
zoster
128 020
(126 377 to 
129 582)
139 665
(138 706 to 
140 700)
8·84* 
(7·73 to 10·73)
1992·7
(1970·9 to 2015·0)
1935·4
(1920·8 to 1950·4)
–2·99*
(–4·00 to –1·54)
Hepatitis B 137 639
(133 533 to 
143 049)
129 191
(124 907 to 
132 890)
–6·22* 
(–9·67 to –2·53)
2644·5
(2562·1 to 2753·9)
1779·2
(1721·7 to 1830·2)
–32·74*
(–35·29 to –29·95)
Gallbladder and biliary 
diseases
78 635
(77 174 to 80 289)
104 111
(101 889 to 
106 283)
32·23* 
(28·62 to 36·23)
2005·6
(1971·1 to 2049·5)
1594·2
(1560·6 to 1627·8)
–20·56*
(–22·64 to –18·22)
Hepatitis A 90 801
(86 969 to 
94 635)
101 711
(97 926 to 
105 499)
11·87* 
(11·35 to 12·46)
1481·7
(1432·5 to 
1529·6)
1396·9
(1345·4 to 1448·4)
–5·76*
(–6·10 to –5·33)
Other unintentional 
injuries
70 771
(69 804 to 71 730)
94 747
(93 084 to 96 457)
33·88* 
(31·03 to 36·83)
1352·1
(1334·1 to 1370·2)
1312·8
(1292·3 to 1334·1)
–2·90*
(–4·93 to –0·83)
Interstitial nephritis 
and urinary tract 
infections
55 473
(54 702 to 56 225)
92 847
(91 652 to 93 940)
67·10* 
(64·28 to 70·38)
1156·8
(1142·6 to 1170·9)
1344·3
(1327·0 to 1360·3)
16·14*
(14·25 to 18·31)
Gastritis and 
duodenitis
76 611
(75 707 to 77 550)
90 638
(89 750 to 91 660)
18·15* 
(16·30 to 19·94)
1809·1
(1789·7 to 1831·4)
1393·6
(1380·1 to 1 409·5)
–23·00*
(–24·12 to –21·88)
Gonococcal infection 56 316
(53 588 to 59 210)
78 197
(74 585 to 81 629)
39·04* 
(28·92 to 48·08)
977·0
(931·8 to 1024·5)
1038·5
(990·4 to 1084·2)
6·53
(–0·93 to 13·10)
Dengue 8220
(3294 to 17 234)
58 435
(23 615 to 121 951)
610·87*
(606·25 to 615·50)
148·3
(59·4 to 311·0)
810·9
(327·7 to 1692·3)
447·31*
(443·59 to 450·91)
Non-venomous animal 
contact
65 300
(63 282 to 67 643)
57 822
(55 870 to 59 726)
–11·43*
(–15·55 to –7·21)
1190·1
(1155·7 to 1228·5)
808·4
(782·9 to 833·1)
–32·06*
(–34·84 to –29·13)
Trichomonas infection 40 045
(37 105 to 43 115)
57 794
(53 923 to 63 336)
43·45*
(31·00 to 61·93)
737·0
(685·1 to 789·3)
771·6
(720·2 to 845·3)
4·31
(–4·66 to 17·24)
Motor vehicle road 
injuries
40 958
(39 248 to 42 998)
54 201
(51 723 to 57 134)
32·35*
(28·52 to 37·35)
782·6
(752·1 to 821·3)
763·3
(729·3 to 802·9)
–2·46
(–5·11 to 0·90)
(Table 3 continues on next page)
Articles
754 www.thelancet.com   Vol 386   August 22, 2015
Cases in 1990 
(× 1000)
Cases in 2013 
(× 1000)
Percentage change Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage change
(Continued from previous page)
Tooth pain due to 
deciduous caries
50 436
(43 544 to 57 157)
53 082
(45 756 to 60 269)
5·07*
(3·77 to 6·37)
748·9
(646·6 to 848·4)
738·4
(636·5 to 838·4)
–1·47*
(–2·66 to –0·25)
Peptic ulcer disease 52 264
(51 134 to 53 504)
50 399
(48 835 to 52 173)
–3·81
(–7·37 to 0·75)
1457·0
(1424·5 to 1491·1)
810·7
(786·1 to 838·9)
–44·43*
(–46·54 to –41·86)
Urolithiasis 33 330
(30 306 to 36 585)
48 615
(43 576 to 54 046)
45·55*
(42·24 to 49·34)
744·9
(679·4 to 820·5)
690·9
(620·4 to 767·8)
–7·34*
(–9·29 to –5·16)
Genital herpes 37 033
(35 871 to 38 277)
46 840
(45 386 to 48 578)
26·27*
(22·76 to 30·12)
633·9
(614·0 to 655·5)
622·6
(603·4 to 645·4)
–1·85
(–4·55 to 1·08)
Cellulitis 31 740
(28 667 to 34 738)
37 449
(33 421 to 41 180)
17·85*
(13·20 to 22·04)
674·3
(607·1 to 739·9)
547·5
(488·2 to 604·0)
–18·80* (–21·35 to 
–16·80)
Fire, heat, and hot 
substances
36 843
(35 438 to 38 193)
33 433
(31 570 to 35 304)
–9·24*
(–14·28 to –3·71)
653·9
(631·3 to 677·0)
450·6
(426·5 to 474·6)
–31·08*
(–34·68 to –27·22)
Foreign body elsewhere 
in body
21 835
(21 544 to 22 091)
31 155
(30 749 to 31 549)
42·69*
(40·10 to 45·46)
455·4
(450·0 to 460·8)
461·0
(455·3 to 466·7)
1·23
(–0·57 to 3·05)
Hepatitis E 23 967
(22 840 to 24 969)
28 446
(27 083 to 30 055)
18·38*
(11·33 to 26·86)
433·2
(414·4 to 451·1)
386·8
(368·4 to 408·5)
–10·88*
(–16·18 to –4·62)
Collective violence and 
legal intervention
60 427
(40 630 to 98 088)
21 567
(11 959 to 48 571)
–64·08*
(–75·95 to –17·39)
1628·5
(1056·4 to 2651·6)
390·4
(229·3 to 842·7)
–75·48*
(–83·87 to –42·03)
Adverse eﬀ ects of 
medical treatment
13 489
(13 334 to 13 646)
19 946
(19 714 to 20 176)
47·88*
(45·68 to 50·11)
273·3
(270·2 to 276·4)
269·1
(266·3 to 271·9)
–1·52*
(–2·93 to –0·16)
Assault by other means 16 174
(15 804 to 16 557)
18 133
(17 708 to 18 553)
12·12*
(9·14 to 15·10)
299·4
(292·7 to 306·3)
249·2
(243·6 to 254·9)
–16·76*
(–18·83 to –14·50)
Other transport 
injuries
16 956
(16 240 to 18 001)
18 083
(17 246 to 19 205)
6·70*
(0·04 to 13·62)
315·7
(302·8 to 332·9)
244·5
(233·3 to 259·8)
–22·50*
(–27·11 to –17·66)
Pancreatitis 10 057
(9954 to 10 157)
17 163
(16 976 to 17 376)
70·45*
(68·14 to 72·80)
234·8
(232·6 to 237·1)
251·0
(248·3 to 253·9)
6·84*
(5·45 to 8·28)
Motorcyclist road 
injuries
14 619
(12 221 to 16 302)
16 692
(13 485 to 18 844)
14·15*
(7·74 to 21·46)
273·5
(227·9 to 305·0)
226·9
(184·0 to 256·2)
–17·08*
(–21·40 to –11·90)
Appendicitis 14 105
(12 914 to 15 603)
16 423
(14 441 to 18 501)
16·60*
(0·89 to 36·82)
263·6
(241·9 to 290·9)
225·2
(198·5 to 253·1)
–14·58
(–25·48 to 0·15)
Pedestrian road 
injuries by road vehicle
10 450
(9702 to 11 340)
14 353
(13 302 to 15 545)
37·38*
(32·69 to 43·65)
209·8
(194·3 to 228·1)
210·5
(194·8 to 227·5)
0·35
(–3·12 to 4·53)
Meningitis cases due 
to other causes
14 177
(13 756 to 14 595)
12 819
(12 410 to 13 260)
–9·58*
(–13·65 to –5·73)
224·6
(217·9 to 231·5)
175·3
(169·7 to 181·2)
–21·89*
(–25·39 to –18·63)
Typhoid fever 13 685
(11 708 to 17 982)
10 955
(9641 to 14 354)
–19·93*
(–30·68 to –6·53)
227·3
(195·5 to 297·7)
151·5
(133·6 to 198·5)
–33·30*
(–41·90 to –22·36)
Hepatitis C 9367
(9188 to 9539)
10 840
(10 650 to 11 014)
15·54*
(12·57 to 19·02)
201·0
(196·3 to 205·6)
157·7
(154·7 to 160·5)
–21·59*
(–23·94 to –18·90)
Cyclist road injuries 9713
(8578 to 10 973)
10 711
(9478 to 12 157)
10·30*
(5·21 to 15·85)
183·8
(164·6 to 205·9)
152·9
(135·9 to 173·6)
–16·84*
(–20·05 to –13·23)
Acute myocardial 
infarction
4862
(4640 to 5074)
8557
(8199 to 8919)
75·77*
(74·24 to 77·72)
141·1
(134·6 to 147·6)
139·3
(133·2 to 145·4)
–1·29*
(–2·09 to –0·34)
Assault by sharp object 6021
(5779 to 6234)
7983
(7641 to 8284)
32·62*
(26·92 to 38·28)
111·8
(107·2 to 115·6)
107·6
(103·1 to 111·5)
–3·75
(–7·87 to 0·21)
Acute ischaemic 
stroke
4309
(4118 to 4532)
6893
(6550 to 7352)
59·61*
(48·61 to 72·86)
128·4
(122·7 to 135·0)
114·3
(108·5 to 122·3)
–11·13*
(–17·29 to –3·14)
Paratyphoid fever 8846
(7761 to 10 194)
6378
(5550 to 7253)
–27·88*
(–41·81 to –12·83)
144·5
(127·5 to 166·1)
88·0
(76·5 to 100·0)
–39·09*
(–50·86 to –26·48)
Maternal hypertensive 
disorders
5582
(3681 to 7427)
5707
(3792 to 7519)
2·08
(–1·25 to 7·48)
96·7
(63·9 to 127·8)
75·2
(50·1 to 98·9)
–22·26*
(–24·37 to –18·54)
Exposure to forces of 
nature
7326
(4728 to 13 492)
5658
(3694 to 11 899)
–21·55
(–45·57 to 31·37)
195·7
(114·9 to 333·1)
97·3
(55·2 to 187·5)
–50·75*
(–71·91 to –9·97)
Venomous animal 
contact
5702
(5390 to 6040)
5548
(5278 to 5843)
–2·68
(–6·78 to 1·46)
106·0
(101·0 to 111·4)
77·1
(73·7 to 80·8)
–27·28*
(–29·90 to –24·43)
Foreign body in eyes 3959
(3692 to 4201)
5298
(4955 to 5607)
33·81*
(30·26 to 37·76)
74·6
(69·6 to 79·1)
73·5
(68·6 to 77·7)
–1·39
(–3·97 to 1·45)
(Table 3 continues on next page)
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lay descriptions for spinal cord injury and the inclusion of 
the psychological consequences of social isolation in 
people with more severe hearing loss, leading to much 
higher disability weights. The statistical analysis generates 
uncertainty distributions for each disability weight that are 
propagated into the uncertainty distributions of the 
estimates of YLDs.
Comorbidity
Many individuals have more than one disease or injury 
sequela at the same time. To accurately account for 
comorbidity and its eﬀ ect on disability for individuals, we 
used the GBD 2010 microsimulation approach. In the 
microsimulations, a set of individuals are exposed to the 
probability of having all the diﬀ erent sequelae included 
in the GBD to estimate a distribution of the combinations 
that might be seen in each country–age–sex–year. We 
modelled the probabilities within each country–
age–sex–year of diﬀ erent sequelae as independent. 
Although there are clear examples of the probability of 
one sequela changing the probability of other sequelae, 
such as diabetes and ischaemic heart disease, testing 
reported by Vos and colleagues1 suggested that modelling 
assuming independence was a reasonable approximation. 
However, for less common sequelae the microsimulation 
tends to increase the estimated uncertainty in the 
number of YLDs substantially because, for example, a 
sequela that is estimated to have a prevalence of less than 
one in 10 000 will not appear randomly in many 
microsimulations of 20 000. Two steps have been taken 
to reduce the inﬂ ation of uncertainty for uncommon 
sequelae. First, the number of simulants in each 
country–age–sex–year was increased to 40 000; the main 
limiting factor for the number of simulants is 
computational resources needed to run each of the 
62 880 country–age–sex–year simulations 1000 times to 
account for uncertainty in each of the input prevalence 
rates. Second, we excluded sequelae in a 
country–age–sex–year with a prevalence of less than one 
in 20 000 from the microsimulation. The combined 
Cases in 1990 
(× 1000)
Cases in 2013 
(× 1000)
Percentage change Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage change
(Continued from previous page)
Obstructed labour 5362
(4833 to 5947)
5122
(4491 to 5610)
–4·23
(–19·90 to 10·21)
93·7
(84·8 to 103·6)
67·2
(59·0 to 73·6)
–27·99*
(–39·42 to –17·41)
Maternal haemorrhage 4429
(3994 to 5014)
4649
(4331 to 5015)
4·72
(–7·62 to 17·74)
77·6
(70·3 to 87·3)
61·1
(57·0 to 65·9)
–21·40*
(–30·27 to –11·77)
Assault by ﬁ rearm 2487
(2266 to 2671)
3609
(3313 to 3881)
45·16*
(39·56 to 51·09)
48·2
(44·0 to 51·7)
50·0
(46·0 to 53·8)
3·77
(–0·17 to 7·93)
Pulmonary aspiration 
and foreign body in 
airway
2777
(2639 to 2986)
3568
(3396 to 3832)
28·50*
(25·60 to 31·45)
52·5
(49·9 to 56·3)
49·7
(47·4 to 53·4)
–5·28*
(–7·23 to –3·18)
Acute haemorrhagic 
stroke
1886
(1817 to 1977)
3366
(3200 to 3543)
78·50*
(65·50 to 89·81)
53·4
(51·5 to 55·9)
54·3
(51·4 to 57·3)
1·61
(–5·68 to 8·55)
Poisonings 3409
(3347 to 3477)
3282
(3208 to 3352)
–3·70*
(–6·17 to –1·39)
61·4
(60·3 to 62·5)
44·6
(43·6 to 45·5)
–27·43*
(–29·23 to –25·83)
Self-harm 3222
(3187 to 3257)
3270
(3240 to 3302)
1·51*
(0·20 to 2·79)
61·2
(60·6 to 61·8)
43·8
(43·3 to 44·2)
–28·48*
(–29·34 to –27·61)
Unintentional ﬁ rearm 
injuries
2749
(2556 to 2925)
3126
(2902 to 3344)
13·71*
(10·07 to 17·66)
49·4
(46·0 to 52·5)
42·7
(39·7 to 45·6)
–13·66*
(–16·30 to –10·85)
Complications of 
abortion
2366
(2235 to 2525)
2642
(2510 to 2784)
11·54*
(1·79 to 20·91)
41·9
(39·6 to 44·6)
34·9
(33·1 to 36·7)
–16·87*
(–24·01 to –10·06)
Paralytic ileus and 
intestinal obstruction
1501
(1481 to 1517)
2530
(2487 to 2572)
68·38* 
(64·90 to 71·76)
38·1
(37·5 to 38·5)
39·6
(38·9 to 40·3)
4·04*
(1·81 to 6·20)
Other sexually 
transmitted diseases
1884
(1771 to 2008)
2393
(2259 to 2540)
27·09* 
(17·35 to 36·22)
36·1
(34·0 to 38·3)
32·3
(30·6 to 34·3)
–10·14*
(–16·70 to –3·89)
Drowning 1803
(1708 to 1921)
1664
(1571 to 1782)
–7·70* 
(–11·01 to –4·22)
32·5
(30·8 to 34·7)
23·6
(22·3 to 25·3)
–27·33*
(–30·05 to –24·60)
Unintentional 
suﬀ ocation
1102
(1003 to 1205)
1593
(1443 to 1741)
44·53*
(40·31 to 48·18)
19·4
(17·7 to 21·2)
21·8
(19·7 to 23·8)
12·17*
(9·16 to 14·93)
Acute myocarditis 961
(909 to 1031)
1481
(1377 to 1592)
53·54*
(41·58 to 69·41)
22·8
(21·5 to 24·5)
22·0
(20·5 to 23·6)
–3·56
(–11·38 to 5·97)
Maternal sepsis and 
other maternal 
infections
1881
(1684 to 2088)
1389
(1227 to 1522)
–26·48*
(–36·40 to –15·31)
32·2
(28·9 to 35·6)
18·3
(16·2 to 20·0)
–43·42*
(–50·97 to –34·94)
Causes are ordered by overall incidence. All data are shown with 95% uncertainty intervals. *Signiﬁ cant percentage change.
Table 3: Global incidence of acute sequelae (for less than 3 months) by cause for incidence greater than 1 million cases per year
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disability weight for individuals with several sequelae 
was computed as in the GBD 2010 using a multiplicative 
model; namely, the individual’s disability weight is equal 
to one minus the cross product of one minus the 
disability weight for each sequela that the individual has. 
An output from the comorbidity microsimulation is 
Figure 2: Population pyramids for developed countries (A), developing countries (excluding sub-Saharan Africa) (B), and sub-Saharan African countries (C) 
with individuals grouped by number of sequelae, 1990 and 2013
250 200 150 100 50 0 50 100 150 200 250
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
≥80
A
Ag
e 
(y
ea
rs
)
Female population Female populationMale population
20131990
Male population
50 40 30 20 10
0
10 20 30 40 50 50 40 30 20 10 10 20 30 40 50
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
≥80
B
Ag
e 
(y
ea
rs
)
250 200 150 100 50 50 100 150 200 250
80 70 50 304060 20 10 2010 30 5040 60 70 80
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
≥80
C
Ag
e 
(y
ea
rs
)
Population (millions)
80 70 50 304060 20 10 2010 30 5040 60 70 80
Population (millions)
0 1 2 3 4 5 6 7 8 9 ≥10
Number of sequelae
0 0 0 0
0 0
0 00 0
Articles
www.thelancet.com   Vol 386   August 22, 2015 757
Cases in 1990 (× 1000) Cases in 2013 
(× 1000)
Percentage 
change
Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage 
change
Asymptomatic 
permanent caries
1 740 088
(1 710 605 to 
1 766 930)
2 389 517
(2 349 584 to 
2 428 957)
37·08*
(35·48 to 39·31)
33 617·4
(33 056·6 to 
34 130·4)
33 152·4
(32 608·9 to 
33 699·8)
–1·47
(–2·57 to 
0·14)
Individuals with 
recurrent tension-type 
headaches
1 072 423
(1 050 263 to 
1 095 165)
1 561 447
(1 537 571 to 
1 585 766)
45·49*
(41·86 to 49·39)
21 751·8
(21 320·8 to 
22 202·5)
21 751·8
(21 428·1 to 
22 092·8)
0·00
(–2·38 to 
2·58)
Iron-deﬁ ciency 
anaemia
1 209 665
(1 205 539 to 
1 213 899)
1 208 216
(1 205 927 to 
1 210 478)
–0·23
(–0·61 to 0·13)
21 421·1
(21 352·1 to 
21 488·1)
16 723·2
(16 690·3 to 
16 756·0)
–21·94*
(–22·22 to 
–21·67)
Glucose-6-phosphate 
dehydrogenase 
deﬁ ciency trait
851 395
(846 058 to 855 869)
1 181 972
(1 174 352 to 
1 188 844)
38·65*
(37·64 to 39·87)
16 022·1
(15 923·3 to 
16 105·6)
16 505·2
(16 399·8 to 
16 600·9)
2·97*
(2·23 to 3·88)
Age-related and other 
hearing loss
724 592
(676 905 to 767 910)
1 128 939
(1 055 658 to 
1 200 476)
55·66*
(52·74 to 58·37)
18 520·8
(17 446·2 to 
19 527·2)
17 318·2
(16 291·8 to 
18 321·9)
–6·50*
(–7·93 to 
–5·15)
Asymptomatic genital 
herpes
760 731
(733 076 to 783 174)
1 124 670
(1 087 191 to 
1 157 170)
47·66*
(44·73 to 50·63)
16 802·1
(16 199·7 to 
17 293·0)
15 914·7
(15 383·0 to 
16 377·5)
–5·32*
(–7·08 to 
–3·50)
Individuals with 
recurrent migraine
581 025
(569 050 to 594 688)
848 366
(831 035 to 864 852)
46·06*
(41·44 to 50·08)
11 690·8
(11 460·6 to 
11 957·8)
11 714·4
(11 480·0 to 
11 939·2)
0·33
(–2·80 to 
2·99)
Ascariasis 1 078 935
(952 859 to 1 239 751)
804 370
(713 418 to 922 212)
–25·52*
(–37·77 to –10·42)
20 218·8
(17 665·1 to 
23 505·4)
11 154·8
(9886·1 to 12 793·7)
–44·81*
(–54·24 to 
–33·09)
Fungal skin diseases 473 167
(410 058 to 543 736)
683 714
(597 898 to 780 963)
44·21*
(41·20 to 47·95)
9324·9
(8194·6 to 10 608·8)
9604·1
(8424·7 to 10 914·0)
3·01*
(1·95 to 3·82)
Acne vulgaris 537 177
(507 605 to 567 912)
661 635
(622 842 to 700 242)
23·17*
(13·86 to 32·63)
8948·3
(8457·6 to 9450·4)
8907·3
(8376·4 to 9425·0)
–0·35
(–7·81 to 
7·29)
Uncorrected refractive 
error
433 575
(425 242 to 442 348)
659 847
(648 299 to 671 447)
51·97*
(49·03 to 54·96)
10 478·6
(10 274·1 to 
10 683·9)
9931·7
(9755·9 to 10 106·6)
–5·24*
(–7·01 to 
–3·43)
Low back pain 414 049
(408 102 to 420 024)
651 009
(641 143 to 662 885)
56·76*
(53·55 to 61·45)
9466·7
(9330·9 to 9594·3)
9442·5
(9302·7 to 9620·4)
–0·43
(–2·40 to 
2·47)
Periodontal diseases 301 876
(298 122 to 305 412)
503 967
(496 870 to 511 448)
66·69*
(63·68 to 70·09)
7218·7
(7132·2 to 7304·6)
7323·2
(7221·2 to 7429·6)
1·38
(–0·42 to 
3·39)
Other skin and 
subcutaneous diseases
314 509
(207 790 to 470 452)
495 328
(319 462 to 761 256)
57·07*
(48·47 to 64·42)
7285·9
(4544·7 to 11 563·8)
7287·5
(4559·1 to 11 527·5)
0·03
(–0·91 to 
0·90)
Trichuriasis 543 402
(465 656 to 645 140)
477 374
(441 257 to 518 365)
–11·63
(–28·72 to 4·95)
10 145·0
(8576·5 to 12 201·3)
6618·1
(6117·5 to 7189·2)
–34·36*
(–47·83 to 
–21·04)
Asymptomatic 
deciduous caries
454 348
(450 942 to 457 847)
474 970
(471 627 to 478 341)
4·38*
(3·56 to 5·12)
6744·0
(6693·9 to 6795·3)
6604·5
(6557·8 to 6651·1)
–2·13*
(–2·88 to 
–1·44)
Hookworm disease 498 224
(436 949 to 577 353)
471 816
(437 050 to 511 319)
–5·10
(–20·16 to 9·75)
9388·3
(8152·9 to 10 982·3)
6537·5
(6053·8 to 7084·4)
–30·06*
(–41·59
to –18·42)
Diabetes mellitus 175 851
(159 924 to 187 156)
409 967
(381 806 to 432 038)
132·91*
(123·69 to 
142·35)
4137·3
(3713·0 to 4442·8)
5991·0
(5560·9 to 6340·8)
44·78*
(38·50 to 
51·33)
Neck pain 226 306
(221 678 to 230 966)
349 305
(341 160 to 359 767)
54·06*
(49·11 to 59·88)
5038·0
(4938·7 to 5141·9)
4968·9
(4854·4 to 5114·9)
–1·46
(–4·58 to 
2·17)
Genital prolapse 218 569
(214 601 to 222 616)
343 708
(336 959 to 350 327)
57·02*
(53·02 to 61·48)
4827·0
(4744·9 to 4911·5)
4785·3
(4693·7 to 4874·3)
–0·91
(–3·30 to 
1·74)
(Table 4 continues on next page)
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Cases in 1990 (× 1000) Cases in 2013 
(× 1000)
Percentage 
change
Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage 
change
(Continued from previous page)
Malaria parisitaemia, 
anaemia, or chronic 
sequelae
258 173
(249 606 to 265 369)
342 598
(332 249 to 351 506)
32·56*
(29·98 to 35·15)
4517·1
(4367·3 to 4643·1)
4702·6
(4560·0 to 4824·8)
4·12*
(2·12 to 6·09)
Glucose-6-phosphate 
dehydrogenase 
deﬁ ciency
229 334
(223 528 to 234 741)
337 629
(329 361 to 345 754)
47·07*
(42·12 to 51·95)
4204·1
(4098·7 to 4302·9)
4681·7
(4567·5 to 4794·1)
11·36*
(7·61 to 
15·07)
Dermatitis 240 442
(208 170 to 274 870)
333 785
(289 927 to 381 312)
38·67*
(36·19 to 41·13)
4703·3 (4071·6 to 
5360·8)
4624·8
(4027·5 to 5266·9)
–1·69*
(–2·38 to 
–0·91)
Chronic obstructive 
pulmonary disease
198 729
(192 134 to 205 570)
328 504
(317 289 to 339 461)
65·13*
(63·80 to 66·27)
4877·7
(4717·9 to 5048·5)
4903·8
(4741·7 to 5066·9)
0·51
(–0·22 to 
1·20)
Chronic hepatitis B 
infection
333 998
(328 310 to 339 584)
316 130
(310 691 to 321 470)
–5·42*
(–7·86 to –3·34)
6493·4
(6379·5 to 6608·3)
4411·5
(4336·6 to 4484·3)
–32·06*
(–33·73 to 
–30·55)
Individuals with 
recurrent premenstrual 
syndrome
196 514
(185 656 to 207 309)
302 732
(284 373 to 321 830)
53·81*
(40·29 to 67·91)
3681·4
(3472·5 to 3887·0)
4025·8
(3779·5 to 4277·6)
9·19
(–0·11 to 
19·41)
Schistosomiasis 219 167
(196 779 to 240 733)
290 628
(252 099 to 337 576)
30·91*
(22·86 to 51·91)
4102·9
(3681·7 to 4505·7)
3998·7
(3468·8 to 4644·8)
–3·69
(–9·69 to 
11·81)
Anxiety disorders 186 837
(148 567 to 228 275)
265 610
(213 015 to 318 817)
42·41*
(36·64 to 46·75)
3706·3
(3001·6 to 4451·5)
3689·2
(2994·3 to 4415·8)
–0·46
(–1·75 to 
0·80)
Sickle cell trait 166 448
(158 185 to 174 094)
261 741
(249 515 to 272 736)
57·01*
(54·22 to 59·66)
3037·0
(2886·3 to 3175·9)
3624·1
(3454·7 to 3776·5)
19·26*
(17·14 to 
21·31)
Major depressive 
disorder
164 643
(136 031 to 195 432)
253 314
(208 457 to 299 691)
53·43*
(49·05 to 58·91)
3409·2
(2812·9 to 4021·7)
3554·7
(2922·5 to 4188·2)
4·24*
(2·37 to 6·17)
Edentulism and severe 
tooth loss
171 998
(169 934 to 174 085)
250 684
(247 512 to 253 463)
45·60*
(43·36 to 47·94)
4845·5
(4788·0 to 4903·4)
4049·5
(4000·7 to 4093·8)
–16·44*
(–17·70 to 
–15·10)
Other musculoskeletal 
disorders
138 898
(121 127 to 157 325)
248 188
(216 691 to 281 934)
78·35 *
(74·99 to 82·54)
3439·0
(2996·0 to 3888·5)
3669·5
(3221·0 to 4140·9)
6·63*
(4·96 to 
8·88)
Osteoarthritis 140 495
(139 147 to 141 802)
241 825
(239 656 to 243 897)
71·94*
(69·79 to 74·29)
3939·1
(3901·3 to 3974·8)
3837·9
(3802·1 to 3871·0)
–2·58*
(–3·81 to 
–1·22)
Asthma 182 776
(180 098 to 185 615)
241 695
(238 151 to 245 465)
32·10*
(29·46 to 34·91)
3626·9
(3576·7 to 3678·6)
3429·7
(3381·0 to 3481·1)
–5·48*
(–7·24 to 
–3·46)
Falls 141 364
(140 330 to 142 427)
232 033
(230 024 to 233 795)
64·14*
(62·46 to 65·66)
2316·5
(2300·0 to 2333·7)
2353·1
(2332·1 to 2372·2)
1·58*
(0·45 to 2·55)
Thalassaemia trait 151 187
(138 147 to 169 166)
207 562
(192 411 to 228 438)
37·33*
(34·66 to 39·59)
2820·3
(2569·0 to 3163·5)
2891·8
(2679·2 to 3184·4)
2·65*
(0·49 to 4·54)
Peripheral vascular 
disease
104 476
(99 440 to 109 950)
185 137
(172 556 to 196 597)
77·98*
(59·95 to 91·18)
2972·2
(2834·7 to 3117·3)
2958·7
(2765·2 to 3128·2)
–0·12
(–9·93 to 
6·69)
Chronic kidney disease 
due to other causes
112 461
(89 218 to 141 835)
173 091
(142 396 to 213 010)
53·86*
(43·54 to 63·60)
2507·9
(2023·0 to 3103·0)
2574·6
(2135·9 to 3149·8)
3·12
(–5·89 to 
10·11)
Uterine ﬁ broids 105 090
(97 076 to 112 367)
171 005
(158 156 to 182 513)
62·46*
(61·24 to 63·78)
2359·7
(2188·2 to 2513·2)
2320·3
(2145·8 to 2475·9)
–1·77*
(–2·33 to 
–1·18)
Chronic hepatitis C 
infection
126 203
(124 380 to 128 156)
146 576
(144 285 to 148 813)
16·04*
(13·61 to 18·52)
2741·8
(2705·6 to 2781·7)
2103·1
(2070·7 to 2134·4)
–23·31*
(–24·84 to 
–21·67)
(Table 4 continues on next page)
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Cases in 1990 (× 1000) Cases in 2013 
(× 1000)
Percentage 
change
Age-standardised 
rate in 1990 
(per 100 000)
Age-standardised 
rate in 2013 
(per 100 000)
Percentage 
change
(Continued from previous page)
Other sense organ 
diseases
108 541
(101 217 to 114 894)
145 834
(135 459 to 154 591)
34·19*
(32·51 to 36·15)
2093·6
(1952·4 to 2216·4)
2090·7
(1942·0 to 2216·7)
–0·17
(–1·35 to 
1·19)
Viral skin diseases 105 924
(87 145 to 124 492)
127 924
(105 593 to 151 636)
20·52*
(17·90 to 24·28)
1805·2
(1487·3 to 2132·6)
1772·1
(1473·3 to 2085·9)
–1·84*
(–3·15 to 
–0·31)
Other mental and 
substance use 
disorders
81 356
(76 311 to 86 284)
124 043
(116 741 to 131 002)
52·34*
(50·95 to 53·76)
1717·0
(1617·4 to 1812·8)
1720·4
(1620·4 to 1816·8)
0·19*
(0·10 to 0·30)
Polycystic ovarian 
syndrome
80 815
(79 286 to 82 412)
122 311
(119 573 to 124 929)
51·11*
(46·63 to 55·58)
1599·8
(1569·8 to 1629·7)
1637·8
(1601·5 to 1672·9)
2·31
(–0·60 to 
5·22)
Iodine deﬁ ciency 130 223
(124 180 to 136 611)
115 602
(110 007 to 120 997)
–11·39*
(–16·77 to –5·38)
2511·9
(2389·3 to 2643·9)
1586·1
(1508·9 to 1660·3)
–36·95*
(–40·87 to 
–32·55)
Chronic kidney disease 
due to 
glomerulonephritis
82 920
(65 067 to 102 663)
108 861
(88 330 to 135 482)
32·70*
(17·31 to 41·29)
1866·1
(1487·2 to 2359·9)
1590·2
(1295·8 to 1966·7)
–13·54*
(–25·56 to 
–6·59)
Dysthymia 66 141
(58 829 to 73 600)
102 410
(91 246 to 113 441)
54·62*
(52·39 to 57·20)
1457·3
(1309·0 to 1611·6)
1453·8
(1301·4 to 1609·6)
–0·27
(–1·25 to 
0·66)
Chronic kidney disease 
due to hypertension
79 945
(61 412 to 104 029)
101 253
(81 410 to 129 993)
26·77*
(18·34 to 34·91)
1634·3
(1283·0 to 2038·2)
1453·8
(1181·4 to 1844·3)
–10·74*
(–17·59 to 
–5·28)
Benign prostatic 
hyperplasia
55 230
(54 318 to 56 058)
99 148
(97 356 to 100 912)
79·29*
(75·37 to 83·71)
1602·7
(1576·4 to 1627·1)
1652·0
(1622·3 to 1681·8)
3·01*
(0·76 to 5·59)
Other cardiovascular 
and circulatory 
diseases
41 600
(29 939 to 54 543)
95 225
(67 433 to 121 734)
130·23*
(53·89 to 234·75)
1068·1
(763·1 to 1402·6)
1446·1
(1024·4 to 1845·6)
36·40
(–8·60 to 
98·75)
Idiopathic intellectual 
disability
76 996
(59 712 to 95 120)
94 673
(75 907 to 116 665)
22·62*
(12·75 to 35·78)
1383·1
(1070·1 to 1714·1)
1305·1
(1044·9 to 1610·0)
–5·77
(–13·46 to 
4·42)
Ischaemic heart disease 
(post-myocardial 
infarction, angina, or 
heart failure)
56 161
(54 049 to 58 489)
92 521
(89 680 to 95 453)
64·71*
(56·94 to 72·15)
1603·1
(1545·1 to 1666·1)
1518·7
(1472·5 to 1566·5)
–5·24*
(–9·61 to 
–0·95)
Chronic kidney disease 
due to diabetes 
mellitus
49 339
(38 328 to 65 278)
88 711
(71 150 to 111 417)
82·45*
(58·65 to 96·83)
1230·2
(951·3 to 1662·1)
1354·9
(1095·5 to 1684·8)
11·85
(–3·59 to 
21·19)
Food-borne 
trematodiases
52 958
(41 937 to 64 062)
80 195
(64 648 to 96 212)
51·08*
(44·23 to 59·68)
1130·9
(892·4 to 1370·7)
1131·2
(906·9 to 1356·0)
–0·14
(–4·77 to 
5·56)
Urticaria 49 676
(47 217 to 52 480)
79 583
(72 812 to 86 296)
60·53*
(44·16 to 74·98)
1061·1
(1007·6 to 1119·3)
1133·2
(1041·5 to 1225·4)
7·33
(–3·79 to 
16·59)
Endocrine, metabolic, 
blood, and immune 
disorders
72 090
(70 251 to 73 866)
79 556
(77 363 to 81 282)
10·27*
(6·92 to 13·83)
1351·4
(1317·8 to 1386·1)
1132·0
(1101·3 to 1156·0)
–16·24*
(–18·76 to 
–13·65)
Urolithiasis 38 598
(30 507 to 47 160)
78 780
(59 732 to 101 143)
103·76*
(91·18 to 115·17)
1017·3
(810·9 to 1245·6)
1226·8
(931·1 to 1557·7)
20·80*
(13·50 to 
26·90)
Alcohol dependence 57 161
(54 423 to 60 107)
76 897
(73 454 to 80 492)
34·38*
(32·30 to 36·42)
1132·4
(1085·9 to 1186·8)
1046·8
(1001·6 to 1094·8)
–7·57*
(–8·78 to 
–6·50)
Other exposure to 
mechanical forces
62 216
(61 710 to 62 739)
76 514
(75 819 to 77 259)
22·98*
(21·63
to 24·51)
1077·0
(1068·9 to 1085·8)
888·7
(880·6 to 897·6)
–17·49*
(–18·38 to 
–16·47)
Causes are ordered by overall prevalence. All data are shown with 95% uncertainty intervals. *Signiﬁ cant percentage change.
Table 4: Global prevalence of chronic sequelae (for longer than 3 months) by cause for prevalence greater than 1%
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counts of the number of sequelae for each simulant in 
the population. The numbers of simulants with diﬀ erent 
comorbidities in a country–age–sex–year was adjusted 
from 40 000 to equal the estimated population in each 
country–age–sex–year to produce the estimated 
distribution of individuals in each country with co-
morbidities. Sequelae with a prevalence of less than one 
in 20 000 that were not included in the microsimulation, 
are also not included in the population pyramids showing 
individuals by numbers of sequelae (ﬁ gure 2A–C). A 
technical description of the comorbidity simulation is 
given in the appendix p 2.
We have reported 95% uncertainty intervals for each 
quantity in this analysis. For disease or sequelae 
incidence or prevalence rates, age-standardised rates or 
counts, the models such as DisMod-MR 2.0 provide 
posterior distributions for each quantity from which 95% 
uncertainty intervals are computed. For YLDs, we 
Total  prevalence (× 1000) Total  YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Mild Moderate Severe
Iron-deﬁ ciency 
anaemia
1 211 369·9 (66·23%) 1 208 360·1 (62·57%) 40 035·5 (64·55%) 36 612·3 (59·51%) 607 890·7 (31·48%) 554 264·6 (28·70%) 46 204·8 (2·39%)
Thalassaemia trait 75 180·1 (4·11%) 104 232·6 (5·40%) 2799·6 (4·51%) 3769·6 (6·13%) 39 777·1 (2·06%) 59 937·8 (3·10%) 4517·7 (0·23%)
Malaria 57 969·1 (3·17%) 80 602·4 (4·17%) 2196·1 (3·54%) 2935·0 (4·77%) 32 347·0 (1·67%) 43 872·2 (2·27%) 4383·2 (0·23%)
Gastritis and 
duodenitis
56 836·8 (3·11%) 63 222·9 (3·27%) 2092·4 (3·37%) 2204·4 (3·58%) 24 768·2 (1·28%) 35 623·0 (1·84%) 2831·7 (0·15%)
Other neglected 
tropical diseases
62 877·1 (3·44%) 59 728·3 (3·09%) 2244·9 (3·62%) 2048·5 (3·33%) 25 996·2 (1·35%) 31 016·3 (1·61%) 2715·8 (0·14%)
Other 
haemoglobinopathies 
and haemolytic 
anaemias
57 242·2 (3·13%) 55 804·0 (2·89%) 1566·7 (2·53%) 1325·5 (2·15%) 34 620·5 (1·79%) 19 594·8 (1·01%) 1588·7 (0·08%)
Other infectious 
diseases
52 324·3 (2·86%) 49 771·4 (2·58%) 1742·5 (2·81%) 1542·4 (2·51%) 24 500·4 (1·27%) 23 327·5 (1·21%) 1943·4 (0·10%)
Endocrine, metabolic, 
blood, and immune 
disorders
49 928·4 (2·73%) 49 327·8 (2·55%) 1549·8 (2·50%) 1376·0 (2·24%) 27 203·1 (1·41%) 20 280·1 (1·05%) 1844·7 (0·10%)
Sickle cell trait 29 862·3 (1·63%) 43 353·9 (2·24%) 1003·5 (1·62%) 1396·6 (2·27%) 20 041·4 (1·04%) 21 564·0 (1·12%) 1748·5 (0·09%)
Uterine ﬁ broids 28 043·2 (1·53%) 36 833·7 (1·91%) 1106·6 (1·78%) 1304·9 (2·12%) 21 328·2 (1·10%) 14 540·7 (0·75%) 964·8 (0·05%)
Hookworm disease 32 039·8 (1·75%) 34 579·6 (1·79%) 1021·8 (1·65%) 1004·0 (1·63%) 18 037·6 (0·93%) 15 308·0 (0·79%) 1233·9 (0·06%)
Peptic ulcer disease 34 671·6 (1·90%) 32 726·7 (1·69%) 980·6 (1·58%) 974·6 (1·58%) 14 995·6 (0·78%) 16 717·0 (0·87%) 1014·1 (0·05%)
Chronic kidney disease 
due to other causes
16 459·1 (0·90%) 26 007·2 (1·35%) 857·2 (1·38%) 1330·6 (2·16%) 13 154·8 (0·68%) 12 140·3 (0·63%) 712·1 (0·04%)
Schistosomiasis 14 488·1 (0·79%) 20 635·1 (1·07%) 485·3 (0·78%) 671·0 (1·09%) 9546·6 (0·49%) 10 151·0 (0·53%) 937·5 (0·05%)
Other gynaecological 
diseases
15 576·9 (0·85%) 17 383·2 (0·90%) 462·8 (0·75%) 448·6 (0·73%) 9842·0 (0·51%) 7108·8 (0·37%) 432·4 (0·02%)
Chronic kidney disease 
due to hypertension
10 850·3 (0·59%) 14 142·6 (0·73%) 587·6 (0·95%) 733·8 (1·19%) 7986·0 (0·41%) 5738·2 (0·30%) 418·5 (0·02%)
Chronic kidney disease 
due to 
glomerulonephritis
11 180·9 (0·61%) 14 059·9 (0·73%) 613·3 (0·99%) 745·9 (1·21%) 6924·4 (0·36%) 6557·2 (0·34%) 578·3 (0·03%)
Chronic kidney disease 
due to diabetes 
mellitus
6569·6 (0·36%) 12 116·3 (0·63%) 348·0 (0·56%) 606·6 (0·99%) 8024·2 (0·42%) 3545·8 (0·18%) 546·3 (0·03%)
Sickle cell disorders 1801·5 (0·10%) 3185·0 (0·16%) 182·5 (0·29%) 321·4 (0·52%) 434·2 (0·02%) 2176·5 (0·11%) 574·3 (0·03%)
Glucose-6-phosphate 
dehydrogenase 
deﬁ ciency trait
1253·7 (0·07%) 1983·8 (0·10%) 39·5 (0·06%) 48·8 (0·08%) 1196·4 (0·06%) 732·9 (0·04%) 54·5 (0·00%)
Maternal haemorrhage 1388·0 (0·08%) 1858·5 (0·10%) 39·4 (0·06%) 45·1 (0·07%) 1099·8 (0·06%) 724·4 (0·04%) 34·4 (0·00%)
Glucose-6-phosphate 
dehydrogenase 
deﬁ ciency
519·3 (0·03%) 743·5 (0·04%) 24·9 (0·04%) 33·8 (0·05%) 389·7 (0·02%) 205·3 (0·01%) 148·5 (0·01%)
Thalassaemias 509·8 (0·03%) 544·2 (0·03%) 43·2 (0·07%) 46·2 (0·08%) 31·2 (0·00%) 375·4 (0·02%) 137·5 (0·01%)
Total prevalence 1 828 942·2 (100·00%) 1 931 202·6 (100·00%) ·· ·· 950 135·2 (49·20%) 905 501·8 (46·89%) 75 565·6 (3·91%)
Total YLDs ·· ·· 62 023·8 (100·00%) 61 525·6 (100·00%) 4298·6 (6·99%) 46 287·9 (75·23%) 10 939·1 (17·78%)
Data are number (%). YLDs=years lived with disability. 
Table 5: Prevalence and YLDs, with percentage of total, for anaemia by cause in 1990 and 2013, and prevalence by severity in 2013
Articles
www.thelancet.com   Vol 386   August 22, 2015 761
incorporated uncertainty in prevalence and uncertainty 
in the disability weight into the posterior distribution of 
YLDs. In practice, we estimated the posterior distribution 
of YLDs by taking 1000 samples from the posterior 
distribution of prevalence and 1000 samples of the 
disability weight to generate 1000 samples of the YLD 
distribution. We estimated the 95% uncertainty interval 
by reporting the 25th and 975th values of the distribution. 
Uncertainty intervals for YLDs at diﬀ erent timepoints 
(1990, 1995, 2000, 2005, 2010, and 2013) for a particular 
disease or sequela are correlated because of the shared 
uncertainty in the disability weight.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Figure 2A–C shows the population pyramid for developed 
countries, developing countries excluding sub-Saharan 
Africa, and sub-Saharan Africa in 1990 and 2013 broken 
down by the number of sequelae, ranging from none to 
more than ten sequelae. Most of the world’s population 
had at least one of the GBD sequelae and most people 
had several. As expected, in view of the strong relation 
between age and disease prevalence for most non-
communicable diseases and injuries, the number of 
individuals with several morbidities rapidly increased 
with age. In developed countries in 2013, 35·9% of the 
age group 0–4 years had no sequelae with only 0·03% 
older than 80 years with no sequelae (ﬁ gure 2A). In the 
age group older than 80 years, 10·3% had one to four 
sequelae, 64·6% had ﬁ ve to nine sequelae and 25·1% 
had ten or more sequelae in 2013. The percentage of each 
age group with several morbidities rose progressively 
with age irrespective of the cutoﬀ  used to deﬁ ne several 
morbidities. Due to this relation and the demographic 
shifts towards older ages in developed countries, the 
number of individuals with more than ten sequelae 
increased by 51·6% from 1990 to 2013. In the oldest age 
group, 23·6% of women and 27·8% of men had more 
than ten sequelae, but the large population imbalance at 
older age favouring women meant that there were 
1·4 times more women than men with ten or more 
sequelae.
Figure 2B shows the pyramids for developing countries 
outside of sub-Saharan Africa, showing that the birth 
cohorts in 2013 were smaller than in 1990. The major 
demographic change was the large expansion of adults in 
the age groups 20–54 years for men and women from 
1990 to 2013. Comparison of 1990 and 2013 showed little 
change in the distribution of the population in each age 
group by the number of sequelae. Rising numbers with 
several morbidities were attributable to ageing. 20·3% of 
the age group 0–4 years and 0·05% older than 80 years 
had no sequelae. In the oldest age group, 12·5% had one 
to four sequelae, 63·9% had ﬁ ve to nine sequelae, and 
23·5% had ten or more sequelae.
As shown in ﬁ gure 2C, the main result was the massive 
growth in population in sub-Saharan African countries 
from 1990 to 2013 and continued pattern of a low 
percentage of the population at older ages driven by high 
fertility and high mortality. Due to several very common 
sequelae that start early in life such as anaemia, 
soil-transmitted helminths, and schisto somiasis, only 
Total  prevalence (× 1000) Total  YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Mild Moderate to severe Profound Complete
Age-related and other 
hearing loss
726 118·3 
(89·96%)
1 130 192·3 
(92·15%)
21 632·6 (86·18%) 32 579·7 (89·37%) 738 005·5 (60·18%) 383 964·4 (31·31%) 1942·7 (0·16%) 6279·8 (0·51%)
Otitis media 56 391·6 
(6·99%)
67 316·9 
(5·49%)
1243·9 (4·96%) 1460·9 (4·01%) 53 201·4 (4·34%) 14 115·5 (1·15%) ·· -
Other congenital 
anomalies
21 013·1 
(2·60%)
25 851·8 
(2·11%)
2065·5 (8·23%) 2299·6 (6·31%) 7654·1 (0·62%) 15278·5 (1·25%) 1232·5 (0·10%) 1686·7 (0·14%)
Pneumococcal 
meningitis
1504·6 
(0·19%)
14 34·1 
(0·12%)
64·4 (0·26%) 51·5 (0·14%) 871·4 (0·07%) 540·1 (0·04%) 14·3 (0·00%) 8·4 (0·00%)
Haemophilus influenzae 
type B meningitis
896·9
(0·11%)
686·1 
(0·06%)
41·4 (0·16%) 27·0 (0·07%) 403·2 (0·03%) 268·7 (0·02%) 9·0 (0·00%) 5·1 (0·00%)
Other meningitis 834·1
(0·10%)
622·5
(0·05%)
36·5 (0·15%) 22·8 (0·06%) 376·5 (0·03%) 235·9 (0·02%) 5·4 (0·00%) 4·6 (0·00%)
Meningococcal 
meningitis
399·2
(0·05%)
315·8
(0·03%)
17·1 (0·07%) 11·7 (0·03%) 198·1 (0·02%) 111·0 (0·01%) 4·8 (0·00%) 1·9 (0·00%)
Total prevalence 807 157·8 
(100·00%)
1 226 419·6 
(100·00%)
·· ·· 800 710·3 (65·29%) 414 514·1 (33·80%) 3208·7 (0·26%) 7986·5 (0·65%)
Total YLDs ·· ·· 25 101·4 
(100·00%)
36 453·1 
(100·00%)
9331·4 (25·60%) 24 390·2 (66·91%) 773·9 (2·12%) 1957·6 (5·37%)
Data are number (%). YLDs=years lived with disability.
Table 6: Prevalence and YLDs, with percentage of total, for hearing impairment by cause in 1990 and 2013, and prevalence by severity in 2013
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7·8% of the age group 0–4 years and 0·002% at age 
80 years and older in sub-Saharan Africa had no sequelae 
in 2013. Although there were few individuals reaching 
the oldest age groups, in the population aged 80 years 
and older, 1·9% had one to four sequelae, 42·6% had 
ﬁ ve to nine, and 55·5% had ten or more sequelae, which 
were higher than in developed countries. Multiple 
morbidities were also common in all regions in working 
age adults (20–64 years): 31·7% with ﬁ ve or more 
sequelae in developed countries, 37·9% in developing 
countries outside of sub-Saharan Africa, and 61·6% in 
sub-Saharan Africa. Of the 2·3 billion individuals in 
2013 with more than ﬁ ve sequelae, 81·4% were younger 
than 65 years.
The comprehensive and systematic nature of GBD 
provides an opportunity to assess the most common 
acute disorders aﬀ ecting people around the world and 
the trends from 1990 to 2013. Table 3 shows the 65 causes 
of acute disease (<3 months’ duration) and injury 
incidence with more than 1 million cases per year in 
2013. For the causes with more than one acute sequela, 
such as typhoid fever (acute infection, intestinal 
perforation, and intestinal bleeding), maternal sepsis 
(puerperal sepsis and other maternal infections), or 
hypertension in pregnancy (eclampsia, pre-eclampsia, 
and other hypertensive disorders in pregnancy), we 
aggregated all the acute sequelae for a cause for 
presentation in table 3. Of note, there are two disorders 
Total  prevalence (× 1000) Total  YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Mild Moderate Severe
Ischaemic heart disease 10 298·9 (32·79%) 20 372·6 (33·04%) 1114·3 (25·51%) 2216·1 (25·89%) 5055·3 (8·20%) 4131·3 (6·70%) 11 186·1 (18·14%)
Hypertensive heart 
disease
5128·4 (16·33%) 10 906·9 (17·69%) 559·1 (12·80%) 1193·9 (13·95%) 2707·3 (4·39%) 2215·8 (3·59%) 5983·8 (9·70%)
Other cardiovascular 
and circulatory diseases
4117·6 (13·11%) 9542·1 (15·48%) 448·9 (10·28%) 1042·6 (12·18%) 2356·1 (3·82%) 1945·8 (3·16%) 5240·3 (8·50%)
Cardiomyopathy and 
myocarditis
4077·6 (12·98%) 7629·9 (12·37%) 451·9 (10·35%) 847·9 (9·91%) 1880·1 (3·05%) 1553·8 (2·52%) 4196·1 (6·81%)
Chronic obstructive 
pulmonary disease
3036·5 (9·67%) 5846·4 (9·48%) 1222·0 (27·98%) 2366·4 (27·65%) 1438·2 (2·33%) 1201·5 (1·95%) 3206·8 (5·20%)
Rheumatic heart 
disease
2837·8 (9·04%) 4274·0 (6·93%) 316·2 (7·24%) 473·2 (5·53%) 1055·5 (1·71%) 873·1 (1·42%) 2345·5 (3·80%)
Endocrine, metabolic, 
blood, and immune 
disorders
338·2 (1·08%) 852·4 (1·38%) 39·2 (0·90%) 97·3 (1·14%) 208·1 (0·34%) 174·2 (0·28%) 470·1 (0·76%)
Congenital heart 
anomalies
495·9 (1·58%) 621·7 (1·01%) 60·0 (1·37%) 74·8 (0·87%) 152·2 (0·25%) 126·8 (0·21%) 342·7 (0·56%)
Iron-deﬁ ciency 
anaemia
373·2 (1·19%) 446·6 (0·72%) 43·1 (0·99%) 51·2 (0·60%) 110·1 (0·18%) 90·8 (0·15%) 245·7 (0·40%)
Chagas disease 280·1 (0·89%) 383·9 (0·62%) 31·4 (0·72%) 42·9 (0·50%) 95·3 (0·15%) 78·3 (0·13%) 210·3 (0·34%)
Endocarditis 136·2 (0·43%) 250·2 (0·41%) 15·7 (0·36%) 29·1 (0·34%) 61·6 (0·10%) 50·9 (0·08%) 137·6 (0·22%)
Other 
haemoglobinopathies 
and haemolytic 
anaemias
93·0 (0·30%) 216·6 (0·35%) 11·0 (0·25%) 25·2 (0·29%) 52·9 (0·09%) 44·3 (0·07%) 119·4 (0·19%)
Thalassaemias 96·4 (0·31%) 117·8 (0·19%) 11·9 (0·27%) 14·5 (0·17%) 29·3 (0·05%) 23·8 (0·04%) 64·7 (0·10%)
Interstitial lung disease 
and pulmonary 
sarcoidosis
51·3 (0·16%) 102·1 (0·17%) 24·3 (0·56%) 48·1 (0·56%) 25·2 (0·04%) 20·8 (0·03%) 56·2 (0·09%)
Other pneumoconiosis 16·2 (0·05%) 37·7 (0·06%) 7·8 (0·18%) 18·0 (0·21%) 9·3 (0·02%) 7·7 (0·01%) 20·7 (0·03%)
Glucose-6-phosphate 
dehydrogenase 
deﬁ ciency
8·1 (0·03%) 20·4 (0·03%) 1·0 (0·02%) 2·5 (0·03%) 5·0 (0·01%) 4·1 (0·01%) 11·3 (0·02%)
Silicosis 10·8 (0·03%) 16·2 (0·03%) 5·2 (0·12%) 7·8 (0·09%) 4·0 (0·01%) 3·3 (0·01%) 8·9 (0·01%)
Coal workers’ 
pneumoconiosis
5·8 (0·02%) 9·0 (0·01%) 2·8 (0·06%) 4·3 (0·05%) 2·2 (0·00%) 1·8 (0·00%) 5·0 (0·01%)
Iodine deﬁ ciency 4·3 (0·01%) 6·9 (0·01%) 0·6 (0·01%) 0·9 (0·01%) 1·7 (0·00%) 1·4 (0·00%) 3·8 (0·01%)
Asbestosis 2·4 (0·01%) 4·1 (0·01%) 1·1 (0·03%) 2·0 (0·02%) 1·0 (0·00%) 0·8 (0·00%) 2·2 (0·00%)
Total prevalence 31 408·5 (100·00%) 61 657·6 (100·00%) ·· ·· 15 250·2 (24·73%) 12 550·3 (20·35%) 33 857·1 (54·91%)
Total YLDs ·· ·· 4367·4 (100·00%) 8558·7 (100·00%) 1069·3 (12·49%) 1211·1 (14·15%) 6278·2 (73·35%)
Data are number (%). YLDs=years lived with disability.
Table 7: Prevalence and YLDs, with percentage of total, for heart failure by cause in 1990 and 2013, and prevalence by severity in 2013
Articles
www.thelancet.com   Vol 386   August 22, 2015 763
with an incidence of greater than 2 billion in 2013: upper 
respiratory infections (18·8 billion) and diarrhoeal 
diseases (2·7 billion). Another 12 diseases and injuries 
accounted for between 100 million to 1 billion incident 
cases per year in 2013: injuries due to other exposure to 
mechanical force, acute otitis media, tooth pain due to 
Total  prevalence (× 1000) Total  YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Borderline Mild Moderate Severe Profound
Idiopathic intellectual 
disability
77 102·5 
(65·24%)
94 680·0 
(61·47%)
3822·3 
(38·30%)
4666·7 
(31·46%)
32 937·9 (21·38%) 38 873·1 (25·24%) 14 804·3 (9·61%) 5946·2 (3·86%) 2118·5 (1·38%)
Preterm birth 
complications
5913·0 
(5·00%)
13 576·3 
(8·81%)
558·1 
(5·59%)
1450·4 
(9·78%)
·· 11 480·7 (7·45%) 1277·6 (0·83%) 535·2 (0·35%) 282·8 (0·18%)
Chromosomal 
unbalanced 
rearrangements
6398·2 
(5·41%)
11 171·7 
(7·25%)
859·1 
(8·61%)
1590·4 
(10·72%)
1411·6 (0·92%) 3733·1 (2·42%) 3038·7 (1·97%) 1953·8 (1·27%) 1034·5 (0·67%)
Neonatal 
encephalopathy due to 
birth asphyxia and 
trauma
9520·3 
(8·06%)
8947·4 
(5·81%)
892·5 
(8·94%)
1228·3 
(8·28%)
·· 7128·4 (4·63%) 833·1 (0·54%) 645·2 (0·42%) 340·8 (0·22%)
Down’s syndrome 4546·4 
(3·85%)
8184·4 
(5·31%)
605·6 
(6·07%)
1157·9 
(7·81%)
1034·0 (0·67%) 2735·1 (1·78%) 2226·2 (1·45%) 1431·3 (0·93%) 757·8 (0·49%)
Ischaemic stroke 2686·4 
(2·27%)
4887·1 
(3·17%)
967·9 
(9·70%)
1764·2 
(11·89%)
·· ·· 2978·2 (1·93%) 1248·5 (0·81%) 660·3 (0·43%)
Pneumococcal 
meningitis
3132·6 
(2·65%)
2803·2 
(1·82%)
382·2 
(3·83%)
344·8 
(2·32%)
751·6 (0·49%) 1213·6 (0·79%) 420·8 (0·27%) 272·9 (0·18%) 144·2 (0·09%)
Haemorrhagic stroke 1040·8 
(0·88%)
1966·8 
(1·28%)
386·6 
(3·87%)
728·8 
(4·91%)
·· ·· 1197·3 (0·78%) 503·4 (0·33%) 266·1 (0·17%)
Haemolytic disease and 
other neonatal jaundice
768·3 
(0·65%)
1400·5 
(0·91%)
425·5 
(4·26%)
781·8 
(5·27%)
·· ·· 641·8 (0·42%) 496·4 (0·32%) 262·2 (0·17%)
Alcohol use disorders 1000·8 
(0·85%)
1382·2 
(0·90%)
62·3 
(0·62%)
85·8 
(0·58%)
383·1 (0·25%) 791·2 (0·51%) 126·6 (0·08%) 81·3 (0·05%) -
Haemophilus inﬂ uenzae 
type B meningitis
1654·4 
(1·40%)
1309·6 
(0·85%)
244·5 
(2·45%)
206·7 
(1·39%)
443·4 (0·29%) 329·0 (0·21%) 270·5 (0·18%) 174·5 (0·11%) 92·2 (0·06%)
Other meningitis 1406·9 
(1·19%)
1050·2 
(0·68%)
220·9 
(2·21%)
172·3 
(1·16%)
340·7 (0·22%) 265·1 (0·17%) 222·5 (0·14%) 145·2 (0·09%) 76·7 (0·05%)
Encephalitis 873·4 
(0·74%)
886·6 
(0·58%)
120·7 
(1·21%)
131·3 
(0·88%)
337·7 (0·22%) 223·7 (0·15%) 162·7 (0·11%) 106·3 (0·07%) 56·1 (0·04%)
Neural tube defects 293·7 
(0·25%)
477·9 
(0·31%)
151·8 
(1·52%)
246·1 
(1·66%)
·· ·· ·· 312·6 (0·20%) 165·3 (0·11%)
Meningococcal 
meningitis
538·7 
(0·46%)
429·2 
(0·28%)
90·4 
(0·91%)
75·3 
(0·51%)
128·2 (0·08%) 107·7 (0·07%) 96·5 (0·06%) 63·3 (0·04%) 33·5 (0·02%)
Syphilis 310·2 
(0·26%)
315·2 
(0·20%)
57·5 
(0·58%)
58·4 
(0·39%)
·· ·· 315·2 (0·20%) ·· ··
Sickle cell disorders 96·3
(0·08%)
197·0 
(0·13%)
39·4 
(0·39%)
79·9 
(0·54%)
·· ·· 197·0 (0·13%) ·· ··
Maternal hypertensive 
disorders
140·9 
(0·12%)
128·9 
(0·08%)
9·5
(0·10%)
8·8 
(0·06%)
·· 128·9 (0·08%) ·· ·· ··
Tetanus 580·2 
(0·49%)
71·6 
(0·05%)
30·7 
(0·31%)
5·9 
(0·04%)
·· 64·9 (0·04%) 3·1 (0·00%) 2·4 (0·00%) 1·2 (0·00%)
Malaria 45·5
(0·04%)
66·7 
(0·04%)
25·4 
(0·25%)
37·7 
(0·25%)
·· ·· 30·6 (0·02%) 23·6 (0·02%) 12·5 (0·01%)
Klinefelter’s syndrome 31·3
(0·03%)
44·5 
(0·03%)
0·5
(0·01%)
0·7 
(0·00%)
41·0 (0·03%) 3·5 (0·00%) ·· ·· ··
Iodine deﬁ ciency 60·0
(0·05%)
38·3 
(0·02%)
10·0 
(0·10%)
6·4 
(0·04%)
·· ·· ·· 28·5 (0·02%) 9·8 (0·01%)
African 
trypanosomiasis
33·8
(0·03%)
9·4
(0·01%)
16·5 
(0·17%)
4·7 
(0·03%)
·· ·· ·· 6·1 (0·00%) 3·2 (0·00%)
Total prevalence 118 174·6 
(100·00%)
154 024·7 
(100·00%)
·· ·· 37 809·3 (24·55%) 67 077·9 (43·55%) 28 842·6 (18·73%) 13977·0 (9·07%) 6317·9 (4·10%)
Total YLDs ·· ·· 9979·7 
(100·00%)
14 833·4
(100·00%)
722·4 (4·87%) 3209·3 (21·64%) 4925·1 (33·20%) 3963·3 (26·72%) 2013·3 (13·57%)
Data are number (%). YLDs=years lived with disability.
Table 8: Prevalence and YLDs, with percentage of total, for intellectual disability by cause in 1990 and 2013, and prevalence by severity in 2013
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caries of permanent teeth, bacterial skin diseases 
(including impetigo and abscess), falls; lower respiratory 
infections, clinical episodes of malaria, chlamydia 
infection, varicella (including chickenpox and herpes 
zoster episodes), acute hepatitis B, gallbladder and biliary 
tract disease, and acute hepatitis A. There were 
28 diseases and injuries with incident cases between 
10 million and 100 million per year including several 
injuries, such as non-venomous animal contact, motor 
vehicle road injuries, ﬁ re, heat, and hot substances, 
motorcycle and pedestrian injuries, and infections such 
as urinary tract infections, typhoid, hepatitis C and E, 
dengue, gonorrhoea, the initial episodes of genital 
herpes, trichomoniasis, and several disorders aﬀ ecting 
the digestive system, including gastritis and duodenitis, 
peptic ulcer disease, pancreatitis, and appendicitis.
Among the most common causes of acute disease 
incidence, 47 increased in absolute numbers of incident 
cases from 1990 to 2013 but only 13 had rising age-
standardised rates of which six had signiﬁ cant increases 
(upper respiratory infections, interstitial nephritis, 
urinary tract infections, dengue, pancreatitis, paralytic 
ileus, intestinal obstruction, and unintentional 
suﬀ ocation; table 3). Numbers declined for 18 of 
Total  prevalence (×1000) Total  YLDs (× 1000) Prevalence by severity in 2013 (×1000)
1990 2013 1990 2013 Moderate Severe Blind Presbyopia
Uncorrected refractive 
error
434 222·6 
(83·74%)
660 118·8 
(85·28%)
7831·1 (56·60%) 11 257·2 (56·00%) 80 451·8 (10·39%) 9943·1 (1·28%) 9482·0 (1·22%) 560 241·9 (72·38%)
Cataract 29 915·0 
(5·77%)
44 223·1 
(5·71%)
1860·6 (13·45%) 2916·7 (14·51%) 31 636·5 (4·09%) 4857·8 (0·63%) 7728·8 (1·00%) ··
Other vision loss 22 358·1 
(4·31%)
26 813·0 
(3·46%)
1450·4 (10·48%) 1793·5 (8·92%) 19 538·5 (2·52%) 2178·7 (0·28%) 5095·8 (0·66%) ··
Macular degeneration 7848·5 
(1·51%)
13 883·8 
(1·79%)
412·9 (2·98%) 725·6 (3·61%) 11 370·5 (1·47%) 1498·4 (0·19%) 1014·9 (0·13%) ··
Glaucoma 6692·0 
(1·29%)
10 900·1 
(1·41%)
495·7 (3·58%) 807·5 (4·02%) 7276·1 (0·94%) 984·4 (0·13%) 2639·6 (0·34%) ··
Preterm birth 
complications*
1844·4 
(0·36%)
4412·0 
(0·57%)
434·9 (3·14%) 1135·4 (5·65%) 1022·1 (0·13%) 563·4 (0·07%) 2359·9 (0·30%) ··
Diabetes mellitus 2631·4 
(0·51%)
3816·9 
(0·49%)
325·8 (2·35%) 477·0 (2·37%) 1098·8 (0·14%) 163·7 (0·02%) 2554·5 (0·33%) ··
Vitamin A deﬁ ciency 4181·5 
(0·81%)
3372·2 
(0·44%)
199·3 (1·44%) 153·7 (0·76%) 3014·5 (0·39%) 203·5 (0·03%) 154·2 (0·02%) ··
Trachoma 3983·4 
(0·77%)
2428·2 
(0·31%)
271·6 (1·96%) 171·2 (0·85%) 1659·4 (0·21%) 329·8 (0·04%) 439·0 (0·06%) ··
Onchocerciasis 1907·5 
(0·37%)
1183·8 
(0·15%)
127·3 (0·92%) 78·4 (0·39%) 856·5 (0·11%) 142·5 (0·02%) 184·8 (0·02%) ··
Pneumococcal 
meningitis*
950·3 
(0·18%)
863·9 
(0·11%)
42·5 (0·31%) 35·5 (0·18%) ·· ·· 136·9 (0·02%) ··
Neonatal encephalopathy 
due to birth asphyxia 
and trauma
293·6 
(0·06%)
478·3 
(0·06%)
158·5 (1·15%) 258·6 (1·29%) ·· ·· 478·3 (0·06%) ··
Other meningitis* 522·7 
(0·10%)
376·1 
(0·05%)
44·2 (0·32%) 30·7 (0·15%) ·· ·· 157·5 (0·02%) ··
Haemolytic disease and 
other neonatal jaundice
196·6 
(0·04%)
373·9 
(0·05%)
105·6 (0·76%) 201·6 (1·00%) ·· ·· 373·9 (0·05%) ··
Haemophilus inﬂ uenzae 
type B meningitis*
395·8 
(0·08%)
298·2 
(0·04%)
9·7 (0·07%) 6·8 (0·03%) ·· ·· 11·9 (0·00%) ··
Meningococcal 
meningitis*
358·2 
(0·07%)
270·0 
(0·03%)
46·0 (0·33%) 34·4 (0·17%) ·· ·· 191·3 (0·02%) ··
Encephalitis* 247·5 
(0·05%)
236·4 
(0·03%)
9·3 (0·07%) 8·1 (0·04%) ·· ·· 25·5 (0·00%) ··
Malaria 11·7
(0·00%)
17·3
(0·00%)
6·2 (0·04%) 9·2 (0·05%) ·· ·· 17·3 (0·00%) ··
Tetanus 6·3
(0·00%)
1·9
(0·00%)
3·4 (0·02%) 1·0 (0·00%) ·· ·· 1·9 (0·00%) ··
Total prevalence 518 567·1 
(100·00%)
774 067·8 
(100·00%)
·· ·· 157 924·6 (20·40%) 20 865·2 (2·70%) 33 048·1 (4·27%) 560 241·9 (72·38%)
Total YLDs ·· ·· 13 835·0 (100·00%) 20 102·2 (100·00%) 4565·7 (22·71%) 3425·7 (17·04%) 6434·4 (32·01%) 5650·6 (28·11%)
Data are number (%). YLDs=years lived with disability. *Mild and monocular vision impairment not listed, but estimates are included in totals. 
 Table 9: Prevalence and YLDs, with percentage of total, for vision impairment by cause in 1990 and 2013, and prevalence by severity in 2013
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65 causes in table 3, seven of which were infectious 
diseases that predominantly aﬀ ected children. Two were 
maternal disorders and for one, peptic ulcer disease, the 
decline was not signiﬁ cant. Some injuries such as non-
venomous animal contact, ﬁ re, heat, and hot substances, 
collective violence and legal intervention, exposure to 
forces of nature, venomous animal contact, poisoning, 
and drowning decreased in absolute incidence numbers. 
For 52 of 65 causes, age-standardised rates declined—for 
34 causes, numbers increased due to demographic 
change even though age-standardised rates declined. In 
the set of causes of more than 1 million cases per year, 
dengue had the most striking increase in the age-
standardised rates (447·3%; table 3).
Table 4 summarises the prevalence of chronic disease 
and injury sequelae (>3 months) aggregated to the cause 
level. This table provides a high-level view of the leading 
causes of chronic disorders worldwide for the 59 causes 
with a global prevalence of greater than 1% in 2013. 
Leading causes were a mixture of oral disorders, 
neurological disorders, skin diseases, musculoskeletal 
disorders, neglected tropical diseases, gynaecological 
disorders, chronic kidney disease, some causes of 
anaemia, age-related hearing, other vision loss, and 
injuries. Eight causes aﬀ ected more than 10% of the 
world population in 2013: permanent caries without 
pain, tension-type headaches, iron-deﬁ ciency anaemia, 
glucose-6-phosphate dehydrogenase deﬁ ciency trait, age-
related and other hearing loss, genital herpes without 
symptoms, migraine, and ascariasis. Another 51 causes 
aﬄ  icted between 1% and 10% of the world’s population. 
In this set of disorders were those that were not 
prominent causes of YLDs because the average disability 
weight was low, but they might have been important in 
terms of health system resources or health service 
planning. These disorders included glucose-6-phosphate 
dehydrogenase deﬁ ciency, genital prolapse, premenstrual 
syndrome, edentulism, polycystic ovary syndrome, 
uterine ﬁ broids, and several skin diseases.
Rates for only six causes of chronic disease 
(micronutrient deﬁ ciencies, worm infestations, and 
chronic hepatitis B; table 4) declined fast enough to lead 
to declines in the absolute numbers for each worldwide. 
As noted in table 3, several acute infectious diseases and 
other acute disorders also declined in absolute numbers. 
The numbers of cases increased for 17 other chronic 
disorders but there were signiﬁ cant reductions in age-
standardised rates: age-related and other hearing loss, 
Figure 3: Top 25 causes of global YLDs in 1990 and 2013
YLD=years lived with disability. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.
Communicable, maternal, neonatal, 
and nutritional disorders
Non-communicable diseases
Injuries
Mean rank 
(95% UI)
Mean rank 
(95% UI)
1990 leading causes Median percentage 
change
2013 leading causesMean YLDs
×1000
Mean YLDs
(×1000)
5827 22·9 (12–38) 23 Acne vulgaris
26 Acne vulgaris
5699 22·1 (17–26) 22 Alcohol use disorders
17 180 6·9 (4–9) 7 Anxiety disorders
8048 14·7 (12–19) 13 Asthma
6643 18·8 (13–26) 19 Bipolar disorder
15 151 7·9 (6–10) 8 COPD
5288 23·9 (17–31) 25 Conduct disorder
29 Conduct disorder
6780 18·5 (14–24) 17 Dermatitis
12 533 9·5 (8–11) 10 Diabetes
7362 16·2 (13–20) 15 Diarrhoeal diseases
6368 19·7 (15–24) 20 Dysthymia
5365 23·5 (18–29) 24 Epilepsy
10 337 11·6 (10–13) 11 Falls
40 079 2·0 (1–3) 2 Iron-deﬁciency anaemia
46 068 1·3 (1–2) 1 Low back pain
33 711 2·8 (1–4) 3 Major depression
19 805 5·8 (4–8) 6 Migraine
22 294 4·7 (4–6) 4 Neck pain
7307 16·4 (14–19) 16 Osteoarthritis
21 633 5·1 (3–7) 5 Other hearing loss
6076 20·6 (15–25) 21 Other mental and substance
12 672 9·5 (7–12) 9 Other musculoskeletal
7831 15·5 (10–23) 14 Refraction and accommodation
9995 12·0 (9–16) 12 Schizophrenia
7491 18·8 (8–36) 18 War and legal intervention
52 War and legal intervention
765423·0 (18–28)22 Alcohol use disorders 34% (32 to 37)
777422·2 (18–26)21 Alzheimer’s disease 92% (85 to 99)
28 Alzheimer’s disease
24 3568·5 (5–10)9 Anxiety disorders 42% (36 to 47)
10 59616·1 (12–21)15 Asthma 32% (29 to 35)
991117·5 (12–25)17 Bipolar disorder 49% (46 to 53)
26 1317·8 (4–10)8 COPD 72% (67 to 79)
927818·8 (15–25)20 Dermatitis 37% (35 to 39)
29 5186·7 (5–9)7 Diabetes 136% (127 to 144)
685426·1 (23–30)25 Diarrhoeal diseases –7% (–9 to –5)
984917·4 (14–21)16 Dysthymia 55% (52 to 57)
685625·9 (21–31)24 Edentulism 46% (43 to 48)
26 Edentulism
754423·2 (18–30)23 Epilepsy 41% (28 to 57)
12 81812·7 (12–14)12 Falls 23% (14 to 35)
36 6633·6 (2–6)3 Iron-deﬁciency anaemia –9% (–10 to –7)
72 3181·0 (1–1)1 Low back pain 57% (53 to 61)
51 7842·1 (2–4)2 Major depression 53% (49 to 59)
984617·8 (12–27)18 Medication overuse headache 120% (109 to 134)
27 Medication overuse headache
28 8986·6 (3–10)6 Migraine 46% (41 to 50)
34 3484·3 (3–6)4 Neck pain 54% (49 to 60)
12 81112·8 (11–15)13 Osteoarthritis 75% (73 to 78)
32 5805·3 (3–9)5 Other hearing loss 51% (45 to 55)
925718·5 (14–24)19 Other mental and substance 52% (50 to 54)
22 6449·2 (7–10)10 Other musculoskeletal 79% (75 to 83)
11 25715·5 (11–22)14 Refraction and accommodation 44% (40 to 47)
15 20411·5 (11–15)11 Schizophrenia 52% (50 to 54)
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genital herpes, uncorrected refractive error, deciduous 
caries without pain, dermatitis, edentulism and severe 
tooth loss, osteoarthritis, uterine ﬁ broids, chronic 
hepatitis C, viral skin diseases, chronic kidney disease 
due to hypertension, ischaemic heart disease (angina, 
post-myocardial infarction, and heart failure), alcohol 
use disorders, asthma, chronic kidney disease due to 
glomerulonephritis, injury due to other exposure to 
mechanical forces, and endocrine, metabolic, blood, and 
immune disorders. Five chronic disease and injury states 
showed signiﬁ cant increases in age-standardised rates of 
greater than 5% from 1990 to 2013: glucose-6-phosphate 
dehydrogenase deﬁ ciency, diabetes mellitus, sickle cell 
trait, other musculoskeletal disorders, and urolithiasis.
Table 5 show the estimated prevalence and the 
distribution of prevalence by cause and severity of ﬁ ve 
major impairments in 1990 and 2013 (the remaining four 
impairments are reported in the appendix pp 15–32). 
Table 5 also provides overall YLDs due to each 
impairment to provide context for the total burden 
related to each impairment.
We estimated that 1·83 billion individuals had anaemia 
in 1990, rising to 1·93 billion in 2013 (table 5). Taking 
into account the distribution of anaemia across mild, 
moderate, and severe, total anaemia YLDs equalled 
62·0 million in 1990, dropping slightly to 61·5 million in 
2013. This number of YLDs made anaemia from all 
causes larger than the second leading disease 
contributing to YLDs, major depressive disorder 
(table 10). In addition to the reduction in overall 
prevalence, there was a small but notable shift towards 
more cases of mild anaemia and less severe and moderate 
anaemia from 1990 to 2013. By 2013, 49·2% of individuals 
had mild anaemia, 46·9% had moderate anaemia, and 
3·9% had severe anaemia (table 5). Iron-deﬁ ciency 
anaemia accounted for 62·6% of all cases and 31·5% of 
mild, 28·7% of moderate, and 2·4% of severe anaemia. 
The next ﬁ ve most common causes of anaemia overall 
were thalassaemia trait, malaria, gastritis, and duodenitis, 
other neglected tropical diseases, and other haemo-
globinopathies and haemolytic anaemias. Hook worm 
and schistosomiasis together accounted for 55·2 million 
cases and malaria accounted for a further 80·6 million 
cases. From 1990 to 2013, the number of anaemia cases 
due to malaria increased by 38·9%. Causes with an 
increase in cases of more than 50% included chronic 
kidney disease due to diabetes mellitus, chronic kidney 
disease due to other causes, and sickle cell disorders.
Table 5 shows that the estimated number of individuals 
with some form of hearing impairment (20 dB or more) 
rose from 807·2 million in 1990 to 1·23 billion in 2013. 
Globally, hearing loss accounted for 25·1 million YLDs in 
1990, increasing 45·3% to 36·5 million YLDs in 2013. In 
2013, 800·7 million people had mild hearing loss (less 
than 35 dB), whereas 414·5 million had moderate or 
moderate to severe hearing loss. The number with 
complete hearing loss (8·0 million) was somewhat 
higher than in 1990 (6·7 million). Just over 90% of 
hearing loss was classiﬁ ed as age-related and other 
hearing loss in 2013. Otitis media was the next most 
important cause of overall hearing loss but only caused 
mild or moderate hearing loss. In 2013, congenital 
anomalies accounted for 2·1% of all hearing loss but 
21·1% of complete hearing loss.
Table 5 provides a detailed breakdown at the global 
level of the 61·7 million cases of heart failure (left-sided 
and right-sided) in the world, more than half of which 
were classed as severe. Worldwide, the number of 
individuals who had heart failure increased 96·4% from 
1990 to 2013. A third of heart failure was due to ischaemic 
heart disease (table 5). Five other causes accounted for 
62·0% of heart failure: hypertensive heart disease, other 
cardiovascular and circulatory diseases, cardiomyopathy 
and myocarditis, COPD, and rheumatic heart disease 
(table 5). All other causes each accounted for about 5% of 
heart failure. Notably, in 2013, Chagas disease accounted 
for 0·6% of heart failure globally but 11·4% in Brazil. All 
causes of heart failure accounted for 8·6 million YLDs in 
2013 (table 5).
Table 5 shows that the number of individuals with 
intellectual impairment increased from 118·2 million in 
1990 to 154·0 million in 2013. In 2013, we estimated that 
borderline (IQ 70–84) and mild intellectual impairment (IQ 
50–69) accounted for 104·9 million cases and moderate, 
severe, and profound intellectual impairment around 
49·1 million cases. The most important causes of intellectual 
impairment in 2013 were idiopathic intellectual disability 
(61·5%) followed by neonatal causes (mainly preterm birth 
complications and neonatal encephalopathy), congenital 
causes (mainly Down’s syndrome and chromosomal 
unbalanced rearrangements), cerebro vascular disease, and 
infectious causes (mainly meningitis; tables 5–9). 
Comparison of the levels by cause in 1990 and 2013 showed 
that idiopathic intellectual disability increased 22·7%, 
intellectual disability from preterm birth complications 
increased 129·6%, and intellectual disability from neonatal 
encephalopathy decreased 5·8%.
Table 5 shows the distribution of visual impairment 
including presbyopia in 1990 and 2013. The numbers of 
individuals with visual impairment, taking into account 
the availability of visual aids, increased from 518·6 million 
in 1990 to 774·1 million in 2013. 72·4% of this total in 
2013 was uncorrected presbyopia. Excluding presbyopia, 
in 1990 there were 137·0 million individuals with 
moderate or severe vision loss increasing to 178·8 million 
in 2013 (table 5). Over the same period there was an 
increase in blindness from 23·1 million to 33·0 million. 
The increase in age-standardised rates per 100 000 for 
visual impairment overall was from 12 702·2 to 11 740·9 
and for blindness from 602·5 to 521·3. The most 
important cause of visual impairment in terms of 
prevalence and YLDs was uncorrected refractive error 
accounting for just over 85% of all cases and 56% of 
YLDs due to vision impairment. In terms of YLDs, the 
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Prevalent cases in 2013 
(× 1000)
Percentage change 
in prevalence
from 1990 to 2013
Percentage change 
in age-standardised 
prevalence from 
1990 to 2013
YLDs in 2013 
(× 1000)
Percentage change in 
YLDs from 
1990 to 2013
Percentage change in 
age-standardised YLDs 
from 1990 to 2013
All causes ·· ·· ·· 764 804·4
(572 379·6 to 
990 467·0)
42·3*
(40·2 to 44·3)
–3·9*
(–5·1 to –3·0)
Communicable, maternal, neonatal, 
and nutritional diseases
·· ·· ·· 101 495·1
(71 533·1 to 
138 458·0)
7·6*
(4·0 to 11·8)
–15·2*
(–18·0 to –12·2)
HIV/AIDS and tuberculosis ·· ·· ·· 7733·3
(5494·4 to 
10 077·9)
125·4*
(113·7 to 141·0)
47·1*
(39·5 to 57·4)
Tuberculosis 12 111·8
(11 791·6 to 12 452·0)
51·6*
(49·3 to 54·0)
–1·9*
(–3·3 to –0·3)
3669·7
(2519·7 to 4889·1)
51·9*
(48·6 to 55·2)
–1·3
(–3·4 to 0·7)
HIV/AIDS ·· ·· ·· 4063·7
(2918·9 to 5327·4)
301·7*
(259·4 to 354·3)
171·5*
(142·0 to 208·7)
HIV/AIDS resulting in mycobacterial 
infection
724·7
(496·0 to 922·5)
275·7*
(221·2 to 335·0)
144·0*
(107·3 to 184·1)
268·3
(162·5 to 388·6)
275·5*
(218·1 to 335·1)
144·6*
(104·9 to 185·4)
HIV/AIDS resulting in other diseases 28 506·6
(27 415·1 to 30 970·4)
234·1*
(217·8 to 262·8)
134·5*
(122·8 to 154·8)
3795·3
(2726·7 to 4974·6)
304·1*
(257·2 to 361·0)
174·0*
(140·9 to 214·3)
Diarrhoea, lower respiratory, and 
other common infectious diseases
·· ·· ·· 14 339·7
(10 108·4 to 
19 541·9)
0·2
(–2·8 to 4·6)
–16·5*
(–18·5 to –13·6)
Diarrhoeal diseases 42 409·6
(41 769·5 to 43 170·2)
–6·9*
(–8·9 to –4·7)
–18·3*
(–20·1 to –16·4)
6854·2
(4701·9 to 9415·3)
–6·9*
(–9·2 to –4·7)
–18·0*
(–19·9 to –16·0)
Intestinal infectious diseases ·· ·· ·· 203·7
(138·5 to 281·4)
–23·3*
(–32·2 to –12·9)
–35·7*
(–43·1 to –27·3)
Typhoid fever 1198·3
(1103·3 to 1300·6)
–19·9*
(–30·7 to –6·5)
–33·3*
(–41·9 to –22·4)
158·6
(109·0 to 223·3)
–19·0*
(–30·5 to –4·2)
–32·3*
(–41·8 to –20·5)
Paratyphoid fever 735·9
(640·4 to 836·9)
–27·9*
(–41·8 to –12·8)
–39·1*
(–50·9 to –26·5)
38·3
(24·0 to 57·6)
–27·1*
(–41·6 to –9·7)
–38·4*
(–50·3 to –23·9)
Other intestinal infectious diseases ·· ·· ·· 6·8
(3·2 to 13·4)
–61·0*
(–67·6 to –51·8)
–67·4*
(–72·9 to –59·7)
Lower respiratory infections 4473·3
(4374·7 to 4554·2)
–12·8*
(–15·7 to –10·7)
–25·5*
(–27·9 to –23·8)
460·9
(310·5 to 642·7)
–14·1*
(–17·4 to –11·7)
–26·1*
(–28·9 to –24·2)
Upper respiratory infections 244 327·5
(240 789·6 to 
247 629·2)
38·4*
(35·7 to 41·5)
6·3*
(4·2 to 8·6)
2863·1
(1597·9 to 4763·5)
38·4*
(35·4 to 41·6)
6·6*
(4·4 to 9·0)
Otitis media 85 228·0
(82 190·3 to 88 667·4)
14·4*
(11·9 to 16·9)
–11·1*
(–12·9 to –9·1)
1696·4
(1017·6 to 2697·9)
14·4*
(11·4 to 17·6)
–10·1*
(–12·2 to –7·7)
Meningitis ·· ·· ·· 1679·1
(1165·8 to 2259·6)
–11·7*
(–15·5 to –7·9)
–31·4*
(–34·4 to –27·8)
Pneumococcal 7805·6
(4929·9 to 11 605·5)
–5·5
(–11·3 to 1·8)
–30·7*
(–34·7 to –25·6)
698·1
(494·1 to 917·8)
–5·2
(–11·5 to 3·4)
–27·6*
(–32·1 to –20·9)
Haemophilus inﬂ uenzae type B 3246·2
(1373·4 to 5962·2)
–19·1*
(–26·4 to –12·0)
–38·5*
(–43·6 to –32·2)
375·5
(258·8 to 510·3)
–13·7*
(–20·5 to –3·3)
–31·0*
(–36·3 to –22·3)
Meningococcal 1321·2
(490·6 to 2847·6)
–19·9*
(–28·5 to –12·0)
–40·9*
(–46·6 to –34·5)
167·3
(106·3 to 251·6)
–17·1*
(–25·0 to –8·0)
–37·2*
(–42·5 to –29·3)
Other meningitis 3595·2
(1901·7 to 6305·8)
–20·2*
(–27·9 to –12·9)
–39·6*
(–44·9 to –33·2)
438·3
(299·2 to 604·2)
–17·4*
(–23·3 to –11·9)
–35·2*
(–39·7 to –30·7)
Encephalitis 1739·8
(795·7 to 4003·7)
3·1
(–16·5 to 12·6)
–27·5*
(–41·1 to –21·1)
229·1
(159·9 to 305·7)
10·8*
(4·7 to 17·9)
–20·6*
(–25·0 to –15·4)
Diphtheria 1·1
(0·7 to 2·0)
–62·1*
(–83·4 to –15·4)
–65·7*
(–84·6 to –25·0)
0·1
(0·0 to 0·2)
–62·1*
(–83·5 to –14·8)
–65·8*
(–84·6 to –25·0)
Whooping cough 2532·5
(1965·7 to 3239·2)
–30·0*
(–30·6 to –29·4)
–32·5*
(–33·1 to –31·8)
125·5
(73·0 to 200·7)
–30·0*
(–31·9 to –27·7)
–32·4*
(–34·3 to –30·2)
Tetanus 177·1
(117·5 to 265·7)
–87·1*
(–92·5 to –77·9)
–90·1*
(–94·2 to –82·9)
13·2
(8·5 to 21·3)
–78·2*
(–85·4 to –64·5)
–82·2*
(–88·2 to –71·0)
Measles 192·4
(150·4 to 242·9)
–77·1*
(–79·2 to –74·9)
–78·0*
(–80·1 to –75·9)
17·3
(10·2 to 26·7)
–77·1*
(–80·0 to –73·8)
–78·0*
(–80·8 to –74·8)
(Table 10 continues on next page)
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Prevalent cases in 2013 
(× 1000)
Percentage change 
in prevalence
from 1990 to 2013
Percentage change 
in age-standardised 
prevalence from 
1990 to 2013
YLDs in 2013 
(× 1000)
Percentage change in 
YLDs from 
1990 to 2013
Percentage change in 
age-standardised YLDs 
from 1990 to 2013
(Continued from previous page)
Varicella and herpes zoster 5715·8
(5587·6 to 5835·3)
28·4*
(25·5 to 31·7)
–2·4
(–4·9 to 0·3)
197·2
(122·1 to 299·2)
47·6*
(41·1 to 54·5)
–1·8
(–5·7 to 2·7)
Neglected tropical diseases and 
malaria
·· ·· ·· 20 100·7
(13 202·4 to 
28 946·1)
–3·3
(–10·2 to 6·7)
–28·7*
(–33·1 to –23·0)
Malaria 351 051·1
(344 772·1 to 
358 013·6)
30·8*
(28·4 to 33·2)
3·0*
(1·1 to 4·9)
3170·5
(2132·3 to 4591·9)
30·1*
(25·2 to 35·0)
7·8*
(3·7 to 11·9)
Chagas disease 9433·9
(9241·1 to 9628·4)
22·4*
(19·5 to 25·7)
–16·3*
(–18·3 to –14·0)
97·5
(64·9 to 137·0)
33·6*
(28·8 to 39·1)
–17·4*
(–20·2 to –14·2)
Leishmaniasis ·· ·· ·· 49·7
(25·5 to 90·4)
134·7*
(107·8 to 165·0)
75·8*
(58·0 to 97·3)
Visceral 113·7
(94·1 to 140·9)
35·1*
(17·1 to 54·9)
14·4
(–0·4 to 30·5)
8·0
(5·2 to 12·3)
35·8*
(14·6 to 61·8)
15·2
(–2·5 to 36·7)
Cutaneous and mucocutaneous 3914·8
(3300·4 to 4669·6)
174·2*
(144·5 to 209·2)
95·3*
(75·2 to 119·9)
41·7
(19·0 to 80·1)
175·1*
(146·0 to 210·9)
97·1*
(76·6 to 122·4)
African trypanosomiasis 19·7
(10·6 to 34·3)
–71·1*
(–75·3 to –65·9)
–79·5*
(–82·4 to –75·8)
5·4
(2·6 to 9·5)
–70·7*
(–75·3 to –64·5)
–79·1*
(–82·3 to –74·7)
Schistosomiasis 290 627·9
(252 098·7 to 337 576·1)
30·9*
(22·9 to 51·9)
–3·7
(–9·7 to 11·8)
2861·7
(1483·6 to 5467·2)
34·1*
(26·4 to 55·4)
0·3
(–5·6 to 16·3)
Cysticercosis 1030·8
(901·4 to 1185·6)
–26·3*
(–37·3 to –10·0)
–50·2*
(–57·5 to –39·0)
310·4
(212·2 to 409·5)
–20·9*
(–33·9 to –3·0)
–46·5*
(–55·1 to –34·4)
Cystic echinococcosis 849·2
(822·5 to 893·2)
–15·4*
(–17·0 to –12·9)
–42·4*
(–43·5 to –40·8)
79·2
(54·9 to 110·3)
–15·3*
(–18·9 to –11·0)
–42·0*
(–44·3 to –39·2)
Lymphatic ﬁ lariasis 43 850·0
(36 940·8 to 52 905·8)
–32·1*
(–39·1 to –24·7)
–53·3*
(–58·0 to –48·4)
2022·1
(1096·3 to 3294·4)
5·9
(–15·7 to 26·4)
–32·3*
(–46·0 to –19·3)
Onchocerciasis 16 956·4
(11 477·5 to 26 789·4)
–31·2*
(–39·8 to –21·9)
–51·5*
(–57·6 to –45·3)
1179·8
(556·6 to 1992·7)
–25·4*
(–37·0 to –10·9)
–48·9*
(–57·7 to –38·4)
Trachoma 2428·8
(1924·2 to 2981·2)
–39·2*
(–46·3 to –30·1)
–65·4*
(–69·5 to –60·3)
171·2
(115·3 to 241·7)
–37·2*
(–43·0 to –30·4)
–64·2*
(–67·5 to –60·5)
Dengue 3485·5
(1283·7 to 7818·6)
610·9*
(606·3 to 615·5)
447·3*
(443·6 to 450·9)
565·9
(186·4 to 1414·6)
607·2*
(558·4 to 659·5)
446·8*
(411·3 to 486·8)
Yellow fever 2·1
(0·7 to 4·9)
–59·8*
(–63·7 to –54·3)
–68·3*
(–71·4 to –64·0)
0·1
(0·0 to 0·2)
–59·8*
(–63·7 to –54·3)
–68·3*
(–71·4 to –64·0)
Rabies 0·9
(0·7 to 1·1)
–39·8*
(–54·3 to –27·3)
–55·2*
(–65·1 to –46·1)
0·1
(0·1 to 0·2)
–39·8*
(–54·3 to –27·2)
–55·2*
(–65·1 to –46·1)
Intestinal nematode infections ·· ·· ·· 3691·6
(2185·8 to 5801·7)
–46·0*
(–50·6 to –41·4)
–58·8*
(–62·3 to –55·3)
Ascariasis 804 370·1
(713 417·5 to 922 212·1)
–25·5*
(–37·8 to –10·4)
–44·8*
(–54·2 to –33·1)
933·9
(516·6 to 1576·1)
–74·2*
(–77·4 to –70·6)
–80·1*
(–82·5 to –77·3)
Trichuriasis 477 374·4
(441 256·8 to 
518 365·1)
–11·6
(–28·7 to 4·9)
–34·4*
(–47·8 to –21·0)
576·0
(310·1 to 972·6)
–27·6*
(–39·4 to –10·4)
–45·9*
(–55·0 to –32·8)
Hookworm disease 471 816·2
(437 049·6 to 
511 318·8)
–5·1
(–20·2 to 9·7)
–30·1*
(–41·6 to –18·4)
2181·7
(1338·6 to 3354·5)
–10·9*
(–17·3 to –4·4)
–32·9*
(–38·0 to –27·7)
Food-borne trematodiases 80 194·5
(64 648·1 to 96 212·4)
51·1*
(44·2 to 59·7)
–0·1
(–4·8 to 5·6)
3634·8
(1160·2 to 7692·4)
50·1*
(40·6 to 60·0)
–1·8
(–8·1 to 4·9)
Other neglected tropical diseases 59 705·9
(58 703·5 to 61 020·1)
–5·0
(–11·0 to 1·6)
–18·3*
(–23·3 to –12·8)
2260·7
(1473·6 to 3358·6)
–8·9*
(–13·4 to –0·1)
–20·6*
(–25·0 to –12·8)
Maternal disorders ·· ·· ·· 1341·8
(924·5 to 1824·3)
18·4*
(8·2 to 27·4)
–15·0*
(–21·9 to –8·4)
Maternal haemorrhage 2027·4
(1932·4 to 2119·8)
30·5*
(22·2 to 39·2)
–2·1
(–8·1 to 4·4)
69·5
(47·4 to 97·5)
11·2
(–0·7 to 22·5)
–16·4*
(–25·2 to –8·1)
Maternal sepsis and other maternal 
infections
1781·4
(1235·4 to 2515·9)
–13·5*
(–23·5 to –5·0)
–41·6*
(–47·7 to –35·6)
21·4
(11·6 to 36·3)
–22·4*
(–35·3 to –9·7)
–43·2*
(–51·8 to –34·5)
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Maternal hypertensive disorders 1277·6
(756·3 to 1978·8)
3·5
(–0·4 to 10·2)
–21·3*
(–23·8 to –17·2)
64·7
(31·5 to 112·8)
2·9
(–2·8 to 9·7)
–21·8*
(–25·6 to –17·3)
Obstructed labour 2902·1
(2600·1 to 3222·1)
20·4*
(12·9 to 27·5)
–14·8*
(–19·8 to –10·2)
951·5
(641·5 to 1304·0)
20·9*
(12·3 to 30·3)
–14·3*
(–20·1 to –8·0)
Complications of abortion 21·8
(14·6 to 29·7)
11·5*
(1·8 to 20·9)
–16·9*
(–24·0 to –10·1)
2·5
(1·4 to 4·0)
12·0*
(2·0 to 22·3)
–16·6*
(–23·8 to –9·1)
Other maternal disorders ·· ·· ·· 232·2
(155·8 to 343·7)
22·1
(–14·3 to 62·2)
–10·5
(–37·3 to 18·5)
Neonatal disorders ·· ·· ·· 12 648·8
(92 91·4 to 
16 262·6)
130·9*
(108·5 to 158·7)
80·5*
(63·1 to 101·7)
Preterm birth complications 56 272·0
(49 504·6 to 64 204·4)
165·4*
(143·0 to 192·5)
98·9*
(81·9 to 118·4)
6689·7
(4914·1 to 8643·6)
187·6*
(166·9 to 210·3)
119·4*
(104·2 to 136·9)
Neonatal encephalopathy due to 
birth asphyxia and trauma
22 858·6
(11 831·4 to 38 618·7)
3·4
(–18·7 to 53·4)
–20·5
(–37·6 to 19·2)
2388·1
(1783·6 to 3153·0)
57·1*
(32·4 to 84·0)
25·6*
(5·4 to 48·1)
Neonatal sepsis and other neonatal 
infections
50·3
(16·5 to 106·6)
110·0*
(100·0 to 127·5)
107·7*
(97·8 to 125·0)
6·6
(2·0 to 15·0)
110·3*
(97·4 to 128·1)
108·1*
(95·3 to 125·7)
Haemolytic disease and other 
neonatal jaundice
4999·3
(3893·0 to 6792·3)
132·9*
(66·8 to 276·7)
84·2*
(33·6 to 197·8)
1606·8
(1122·3 to 2234·6)
112·4*
(61·1 to 220·9)
66·7*
(28·2 to 151·9)
Other neonatal disorders ·· ·· ·· 1957·6
(1334·4 to 2698·5)
128·8*
(82·2 to 189·1)
80·3*
(43·8 to 126·6)
Nutritional deﬁ ciencies ·· ·· ·· 41 765·3
(27 678·6 to 
60 351·7)
–9·4*
(–12·0 to –7·0)
–26·1*
(–27·8 to –24·5)
Protein-energy malnutrition 20 756·9
(16 985·3 to 25 759·4)
–13·2
(–34·7 to 16·1)
–16·7
(–37·0 to 11·6)
2574·3
(1588·3 to 3920·3)
–13·0
(–34·9 to 16·9)
–16·3
(–37·0 to 12·3)
Iodine deﬁ ciency 115 602·4
(110 007·2 to 120 997·1)
–11·4*
(–16·8 to –5·4)
–37·0*
(–40·9 to –32·5)
2075·0
(1294·6 to 3291·9)
–11·4*
(–17·1 to –5·4)
–36·7*
(–40·8 to –32·3)
Vitamin A deﬁ ciency 3372·4
(2732·4 to 3926·3)
–19·4*
(–24·4 to –14·6)
–34·9*
(–39·3 to –31·1)
153·7
(99·0 to 224·9)
–22·9*
(–28·7 to –16·9)
–39·1*
(–44·1 to –33·5)
Iron-deﬁ ciency anaemia 1 208 216·4
(1 205 927·2 to 
1 210 477·8)
–0·2
(–0·6 to 0·1)
–21·9*
(–22·2 to –21·7)
36 663·5
(24 371·0 to 
53 084·7)
–8·6*
(–9·8 to –7·1)
–25·8*
(–26·7 to –24·9)
Other nutritional deﬁ ciencies ·· ·· ·· 298·8
(157·9 to 535·4)
–43·8*
(–63·9 to –10·0)
–45·7*
(–65·2 to –13·1)
Other communicable, maternal, 
neonatal, and nutritional diseases
·· ·· ·· 3565·4
(2282·3 to 5460·0)
9·7*
(5·6 to 15·8)
–13·4*
(–15·8 to –9·9)
Sexually transmitted diseases 
excluding HIV
·· ·· ·· 1383·8
(830·1 to 2404·6)
38·0*
(33·1 to 42·5)
–2·6
(–5·6 to 0·5)
Syphilis 315·2
(306·5 to 324·5)
1·5
(–2·5 to 6·4)
–37·1*
(–39·5 to –34·3)
58·4
(39·6 to 81·8)
1·5
(–5·3 to 9·9)
–36·9*
(–40·8 to –32·0)
Chlamydial infection 147846·5
(144 169·7 to 151 027·5)
29·5*
(24·8 to 33·4)
–5·5*
(–8·8 to –2·8)
646·5
(411·0 to 1019·4)
37·1*
(31·0 to 43·3)
0·4
(–4·2 to 4·8)
Gonococcal infection 32 726·1
(31 162·7 to 34 316·7)
38·8*
(29·6 to 47·6)
4·8
(–2·0 to 11·4)
225·4
(144·8 to 344·1)
43·4*
(29·1 to 61·0)
7·9
(–2·6 to 20·9)
Trichomoniasis 67 075·9
(62 762·6 to 72 764·6)
45·6*
(33·3 to 62·3)
4·0
(–4·4 to 15·6)
113·9
(45·1 to 242·9)
45·5*
(32·3 to 64·1)
4·2
(–4·9 to 16·9)
Genital herpes 1 176 494·5
(1 160 277·4 to 
1 194 517·2)
47·6*
(44·7 to 50·6)
–5·3*
(–7·1 to –3·5)
311·6
(98·3 to 748·5)
45·7*
(40·8 to 49·6)
–4·8*
(–6·8 to –2·6)
Other sexually transmitted diseases 1248·2
(971·7 to 1612·4)
1·9
(–4·1 to 10·2)
–31·9*
(–35·8 to –26·5)
27·9
(19·0 to 40·2)
20·0*
(9·2 to 32·4)
–16·9*
(–24·3 to –8·1)
Hepatitis ·· ·· ·· 444·1
(290·5 to 641·1)
14·9*
(12·1 to 17·5)
–17·3*
(–19·4 to –15·3)
Hepatitis A 7823·9
(7532·8 to 8115·3)
11·9*
(11·3 to 12·5)
–5·8*
(–6·1 to –5·3)
198·0
(128·3 to 287·8)
25·9*
(22·9 to 29·1)
–0·9
(–3·5 to 2·0)
(Table 10 continues on next page)
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Hepatitis B 331 037·0
(325 359·6 to 
336 638·4)
–5·5*
(–7·9 to –3·4)
–32·1*
(–33·7 to –30·6)
172·6
(112·0 to 247·4)
2·2
(–2·3 to 6·7)
–31·8*
(–35·0 to –28·6)
Hepatitis C 147 826·3
(145 520·7 to 
150 080·2)
16·0*
(13·6 to 18·5)
–23·3*
(–24·8 to –21·7)
16·9
(11·0 to 24·3)
15·5*
(10·0 to 21·4)
–21·2*
(–25·1 to –17·1)
Hepatitis E 2188·2
(2083·3 to 2311·9)
18·4*
(11·3 to 26·9)
–10·9*
(–16·2 to –4·6)
56·6
(36·3 to 82·1)
22·9*
(12·1 to 34·4)
–8·6*
(–16·4 to –0·0)
Leprosy 658·8
(613·6 to 707·5)
61·3*
(54·0 to 69·6)
–1·5
(–6·0 to 3·5)
39·7
(26·6 to 56·0)
73·4*
(61·0 to 86·6)
5·7
(–1·5 to 13·4)
Other infectious diseases 49 759·6
(48 625·5 to 51 029·0)
–4·9*
(–7·8 to –2·0)
–20·6*
(–22·9 to –18·2)
1697·9
(1130·0 to 2469·8)
–7·5*
(–11·7 to –1·1)
–19·8*
(–23·4 to –14·6)
Non-communicable diseases ·· ·· ·· 626 477·7
(465 287·7 to 
806 573·8)
54·2*
(53·0 to 55·8)
1·4*
(0·7 to 2·2)
Neoplasms ·· ·· ·· 6763·9
(4989·2 to 8715·9)
82·5*
(75·4 to 90·8)
8·5*
(4·4 to 13·5)
Oesophageal cancer 840·5
(706·3 to 1015·2)
56·2*
(30·8 to 90·0)
–9·5
(–24·2 to 9·9)
125·7
(88·9 to 167·2)
49·6*
(30·2 to 72·8)
–13·6*
(–24·4 to –0·3)
Stomach cancer 2532·1
(2347·7 to 2736·5)
36·1*
(25·8 to 47·4)
–21·0*
(–26·9 to –14·7)
290·4
(209·4 to 368·1)
28·2*
(19·1 to 38·3)
–25·7*
(–30·9 to –20·0)
Liver cancer ·· ·· ·· 190·6
(133·3 to 253·2)
76·9*
(55·6 to 102·0)
4·5
(–7·6 to 19·0)
Liver cancer due to hepatitis B 450·9
(373·3 to 538·8)
91·2*
(48·7 to 150·7)
14·2
(–10·8 to 48·5)
67·0
(46·3 to 89·9)
70·7*
(44·5 to 102·0)
2·0
(–13·6 to 20·5)
Liver cancer due to hepatitis C 512·6
(438·6 to 599·8)
367·6*
(284·7 to 478·2)
168·7*
(120·7 to 230·0)
74·6
(52·6 to 99·9)
310·5*
(256·5 to 378·5)
135·7*
(106·8 to 174·3)
Liver cancer due to alcohol use 197·2
(168·7 to 226·8)
10·2
(–8·8 to 34·4)
–35·8*
(–46·5 to –22·2)
29·9
(20·7 to 40·1)
2·0
(–10·3 to 16·3)
–40·4*
(–47·6 to –32·1)
Liver cancer due to other causes 121·5
(102·1 to 143·0)
–1·0
(–23·1 to 22·3)
–40·7*
(–54·1 to –27·0)
19·1
(13·1 to 25·6)
–9·8
(–24·0 to 4·4)
–45·8*
(–54·2 to –37·5)
Larynx cancer 899·8
(749·7 to 1069·8)
41·6*
(30·2 to 58·1)
–16·6*
(–23·0 to –7·1)
86·0
(60·0 to 115·2)
32·8*
(22·0 to 49·6)
–22·0*
(–28·3 to –12·4)
Tracheal, bronchus, and lung cancer 3227·4
(3039·7 to 3426·8)
72·2*
(61·9 to 82·1)
0·8
(–5·4 to 6·5)
467·4
(338·5 to 593·2)
64·6*
(54·9 to 72·9)
–3·7
(–9·3 to 1·2)
Breast cancer 18 419·0
(17 740·6 to 19 141·4)
126·9*
(115·5 to 139·4)
29·7*
(23·5 to 36·5)
1068·2
(760·8 to 1428·1)
100·7*
(86·6 to 114·3)
15·7*
(7·8 to 23·2)
Cervical cancer 3180·8
(2623·1 to 3599·0)
7·2
(–5·4 to 21·9)
–35·2*
(–42·6 to –26·8)
243·8
(169·8 to 333·0)
8·3
(–3·5 to 22·3)
–34·6*
(–41·7 to –26·6)
Uterine cancer 2960·8
(2307·9 to 3516·4)
66·5*
(39·0 to 97·8)
–3·8
(–19·0 to 13·3)
193·7
(123·7 to 273·6)
62·9*
(36·4 to 92·1)
–6·0
(–20·6 to 9·8)
Prostate cancer 11 135·9
(10 002·5 to 13 123·4)
178·8*
(158·1 to 212·7)
56·0*
(44·6 to 75·0)
893·7
(656·7 to 1192·5)
164·2*
(142·0 to 208·3)
48·2*
(35·8 to 72·9)
Colon and rectum cancer 8591·6
(8252·7 to 8917·0)
107·2*
(97·8 to 115·6)
18·4*
(13·1 to 23·2)
701·9
(512·7 to 899·1)
95·5*
(86·5 to 104·1)
11·5*
(6·3 to 16·5)
Lip and oral cavity cancer 2416·5
(2044·4 to 2782·1)
76·8*
(56·3 to 103·4)
2·9
(–9·0 to 18·2)
206·9
(145·2 to 278·3)
72·3*
(52·9 to 98·2)
0·0
(–11·1 to 14·6)
Nasopharynx cancer 501·1
(422·3 to 596·2)
29·7*
(5·8 to 58·5)
–21·1*
(–35·7 to –4·0)
47·9
(33·1 to 64·3)
25·9*
(5·6 to 49·6)
–23·5*
(–36·0 to –9·4)
Other pharynx cancer 752·5
(644·9 to 857·1)
81·2*
(53·9 to 109·4)
4·7
(–10·9 to 20·6)
66·0
(45·5 to 88·5)
75·5*
(51·3 to 101·5)
1·4
(–12·6 to 16·3)
Gallbladder and biliary tract cancer 158·3
(135·9 to 177·6)
46·7*
(29·3 to 62·7)
–17·1*
(–27·2 to –8·0)
39·1
(27·0 to 52·1)
39·8*
(22·7 to 54·9)
–20·5*
(–30·6 to –11·5)
Pancreatic cancer 384·3
(355·9 to 412·9)
100·5*
(84·2 to 117·8)
14·3*
(5·2 to 24·5)
73·6
(52·1 to 96·2)
92·1*
(80·6 to 103·7)
9·9*
(3·1 to 16·8)
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Malignant skin melanoma 2341·5
(1808·4 to 3151·3)
87·9*
(65·9 to 107·1)
13·9*
(0·5 to 24·9)
137·9
(91·7 to 205·0)
80·8*
(59·5 to 99·7)
9·1
(–3·8 to 20·2)
Non-melanoma skin cancer 5529·6
(4962·1 to 6204·9)
108·8*
(78·8 to 141·7)
18·2*
(0·3 to 36·9)
126·2
(82·5 to 188·1)
152·8*
(116·5 to 200·2)
42·5*
(21·3 to 70·3)
Ovarian cancer 1053·8
(975·7 to 1145·0)
68·3*
(56·1 to 82·3)
–0·9
(–8·1 to 7·0)
134·9
(97·0 to 174·6)
65·1*
(52·0 to 79·7)
–2·9
(–10·7 to 4·8)
Testicular cancer 556·0
(423·6 to 681·0)
60·8*
(32·1 to 84·9)
9·4
(–9·7 to 25·6)
34·3
(22·2 to 49·0)
57·6*
(30·8 to 80·5)
6·6
(–10·8 to 21·9)
Kidney cancer 1960·6
(1829·8 to 2099·4)
117·3*
(104·5 to 131·6)
31·8*
(23·9 to 40·4)
139·2
(99·2 to 185·8)
109·7*
(97·0 to 123·5)
26·1*
(18·2 to 34·3)
Bladder cancer 2359·6
(2077·2 to 2563·2)
58·5*
(49·8 to 69·1)
–8·8*
(–14·2 to –2·8)
179·8
(132·1 to 235·5)
52·5*
(44·1 to 62·5)
–12·8*
(–17·8 to –6·9)
Brain and nervous system cancer 1193·2
(1010·6 to 1373·3)
52·2*
(28·6 to 70·9)
7·2
(–7·2 to 18·9)
121·9
(87·1 to 165·1)
55·4*
(34·3 to 71·8)
5·6
(–6·7 to 15·9)
Thyroid cancer 2179·4
(1815·3 to 2509·2)
100·2*
(74·8 to 129·9)
24·4*
(9·6 to 41·3)
127·6
(85·7 to 180·9)
94·9*
(71·3 to 122·4)
19·7*
(6·6 to 35·6)
Mesothelioma 50·4
(44·2 to 57·6)
94·7*
(65·9 to 110·9)
12·9
(–4·3 to 22·0)
10·8
(7·4 to 14·4)
96·6*
(66·5 to 113·0)
14·1
(–4·4 to 23·5)
Hodgkin’s lymphoma 725·3
(625·0 to 997·2)
–12·7
(–30·9 to 59·0)
–34·7
(–46·7 to 16·7)
57·5
(38·7 to 82·1)
–12·0
(–26·8 to 56·4)
–36·2
(–45·7 to 11·0)
Non-Hodgkin lymphoma 2956·4
(2448·0 to 3253·1)
121·7*
(82·7 to 142·0)
38·4*
(12·3 to 50·7)
216·2
(151·6 to 292·6)
112·2*
(75·7 to 131·1)
31·4*
(6·4 to 43·3)
Multiple myeloma 427·4
(349·3 to 528·8)
107·8*
(78·1 to 137·1)
19·0*
(1·3 to 36·9)
86·3
(59·7 to 114·9)
98·6*
(68·9 to 124·1)
13·4
(–4·5 to 28·6)
Leukaemia 2117·3
(1978·7 to 2248·2)
44·3*
(24·8 to 58·6)
6·7
(–4·6 to 15·6)
249·6
(182·7 to 320·2)
52·1*
(38·4 to 63·8)
4·1
(–4·0 to 11·4)
Other neoplasms 6785·0
(5938·1 to 7417·5)
185·5*
(104·5 to 215·4)
93·2*
(47·0 to 113·0)
446·8
(312·5 to 596·4)
172·3*
(102·3 to 199·0)
78·3*
(39·6 to 97·0)
Cardiovascular diseases ·· ·· ·· 21 177·0
(14 947·8 to 
28 436·7)
89·2*
(69·1 to 108·7)
10·3
(–1·0 to 21·3)
Rheumatic heart disease 32 903·9
(31 608·5 to 34 023·7)
62·8*
(51·3 to 72·0)
13·5*
(6·0 to 19·7)
1821·3
(1211·3 to 2530·8)
60·8*
(47·5 to 73·7)
9·5
(–0·3 to 18·1)
Ischaemic heart disease 92 936·7
(90 091·9 to 95 860·8)
64·7*
(57·0 to 72·2)
–5·2*
(–9·6 to –1·0)
5804·1
(4055·2 to 7902·3)
67·5*
(58·8 to 76·6)
–4·0
(–8·8 to 1·2)
Cerebrovascular disease ·· ·· ·· 3743·6
(2669·9 to 4843·9)
83·5*
(75·9 to 93·5)
5·0*
(0·5 to 11·2)
Ischaemic stroke 18 305·5
(17 767·4 to 18 920·7)
81·5*
(72·6 to 92·7)
2·4
(–2·8 to 9·1)
2650·1
(1875·1 to 3492·3)
81·8*
(72·6 to 93·3)
3·0
(–2·2 to 9·9)
Haemorrhagic stroke 7363·5
(7139·7 to 7616·1)
88·9*
(80·6 to 98·6)
10·2*
(5·4 to 16·1)
1093·5
(759·0 to 1438·1)
88·5*
(79·7 to 99·0)
10·6*
(5·6 to 17·1)
Hypertensive heart disease 10 893·7
(10 526·7 to 11246·4)
112·8*
(101·6 to 123·9)
19·1*
(12·7 to 25·4)
1193·9
(844·9 to 1633·9)
113·8*
(102·8 to 124·9)
20·0*
(13·7 to 26·3)
Cardiomyopathy and myocarditis 7993·0
(7738·3 to 8269·3)
85·0*
(77·9 to 93·0)
8·5*
(4·3 to 13·4)
865·7
(591·5 to 1159·6)
86·8*
(79·0 to 95·1)
9·8*
(5·2 to 14·8)
Atrial ﬁ brillation and ﬂ utter 11 178·6
(10 655·1 to 11 683·7)
63·6*
(53·9 to 71·4)
–10·3*
(–15·6 to –5·8)
857·8
(603·7 to 1177·4)
64·2*
(54·3 to 71·9)
–9·7*
(–15·1 to –5·2)
Peripheral vascular disease 185 137·2
(172 555·7 to 196 597·2)
78·0*
(59·9 to 91·2)
–0·1
(–9·9 to 6·7)
127·7
(62·4 to 223·8)
49·6*
(31·2 to 64·3)
–19·7*
(–29·5 to –12·0)
Endocarditis 310·3
(252·1 to 361·0)
71·7*
(55·9 to 86·2)
4·6
(–5·1 to 13·6)
32·5
(21·2 to 46·7)
77·4*
(59·7 to 96·2)
7·0
(–3·9 to 18·4)
Other cardiovascular and circulatory 
diseases
95 225·2
(67 433·2 to 121 733·8)
130·2*
(53·9 to 234·7)
36·4
(–8·6 to 98·7)
6730·4
(3926·1 to 10 097·9)
131·2*
(53·7 to 236·5)
37·1
(–8·4 to 99·7)
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Chronic respiratory diseases ·· ·· ·· 38 618·7
(26 864·7 to 
51 458·3)
55·1*
(50·3 to 60·6)
0·0
(–2·5 to 2·8)
Chronic obstructive pulmonary 
disease
328 503·6
(317 289·1 to 
339 461·0)
65·1*
(63·8 to 66·3)
0·5
(–0·2 to 1·2)
26 131·3
(17 785·3 to 
35 786·9)
72·3*
(67·4 to 78·6)
5·5*
(2·7 to 9·3)
Pneumoconiosis ·· ·· ·· 50·8
(36·0 to 69·0)
96·9*
(89·2 to 103·3)
17·3*
(12·5 to 21·3)
Silicosis 56·2
(52·6 to 59·6)
49·8*
(47·3 to 52·3)
–11·8*
(–13·3 to –10·5)
10·7
(6·9 to 15·1)
49·9*
(47·2 to 52·3)
–11·8*
(–13·3 to –10·5)
Asbestosis 14·8
(14·0 to 15·5)
67·5*
(64·0 to 71·4)
–0·7
(–2·8 to 1·7)
2·8
(1·8 to 3·9)
68·1*
(64·6 to 72·1)
–0·4
(–2·5 to 2·0)
Coal workers’ pneumoconiosis 36·4
(34·6 to 38·1)
55·1*
(53·1 to 56·8)
–6·9*
(–8·0 to –5·9)
6·8
(4·6 to 9·8)
55·1*
(53·0 to 56·9)
–6·9*
(–8·1 to –5·9)
Other pneumoconiosis 164·9
(154·0 to 174·3)
144·2*
(137·9 to 150·3)
47·4*
(44·0 to 51·1)
30·5
(19·9 to 43·9)
141·8*
(136·0 to 148·2)
45·7*
(42·3 to 49·7)
Asthma 241 694·7
(238 151·1 to 
245 464·6)
32·1*
(29·5 to 34·9)
–5·5*
(–7·2 to –3·5)
10 595·8
(6924·6 to 15 102·0)
31·6*
(28·9 to 34·6)
–5·3*
(–7·2 to –3·2)
Interstitial lung disease and 
pulmonary sarcoidosis
595·0
(569·1 to 622·5)
69·8*
(58·9 to 78·9)
5·1
(–1·5 to 10·6)
80·7
(50·7 to 117·9)
70·9*
(59·5 to 80·2)
5·4
(–1·5 to 11·2)
Other chronic respiratory diseases ·· ·· ·· 1760·0
(1150·0 to 2617·9)
8·4
(–4·6 to 26·4)
–32·8*
(–40·7 to –21·8)
Cirrhosis ·· ·· ·· 544·6
(381·1 to 750·4)
29·2*
(25·5 to 33·2)
–14·9*
(–17·2 to –12·6)
Cirrhosis due to hepatitis B 869·0
(813·2 to 923·0)
21·6*
(11·4 to 30·2)
–20·8*
(–27·2 to –15·3)
143·2
(98·8 to 197·7)
20·9*
(9·1 to 31·6)
–21·0*
(–28·1 to –13·9)
Cirrhosis due to hepatitis C 884·9
(837·2 to 947·7)
60·5*
(52·0 to 74·4)
1·6
(–3·6 to 10·5)
144·9
(100·8 to 201·3)
59·9*
(49·8 to 75·3)
1·6
(–4·2 to 11·4)
Cirrhosis due to alcohol use 801·5
(746·6 to 864·3)
10·0*
(1·1 to 21·4)
–33·4*
(–38·6 to –27·1)
131·2
(89·3 to 180·1)
10·3
(–0·2 to 22·7)
–33·1*
(–39·2 to –26·0)
Cirrhosis due to other causes 742·0
(693·9 – 789·5)
33·6*
(24·4 to 46·3)
3·6
(–3·5 to 13·2)
125·3
(85·6 to 175·1)
33·3*
(20·7 to 50·5)
3·5
(–6·3 to 16·4)
Digestive diseases ·· ·· ·· 8457·9
(6066·5 to 
11 283·9)
24·4*
(19·9 to 28·8)
–21·9*
(–24·7 to –19·2)
Peptic ulcer disease 35 515·2
(33 962·5 to 36 907·1)
–5·4*
(–7·9 to –2·5)
–45·8*
(–47·1 to –44·1)
1268·6
(873·2 to 1774·5)
–1·4
(–5·9 to 3·7)
–43·2*
(–45·5 to –40·3)
Gastritis and duodenitis 64 799·9
(63 317·5 to 66 212·6)
11·4*
(7·8 to 14·9)
–26·7*
(–28·7 to –24·7)
2384·2
(1617·0 to 3388·7)
6·3*
(1·7 to 10·3)
–27·6*
(–30·4 to –25·2)
Appendicitis 621·7
(546·4 to 699·6)
17·0*
(1·0 to 37·2)
–14·6
(–25·4 to 0·0)
190·2
(126·9 to 263·1)
17·4
(–1·0 to 39·2)
–13·6
(–26·7 to 1·8)
Paralytic ileus and intestinal 
obstruction
114·6
(111·4 to 117·6)
50·4*
(44·7 to 56·3)
4·6*
(1·2 to 8·0)
35·1
(23·8 to 47·5)
49·2*
(41·2 to 57·4)
4·7
(–0·6 to 10·6)
Inguinal, femoral, and abdominal 
hernia
25 393·4
(24 084·5 to 26 361·0)
45·7*
(36·0 to 53·1)
–10·5*
(–16·1 to –5·9)
262·3
(129·4 to 490·8)
45·7*
(35·8 to 53·1)
–9·9*
(–15·6 to –5·3)
Inﬂ ammatory bowel disease 10 575·9
(10 410·1 to 10 737·6)
75·7*
(72·7 to 78·6)
9·6*
(7·7 to 11·4)
2223·2
(1544·1 to 3028·2)
75·6*
(71·5 to 79·5)
10·1*
(7·6 to 12·5)
Vascular intestinal disorders 35·3
(33·2 to 38·6)
69·9*
(58·7 to 81·6)
–0·7
(–7·6 to 6·5)
10·8
(7·2 to 14·6)
68·8*
(54·1 to 83·7)
–0·2
(–9·7 to 9·8)
Gallbladder and biliary diseases 5893·8
(5737·7 to 6119·0)
37·0*
(32·6 to 43·9)
–18·2*
(–20·8 to –14·3)
614·9
(428·8 to 826·8)
36·9*
(31·5 to 43·6)
–17·9*
(–21·0 to –14·3)
Pancreatitis 1972·8
(1951·7 to 1997·4)
70·8*
(68·4 to 73·3)
6·9*
(5·5 to 8·4)
579·8
(398·9 to 771·6)
70·5*
(65·1 to 75·8)
7·3*
(4·1 to 10·5)
Other digestive diseases ·· ·· ·· 888·8
(612·7 to 1228·4)
5·9
(–8·5 to 17·1)
–34·2*
(–43·3 to –27·2)
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Neurological disorders ·· ·· ·· 59 360·1
(41 036·0 to 
80 871·8)
59·6*
(54·8 to 64·5)
5·0*
(2·4 to 7·9)
Alzheimer’s disease and other 
dementias
53 050·5
(51 663·7 to 54 359·8)
88·5*
(82·1 to 95·0)
–0·7
(–4·0 to 2·8)
7773·6
(5703·1 to 9867·3)
91·8*
(85·3 to 98·5)
0·0
(–3·5 to 3·8)
Parkinson’s disease 5866·3
(4777·2 to 6950·0)
80·9*
(77·7 to 83·6)
2·1*
(0·4 to 3·5)
694·8
(468·5 to 964·1)
81·2*
(77·3 to 85·2)
2·7*
(0·6 to 4·6)
Epilepsy 21 712·0
(20 160·3 to 23 108·4)
31·6*
(20·2 to 43·8)
–2·5
(–10·8 to 6·7)
7544·2
(5164·1 to 9925·9)
40·5*
(28·5 to 56·5)
4·4
(–4·5 to 15·9)
Multiple sclerosis 2293·6
(2238·9 to 2345·6)
117·2*
(110·0 to 124·0)
35·4*
(30·7 to 39·5)
754·6
(547·6 to 951·0)
116·1*
(106·3 to 125·7)
35·1*
(29·0 to 41·1)
Migraine 848 366·5
(831 034·6 to 
864 852·1)
46·1*
(41·4 to 50·1)
0·3
(–2·8 to 3·0)
28 898·1
(17 585·8 to 
42 420·1)
46·1*
(41·4 to 50·5)
0·8
(–2·4 to 3·7)
Tension-type headache 1 561 446·5
(1 537 571·4 to 
1 585 765·8)
45·5*
(41·9 to 49·4)
0·0
(–2·4 to 2·6)
2363·2
(1151·9 to 4155·0)
45·5*
(41·7 to 49·5)
0·3
(–2·1 to 2·9)
Medication overuse headache 62 899·3
(43 143·0 to 80 656·0)
120·2*
(109·5 to 133·8)
42·8*
(35·9 to 51·9)
9845·7
(5777·9 to 15 100·3)
120·2*
(109·3 to 133·7)
43·3*
(36·2 to 52·4)
Other neurological disorders 11·6
(10·0 to 13·3)
45·9*
(36·0 to 56·3)
0·9
(–5·6 to 7·9)
1485·8
(1056·6 to 1918·6)
31·4*
(12·7 to 40·4)
–29·6*
(–39·2 to –24·8)
Mental and substance use disorders ·· ·· ·· 161 811·9
(116 057·8 to 
210 256·0)
45·0*
(42·9 to 47·2)
1·0*
(0·3 to 1·9)
Schizophrenia 23 600·6
(22 170·6 to 25 038·7)
52·1*
(50·3 to 53·6)
–1·5*
(–2·4 to –0·6)
15 204·4
(11 169·3 to 
18 188·6)
52·1*
(50·3 to 54·1)
–1·1
(–2·2 to 0·1)
Alcohol use disorders 76 896·6
(73 454·0 to 80 491·9)
34·4*
(32·3 to 36·4)
–7·6*
(–8·8 to –6·5)
7653·6
(5150·7 to 10 952·3)
34·3*
(32·0 to 36·6)
–7·5*
(–8·8 to –6·1)
Drug use disorders ·· ·· ·· 12 222·4
(8513·1 to 16 172·8)
41·3*
(36·3 to 46·3)
0·6
(–2·4 to 3·8)
Opioid use disorders 14 071·8
(11 103·0 to 181 39·2)
58·9*
(54·4 to 62·8)
6·4*
(3·0 to 9·5)
5849·5
(3907·9 to 8184·0)
59·1*
(54·0 to 63·6)
6·7*
(3·2 to 10·2)
Cocaine use disorders 7384·6
(7216·3 to 7549·3)
32·1*
(28·4 to 35·8)
–5·9*
(–8·5 to –3·3)
1012·9
(666·9 to 1430·2)
32·1*
(27·2 to 37·1)
–5·7*
(–9·2 to –2·3)
Amphetamine use disorders 14 922·9
(14 490·6 to 15 370·7)
26·4*
(21·2 to 31·3)
–4·1*
(–8·0 to –0·6)
1961·0
(1233·0 to 2832·9)
26·6*
(20·8 to 32·2)
–3·8
(–8·1 to 0·3)
Cannabis use disorders 13 625·0
(12 429·2 to 14 938·0)
22·4*
(20·6 to 24·0)
–6·5*
(–7·6 to –5·5)
395·6
(261·2 to 576·2)
22·4*
(19·0 to 26·1)
–6·4*
(–8·9 to –3·7)
Other drug use disorders ·· ·· ·· 3003·3
(1998·9 to 4164·5)
28·5*
(21·5 to 36·5)
–4·4
(–9·7 to 1·4)
Depressive disorders ·· ·· ·· 61 632·8
(41 353·8 to 
85 621·4)
53·6*
(49·6 to 58·4)
4·0*
(2·2 to 5·6)
Major depressive disorder 253 314·2
(208 457·2 to 
299 691·3)
53·4*
(49·0 to 58·9)
4·2*
(2·4 to 6·2)
51 783·9
(33 888·2 to 
73 665·8)
53·4*
(48·8 to 59·2)
4·7*
(2·7 to 6·7)
Dysthymia 102 409·6
(91 246·2 to 113 441·2)
54·6*
(52·4 to 57·2)
–0·3
(–1·2 to 0·7)
9848·9
(6586·6 to 
14 166·0)
54·6*
(52·1 to 57·2)
0·1
(–1·0 to 1·2)
Bipolar disorder 48 778·4
(43 498·9 to 54 371·2)
49·1*
(46·7 to 52·2)
0·9
(–0·4 to 2·4)
9911·1
(6260·6 to 
14 791·0)
49·2*
(46·4 to 52·5)
1·3
(–0·4 to 2·9)
Anxiety disorders 265 610·1
(213 015·1 to 318 817·0)
42·4*
(36·6 to 46·8)
–0·5
(–1·7 to 0·8)
24 355·8
(16 148·6 to 
35 139·0)
42·1*
(36·4 to 46·5)
–0·2
(–1·6 to 1·3)
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Eating disorders ·· ·· ·· 1820·0
(1154·5 to 2720·3)
27·6*
(23·7 to 32·1)
–1·2
(–4·2 to 1·7)
Anorexia nervosa 2063·6
(1683·5 to 2535·0)
35·4*
(31·1 to 40·7)
5·5*
(2·2 to 9·2)
440·4
(285·5 to 648·3)
35·9*
(30·2 to 41·8)
6·0*
(1·7 to 10·3)
Bulimia nervosa 6537·9
(4917·2 to 8857·6)
24·8*
(20·4 to 29·2)
–3·7*
(–6·9 to –0·8)
1379·7
(850·7 to 2136·6)
25·1*
(20·2 to 30·2)
–3·4
(–7·1 to 0·1)
Autistic spectrum disorders ·· ·· ·· 8449·0
(5888·1 to 11 458·7)
33·8*
(32·7 to 34·9)
0·7
(–0·0 to 1·5)
Autism 21 716·7
(20 731·8 to 22 713·5)
34·1*
(33·5 to 34·8)
0·3*
(0·1 to 0·6)
5345·0
(3583·6 to 7309·9)
33·9*
(32·4 to 35·5)
0·7
(–0·3 to 1·8)
Asperger’s syndrome 31 100·1
(29 251·7 to 32 905·1)
33·7*
(32·9 to 34·5)
0·4*
(0·3 to 0·5)
3104·0
(2169·6 to 4325·0)
33·6*
(32·3 to 35·0)
0·7
(–0·1 to 1·5)
Attention-deﬁ cit or hyperactivity 
disorder
39 343·5
(36 574·2 to 42 093·6)
13·8*
(12·8 to 14·9)
–0·5
(–1·3 to 0·5)
479·9
(287·4 to 745·8)
13·9*
(12·1 to 16·0)
–0·3
(–1·9 to 1·5)
Conduct disorder 51 109·7
(48 006·9 to 54 557·0)
16·3*
(15·4 to 17·2)
2·2*
(1·4 to 3·1)
6159·0
(3868·2 to 8911·6)
16·5*
(15·0 to 18·0)
2·4*
(1·1 to 3·8)
Idiopathic intellectual disability 94 672·8
(75 906·5 to 116 664·7)
22·6*
(12·7 to 35·8)
–5·8
(–13·5 to 4·4)
4666·7
(3084·8 to 6640·0)
22·0*
(12·1 to 35·0)
–6·1
(–13·9 to 3·8)
Other mental and substance use 
disorders
124 042·9
(116 741·4 to 131 001·8)
52·3*
(50·9 to 53·8)
0·2*
(0·1 to 0·3)
9257·2
(6277·9 to 12411·5)
52·3*
(50·5 to 54·1)
0·6
(–0·1 to 1·3)
Diabetes, urogenital, blood, and 
endocrine diseases
·· ·· ·· 65 561·4
(46 201·5 to 
87 834·5)
72·7*
(69·2 to 76·6)
14·1*
(11·9 to 16·4)
Diabetes mellitus 409 967·0
(381 806·3 to 
432 038·4)
132·9*
(123·7 to 142·4)
44·8*
(38·5 to 51·3)
29 518·1
(20 419·1 to 
40 169·3)
135·7*
(127·2 to 143·7)
43·4*
(37·9 to 48·5)
Acute glomerulonephritis 37·7
(35·1 to 40·5)
–3·4*
(–6·0 to –1·2)
–22·2*
(–24·2 to –20·6)
1·9
(1·2 to 2·8)
–3·3*
(–6·0 to –1·1)
–22·2*
(–24·2 to –20·6)
Chronic kidney disease ·· ·· ·· 12 347·3
(9101·6 to 15 814·9)
49·5*
(43·4 to 53·9)
–2·8*
(–6·4 to –0·4)
Chronic kidney disease due to 
diabetes mellitus
88 710·9
(71 150·1 to 111 417·2)
82·4*
(58·6 to 96·8)
11·9
(–3·6 to 21·2)
2491·8
(1802·9 to 3220·7)
80·5*
(65·7 to 92·6)
10·6*
(2·0 to 17·7)
Chronic kidney disease due to 
hypertension
101 253·4
(81 410·4 to 129 993·0)
26·8*
(18·3 to 34·9)
–10·7*
(–17·6 to –5·3)
2635·3
(1915·3 to 3415·5)
23·1*
(16·3 to 33·2)
–22·4*
(–26·9 to –16·3)
Chronic kidney disease due to 
glomerulonephritis
108 860·9
(88 330·3 to 135 481·9)
32·7*
(17·3 to 41·3)
–13·5*
(–25·6 to –6·6)
2495·9
(1809·0 to 3252·0)
33·9*
(25·6 to 43·3)
–6·9*
(–11·9 to –0·5)
Chronic kidney disease due to other 
causes
173 090·7
(142 395·9 to 
213 010·4)
53·9*
(43·5 to 63·6)
3·1
(–5·9 to 10·1)
4724·3
(3503·0 to 6063·2)
63·4*
(55·9 to 71·9)
6·9*
(0·9 to 12·7)
Urinary diseases and male infertility ·· ·· ·· 4880·3
(3212·9 to 7017·1)
83·8*
(77·8 to 91·1)
8·5*
(5·1 to 12·4)
Interstitial nephritis and urinary tract 
infections
1753·7
(1730·2 to 1775·3)
67·5*
(64·6 to 70·9)
16·2*
(14·3 to 18·4)
58·1
(36·4 to 85·6)
66·8*
(59·9 to 74·7)
16·4*
(11·8 to 21·3)
Urolithiasis 80 622·5
(61 562·7 to 103 069·9)
101·9*
(89·6 to 113·3)
20·0*
(12·9 to 26·1)
661·8
(411·4 to 984·0)
95·8*
(83·0 to 109·3)
20·4*
(13·0 to 27·6)
Benign prostatic hyperplasia 99 148·4
(97 356·1 to 100 911·6)
79·3*
(75·4 to 83·7)
3·0*
(0·8 to 5·6)
3552·9
(2316·5 to 4993·7)
80·0*
(75·9 to 84·5)
3·6*
(1·3 to 6·3)
Male infertility due to other causes 39 276·2
(36 950·6 to 41 618·7)
44·0*
(33·3 to 55·3)
2·9
(–4·8 to 11·0)
258·6
(111·8 to 531·4)
43·6*
(32·3 to 56·6)
3·0
(–5·1 to 12·0)
Other urinary diseases ·· ·· ·· 348·9
(175·8 to 544·0)
195·7*
(94·2 to 241·5)
86·0*
(23·4 to 114·7)
Gynaecological diseases ·· ·· ·· 9131·4
(5982·5 to 13 595·8)
44·5*
(40·3 to 49·3)
–3·5*
(–6·1 to –0·5)
Uterine ﬁ broids 171 005·4
(158 155·9 to 182 513·5)
62·5*
(61·2 to 63·8)
–1·8*
(–2·3 to –1·2)
2164·7
(1242·3 to 3677·9)
36·6*
(29·4 to 43·6)
–14·3*
(–18·3 to –10·6)
Polycystic ovarian syndrome 122 310·6
(119 572·7 to 124 929·3)
51·1*
(46·6 to 55·6)
2·3
(–0·6 to 5·2)
1191·2
(562·3 to 2227·4)
51·7*
(47·1 to 56·4)
3·0*
(0·1 to 6·1)
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Female infertility due to other causes 34 678·6
(31 103·9 to 38 009·3)
58·3*
(44·8 to 72·4)
10·7*
(1·7 to 20·3)
191·9
(75·2 to 399·1)
56·9*
(42·4 to 71·6)
11·0*
(1·0 to 21·0)
Endometriosis 14 661·2
(14 230·8 to 15 094·4)
47·9*
(41·9 to 53·5)
–1·6
(–5·6 to 2·1)
1359·6
(906·4 to 1861·5)
48·1*
(42·1 to 54·3)
–1·3
(–5·3 to 2·8)
Genital prolapse 343 707·8
(336 958·8 to 
350 327·4)
57·0*
(53·0 to 61·5)
–0·9
(–3·3 to 1·7)
1094·2
(534·5 to 2041·0)
57·1*
(52·9 to 61·7)
–0·7
(–3·3 to 2·1)
Premenstrual syndrome 302 731·7
(284 373·1 to 
321 829·6)
53·8*
(40·3 to 67·9)
9·2
(–0·1 to 19·4)
2548·6
(1581·3 to 3777·0)
54·0*
(40·7 to 67·9)
9·5*
(0·1 to 19·5)
Other gynaecological diseases 20 758·0
(19 699·4 to 21 792·8)
15·7*
(6·9 to 26·4)
–19·3*
(–25·6 to –11·8)
581·3
(395·7 to 826·6)
4·2
(–4·6 to 21·3)
–27·2*
(–33·5 to –14·7)
Haemoglobinopathies and 
haemolytic anaemias
·· ·· ·· 7071·9
(4730·8 to 10107·0)
23·2*
(20·7 to 26·5)
–2·3
(–4·2 to 0·3)
Thalassaemias 766·7
(691·8 to 849·8)
11·6*
(8·5 to 19·1)
–2·5
(–5·1 to 3·8)
61·9
(42·1 to 88·0)
10·2*
(1·8 to 22·1)
–4·2
(–11·3 to 5·8)
Thalassaemia trait 207 561·8
(192 411·3 to 
228 437·6)
37·3*
(34·7 to 39·6)
2·7*
(0·5 to 4·5)
3769·6
(2508·9 to 5442·2)
34·6*
(31·0 to 38·8)
5·9*
(3·1 to 9·3)
Sickle cell disorders 3250·4
(3091·7 to 3400·5)
77·6*
(69·9 to 86·1)
52·3*
(45·8 to 59·6)
342·1
(246·2 to 455·9)
79·4*
(68·1 to 90·9)
49·7*
(40·1 to 59·0)
Sickle cell trait 261 740·7
(249 515·4 to 
272 735·9)
57·0*
(54·2 to 59·7)
19·3*
(17·1 to 21·3)
1396·6
(929·4 to 2004·9)
39·0*
(32·0 to 49·0)
13·8*
(8·0 to 23·6)
Glucose-6-phosphate 
dehydrogenase deﬁ ciency
337 628·8
(329 360·6 to 
345 753·7)
47·1*
(42·1 to 51·9)
11·4*
(7·6 to 15·1)
36·3
(24·8 to 50·4)
40·5*
(31·7 to 49·5)
11·4*
(4·8 to 18·1)
Glucose-6-phosphate 
dehydrogenase deﬁ ciency trait
1 181 972·5
(1 174 352·1 to 
1 188 844·0)
38·6*
(37·6 to 39·9)
3·0*
(2·2 to 3·9)
48·8
(30·1 to 73·3)
23·6
(–1·0 to 50·9)
–0·7
(–20·6 to 20·4)
Other haemoglobinopathies and 
haemolytic anaemias
56 010·1
(54 470·2 to 57 258·6)
–2·3
(–5·5 to 1·3)
–26·6*
(–29·0 to –24·0)
1416·5
(936·5 to 2051·7)
–12·7*
(–17·5 to –6·4)
–31·4*
(–35·1 to –26·4)
Endocrine, metabolic, blood, and 
immune disorders
79 556·0
(77 363·2 to 81 282·3)
10·3*
(6·9 to 13·8)
–16·2*
(–18·8 to –13·7)
2610·6
(1797·9 to 3629·0)
6·9*
(2·2 to 12·8)
–16·7*
(–20·2 to –12·3)
Musculoskeletal disorders ·· ·· ·· 146 231·3
(103 763·1 to 
194 304·6)
60·7*
(58·6 to 63·6)
0·6
(–0·5 to 2·3)
Rheumatoid arthritis 16 863·2
(16 714·4 to 17 035·8)
57·0*
(54·7 to 59·1)
–5·1*
(–6·5 to –3·8)
3925·6
(2818·6 to 5178·5)
56·8*
(53·9 to 59·4)
–4·6*
(–6·3 to –3·1)
Osteoarthritis 241 825·0
(239 655·8 to 
243 896·7)
71·9*
(69·8 to 74·3)
–2·6*
(–3·8 to –1·2)
12 811·1
(9030·0 to 17 281·2)
75·4*
(72·9 to 77·8)
–0·2
(–1·6 to 1·2)
Low back and neck pain ·· ·· ·· 106 665·5
(74 116·9 to 
142 959·7)
55·8*
(53·3 to 59·6)
–0·4
(–1·9 to 1·9)
Low back pain 651 008·8
(641 143·4 to 
662 885·1)
56·8*
(53·6 to 61·4)
–0·4
(–2·4 to 2·5)
72 317·6
(49 051·0 to 
99 738·5)
56·7*
(53·5 to 61·5)
0·0
(–2·0 to 2·9)
Neck pain 349 305·2
(341 160·3 to 
359 767·4)
54·1*
(49·1 to 59·9)
–1·5
(–4·6 to 2·2)
34 347·9
(23 792·0 to 
47 418·5)
54·0*
(49·0 to 59·9)
–1·2
(–4·3 to 2·6)
Gout 5825·6
(5750·0 to 5904·8)
67·5*
(64·6 to 70·8)
–2·3*
(–4·0 to –0·3)
185·5
(129·0 to 249·2)
67·7*
(62·6 to 73·3)
–1·8
(–4·7 to 1·4)
Other musculoskeletal disorders 248 188·2
(216 691·1 to 
281 933·6)
78·4*
(75·0 to 82·5)
6·6*
(5·0 to 8·9)
22 643·6
(15 253·8 to 
31 684·6)
78·6*
(75·0 to 82·9)
7·0*
(5·3 to 9·3)
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Other non-communicable diseases ·· ·· ·· 117 951·0
(78 473·3 to 
170 905·6)
44·8*
(42·8 to 46·7)
–4·1*
(–5·4 to –3·0)
Congenital anomalies ·· ·· ·· 8022·5
(5922·6 to 10 168·4)
61·4*
(52·5 to 72·8)
19·7*
(13·2 to 28·2)
Neural tube defects 1470·2
(1434·6 to 1508·2)
59·2*
(53·8 to 64·4)
25·4*
(21·2 to 29·6)
461·2
(325·4 to 599·6)
61·6*
(53·7 to 70·7)
27·9*
(21·4 to 35·1)
Congenital heart anomalies 34 315·9
(33 178·0 to 35 691·2)
88·0*
(80·3 to 98·5)
40·0*
(34·5 to 47·8)
1230·4
(540·8 to 2079·5)
86·8*
(77·3 to 97·6)
40·7*
(34·5 to 48·5)
Orofacial clefts 5807·6
(5621·9 to 5988·1)
94·4*
(86·1 to 105·9)
47·9*
(41·2 to 56·6)
68·8
(45·6 to 98·8)
76·3*
(65·2 to 89·5)
37·1*
(28·4 to 47·3)
Down’s syndrome 8538·5
(8185·7 to 8897·8)
79·5*
(70·1 to 88·2)
32·8*
(26·0 to 39·2)
1167·1
(894·8 to 1459·7)
91·3*
(80·5 to 101·4)
36·4*
(29·3 to 42·9)
Turner’s syndrome 257·5
(246·6 to 271·2)
51·2*
(42·6 to 62·3)
14·8*
(8·4 to 23·3)
4·3
(2·2 to 6·9)
52·1*
(42·9 to 64·8)
14·5*
(7·5 to 23·8)
Klinefelter’s syndrome 216·3
(207·1 to 226·7)
42·0*
(33·2 to 52·7)
6·5*
(0·0 to 14·5)
1·3
(0·6 to 2·4)
47·2*
(37·0 to 58·8)
5·5
(–1·8 to 13·9)
Chromosomal unbalanced 
rearrangements
11 649·3
(11 154·1 to 12 235·1)
74·0*
(66·0 to 83·0)
27·5*
(21·7 to 34·0)
1602·9
(1203·6 to 2038·4)
85·1*
(75·6 to 95·0)
30·6*
(24·8 to 37·1)
Other congenital anomalies 25 840·0
(22 170·5 to 29 283·1)
22·9*
(17·2 to 28·7)
–10·6*
(–14·7 to –6·5)
3486·4
(2436·6 to 4641·2)
38·7*
(26·5 to 56·4)
4·3
(–4·6 to 17·4)
Skin and subcutaneous diseases ·· ·· ·· 39 051·0
(25 044·5 to 
60 125·8)
37·3*
(33·8 to 40·3)
0·3
(–2·0 to 2·3)
Dermatitis 333 785·4
(289 927·3 to 
381 312·4)
38·7*
(36·2 to 41·1)
–1·7*
(–2·4 to –0·9)
9278·4
(6029·0 to 13 326·7)
36·8*
(34·7 to 39·2)
–0·6
(–1·4 to 0·3)
Psoriasis 58 264·1
(51 720·2 to 64 609·4)
46·0*
(44·0 to 48·8)
–2·2*
(–3·0 to –1·6)
4726·7
(3254·7 to 6621·9)
45·9*
(43·2 to 48·8)
–1·9*
(–3·0 to –0·6)
Cellulitis 1705·9
(1429·7 to 2040·3)
19·1*
(13·2 to 25·1)
–18·2*
(–21·2 to –15·9)
120·2
(78·6 to 170·2)
18·6*
(11·3 to 26·6)
–18·0*
(–21·9 to –13·8)
Bacterial skin diseases 5759·7
(4693·5 to 7278·2)
–6·7
(–16·2 to 3·7)
–23·8*
(–29·9 to –17·6)
32·6
(12·4 to 72·1)
–7·1
(–16·3 to 2·9)
–24·0*
(–29·8 to –17·7)
Scabies 66 107·5
(62 430·1 to 70 635·9)
24·8*
(15·0 to 40·1)
–4·0
(–11·3 to 7·3)
1705·4
(967·2 to 2711·6)
24·8*
(14·8 to 40·3)
–3·7
(–11·2 to 7·8)
Fungal skin diseases 683 713·8
(597 898·2 to 
780 963·4)
44·2*
(41·2 to 47·9)
3·0*
(1·9 to 3·8)
3847·2
(1574·5 to 8139·8)
44·1*
(41·1 to 47·9)
3·3
(2·2 to 4·1)
Viral skin diseases 127 923·6
(105 593·4 to 
151 635·9)
20·5*
(17·9 to 24·3)
–1·8*
(–3·1 to –0·3)
3955·0
(2398·4 to 6150·9)
20·4*
(17·8 to 24·1)
–1·7
(–3·0 to 0·0)
Acne vulgaris 661 634·9
(622 842·5 to 
700 241·7)
23·2*
(13·9 to 32·6)
–0·4
(–7·8 to 7·3)
7180·8
(3451·6 to 13 214·1)
23·2*
(13·7 to 32·7)
–0·3
(–7·7 to 7·4)
Alopecia areata 8775·5
(8614·4 to 8937·9)
46·1*
(42·5 to 49·4)
–1·1
(–3·4 to 1·2)
292·4
(186·8 to 435·2)
45·6*
(41·2 to 50·0)
–0·9
(–3·6 to 1·8)
Pruritus 1024·6
(988·1 to 1074·1)
55·3*
(46·3 to 63·1)
–0·2
(–5·9 to 5·3)
10·8
(5·1 to 20·0)
54·8*
(44·9 to 64·9)
0·0
(–6·4 to 6·5)
Urticaria 79 582·8
(72 812·3 to 86 296·3)
60·5*
(44·2 to 75·0)
7·3
(–3·8 to 16·6)
4720·7
(3036·5 to 6737·2)
60·7*
(43·4 to 75·5)
7·7
(–3·5 to 17·6)
Decubitus ulcer 1921·4
(1853·0 to 2001·2)
59·5*
(51·8 to 67·1)
–8·1*
(–13·1 to –3·3)
277·5
(196·0 to 371·2)
58·1*
(49·8 to 66·8)
–7·7*
(–12·9 to –2·5)
Other skin and subcutaneous 
diseases
495 327·6
(319 462·3 to 
761 255·5)
57·1*
(48·5 to 64·4)
0·0
(–0·9 to 0·9)
2903·1
(1274·1 to 6123·6)
57·0*
(48·5 to 64·5)
0·4
(–0·6 to 1·3)
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Sense organ diseases ·· ·· ·· 54 428·1
(36 458·4 to 
76 075·4)
47·4*
(44·1 to 50·1)
–8·2*
(–9·7 to –6·7)
Glaucoma 10 899·9
(9853·2 to 12 002·8)
63·0*
(50·2 to 74·7)
–3·5
(–10·6 to 2·9)
807·5
(571·6 to 1102·8)
63·1*
(54·8 to 70·9)
–4·6*
(–9·7 to –0·2)
Cataract 44 221·6
(39 326·0 to 48 603·1)
47·5*
(41·3 to 56·4)
–17·6*
(–20·8 to –13·0)
2916·7
(2055·1 to 3962·2)
56·7*
(50·6 to 63·9)
–12·5*
(–15·7 to –8·6)
Macular degeneration 13 873·8
(12 176·5 to 15 562·6)
76·3*
(69·4 to 89·3)
–1·6
(–5·6 to 5·1)
725·6
(509·4 to 985·1)
75·0*
(69·0 to 87·8)
–4·4
(–8·6 to 1·4)
Uncorrected refractive error 659 847·2
(648 298·7 to 
671 446·7)
52·0*
(49·0 to 55·0)
–5·2*
(–7·0 to –3·4)
11 257·2
(7149·8 to 17 452·3)
43·5*
(40·4 to 47·2)
–8·9*
(–10·6 to –7·0)
Age-related and other hearing loss 1 128 939·1
(1 055 657·5 to 
1 200 476·4)
55·7*
(52·7 to 58·4)
–6·5*
(–7·9 to –5·2)
32 579·7
(22 083·7 to 
45 846·1)
50·7*
(45·4 to 54·8)
–7·9*
(–10·2 to –5·4)
Other vision loss 26 806·0
(24 116·0 to 29 696·9)
19·9*
(16·0 to 23·8)
–22·2*
(–25·0 to –19·9)
1793·5
(1260·4 to 2452·0)
23·7*
(19·4 to 27·6)
–21·1*
(–23·5 to –19·0)
Other sense organ diseases 164 612·2
(163 116·9 to 
166 389·9)
34·2*
(32·5 to 36·2)
–0·2
(–1·4 to 1·2)
4348·0
(2704·3 to 6435·1)
33·7*
(31·7 to 35·8)
0·1
(–1·3 to 1·6)
Oral disorders ·· ·· ·· 16 449·5
(10 022·3 to 
25 506·3)
47·6*
(45·8 to 49·7)
–7·7*
(–9·7 to –5·5)
Deciduous caries 492 920·5
(490 657·1 to 
495 385·2)
4·4*
(3·6 to 5·2)
–2·1*
(–2·8 to –1·4)
181·1
(79·0 to 350·9)
5·7*
(4·1 to 7·5)
–0·9
(–2·3 to 0·8)
Permanent caries 2 633 328·8
(2 607 931·9 to 
2 658 749·5)
37·4*
(35·8 to 39·6)
–1·2
(–2·3 to 0·4)
2411·0
(1102·6 to 4664·5)
40·5*
(38·3 to 43·0)
1·8*
(0·1 to 3·7)
Periodontal diseases 503 967·2
(496 870·4 to 
511 448·4)
66·7*
(63·7 to 70·1)
1·4
(–0·4 to 3·4)
3286·0
(1318·3 to 6750·3)
66·8*
(63·8 to 70·3)
1·7
(–0·2 to 3·7)
Edentulism and severe tooth loss 250 683·6
(247 512·3 to 
253 463·0)
45·6*
(43·4 to 47·9)
–16·4*
(–17·7 to –15·1)
6855·6
(4647·2 to 9420·4)
45·6*
(43·3 to 47·9)
–16·2*
(–17·6 to –14·9)
Other oral disorders 126 945·5
(125 452·3 to 
128 568·2)
44·7*
(42·5 to 46·9)
–0·5
(–2·0 to 0·9)
3715·7
(2347·5 to 5558·6)
44·6*
(42·2 to 46·9)
–0·3
(–1·9 to 1·2)
Injuries ·· ·· ·· 36 831·5
(26 895·7 to 
48 748·0)
0·3
(–13·7 to 11·3)
–37·0*
(–45·4 to –30·0)
Transport injuries ·· ·· ·· 10 194·9
(7477·9 to 
13 437·8)
6·2
(–1·0 to 14·5)
–31·7*
(–36·2 to –26·8)
Road injuries ·· ·· ·· 8593·4
(6305·9 to 11 313·7)
6·9
(–0·7 to 15·8)
–31·0*
(–35·8 to –25·8)
Pedestrian road injuries 37 844·1
(37 457·1 to 38 216·7)
53·7*
(51·7 to 55·6)
0·6
(–0·7 to 1·9)
2271·8
(1657·1 to 2993·5)
17·2*
(8·9 to 27·0)
–23·6*
(–28·5 to –17·8)
Cyclist road injuries 13 678·6
(13 439·2 to 13 925·1)
24·1*
(22·1 to 26·2)
–14·9*
(–16·3 to –13·4)
812·4
(594·6 to 1074·2)
2·8
(–3·5 to 9·9)
–33·9*
(–37·9 to –29·5)
Motorcyclist road injuries 32 483·6
(31 964·6 to 33 019·7)
28·0*
(25·5 to 30·0)
–17·2*
(–18·9 to –15·9)
1649·2
(1201·7 to 2204·5)
–4·2
(–12·2 to 5·1)
–38·2*
(–43·1 to –32·5)
Motor vehicle road injuries 60 733·7
(59 848·5 to 61 593·1)
40·8*
(39·3 to 42·4)
–2·7*
(–3·7 to –1·5)
3777·8
(2811·0 to 4946·9)
8·1*
(0·3 to 16·7)
–30·9*
(–35·6 to –25·8)
Other road injuries 1371·5
(1351·1 to 1393·6)
17·9*
(15·9 to 19·8)
–22·8*
(–24·2 to –21·5)
82·3
(61·0 to 107·3)
–5·7
(–11·4 to 1·0)
–40·1*
(–43·4 to –36·1)
Other transport injuries 26 293·0
(25 899·6 to 26 709·0)
22·9*
(20·3 to 25·2)
–21·7*
(–23·5 to –20·1)
1601·5
(1173·2 to 2118·5)
2·2
(–3·1 to 8·5)
–35·1*
(–38·5 to –31·2)
(Table 10 continues on next page)
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Prevalent cases in 2013 
(× 1000)
Percentage change 
in prevalence
from 1990 to 2013
Percentage change 
in age-standardised 
prevalence from 
1990 to 2013
YLDs in 2013 
(× 1000)
Percentage change in 
YLDs from 
1990 to 2013
Percentage change in 
age-standardised YLDs 
from 1990 to 2013
(Continued from previous page)
Unintentional injuries ·· ·· ·· 21 649·4
(16 036·0 to 
28 726·9)
17·9*
(10·5 to 25·8)
–28·0*
(–32·8 to –22·7)
Falls 250 044·4
(247 438·2 to 252 548·9)
61·3*
(59·7 to 62·8)
0·9
(–0·2 to 1·8)
12 818·1
(9356·9 to 16 996·8)
23·5*
(13·6 to 35·0)
–28·3*
(–34·5 to –21·1)
Drowning 6149·1
(6022·3 to 6275·4)
13·7*
(10·6 to 16·7)
–23·9*
(–25·9 to –21·9)
373·6
(273·4 to 485·1)
–8·6*
(–13·5 to –2·4)
–37·9*
(–40·9 to –34·1)
Fire, heat, and hot substances 35 326·2
(34 097·3 to 36 575·8)
7·4*
(3·4 to 11·8)
–28·7*
(–31·4 to –25·5)
1172·2
(867·1 to 1551·4)
–4·7
(–10·0 to 0·6)
–36·8*
(–39·8 to –33·8)
Poisonings 925·2
(910·3 to 939·5)
5·1*
(2·8 to 7·0)
–29·2*
(–30·7 to –27·9)
78·7
(56·2 to 104·5)
–6·3*
(–9·8 to –2·7)
–36·7*
(–39·0 to –34·4)
Exposure to mechanical forces ·· ·· ·· 3758·0
(2748·6 to 4985·4)
5·2*
(0·3 to 10·4)
–30·1*
(–33·0 to –26·9)
Unintentional ﬁ rearm injuries 3729·0
(3639·3 to 3820·9)
29·9*
(26·7 to 33·3)
–13·3*
(–15·4 to –11·1)
146·6
(109·0 to 194·3)
6·4
(–0·3 to 14·2)
–29·8*
(–34·0 to –25·1)
Unintentional suﬀ ocation 949·6
(923·4 to 979·8)
66·5*
(63·2 to 69·4)
13·4*
(11·6 to 15·0)
54·2
(40·2 to 71·6)
42·2*
(34·7 to 50·1)
–3·3
(–8·1 to 1·6)
Other exposure to mechanical forces 113 111·5
(105 859·7 to 120 514·4)
15·7*
(12·9 to 18·0)
–18·0*
(–19·7 to –16·5)
3557·2
(2597·7 to 4726·4)
4·7
(0·0 to 9·8)
–30·4*
(–33·3 to –27·3)
Adverse eﬀ ects of medical treatment 1526·1
(1226·7 to 1820·2)
46·2*
(44·0 to 48·5)
–1·0
(–2·4 to 0·4)
201·0
(127·1 to 295·2)
48·4*
(46·1 to 50·7)
–5·7*
(–7·2 to –4·0)
Animal contact ·· ·· ·· 403·5
(299·5 to 527·6)
–6·3*
(–10·6 to –1·4)
–36·4*
(–39·0 to –33·5)
Venomous 2274·1
(2204·9 to 2346·6)
2·6
(–2·1 to 6·8)
–31·1*
(–34·2 to –28·3)
153·1
(110·5 to 201·1)
–7·5*
(–12·6 to –2·2)
–37·1*
(–40·5 to –33·6)
Non-venomous 12 089·8
(10 522·9 to 13 775·5)
–5·6
(–10·9 to 0·0)
–32·8*
(–35·9 to –29·6)
250·5
(183·9 to 337·8)
–5·4
(–10·9 to 0·6)
–36·0*
(–38·9 to –32·8)
Foreign body ·· ·· ·· 254·8
(186·8 to 325·0)
22·1*
(16·2 to 29·0)
–19·4*
(–23·3 to –15·0)
Pulmonary aspiration and foreign 
body in airway
887·8
(873·4 to 902·7)
42·5*
(39·7 to 45·5)
–4·6*
(–6·3 to –2·8)
50·2
(38·4 to 64·6)
–2·7
(–10·5 to 7·4)
–33·7*
(–38·6 to –27·2)
Foreign body in eyes 1164·8
(737·5 to 1586·1)
41·5*
(37·7 to 46·7)
0·4
(–1·5 to 2·3)
60·3
(35·0 to 91·7)
30·6*
(26·0 to 34·9)
–10·4*
(–15·4 to –6·9)
Foreign body in other body part 3912·3
(3465·6 to 4383·6)
42·0*
(34·0 to 49·6)
–4·0*
(–8·3 to –0·2)
144·3
(108·0 to 186·5)
30·1*
(23·9 to 36·9)
–16·5*
(–20·1 to –12·7)
Other unintentional injuries 51 132·0
(49 359·0 to 52 946·0)
45·2*
(43·1 to 47·7)
–3·9*
(–5·2 to –2·5)
2589·5
(1905·1 to 3445·3)
34·2*
(29·7 to 39·1)
–16·0*
(–18·5 to –13·3)
Self-harm and interpersonal violence ·· ·· ·· 1053·5
(778·0 to 1388·0)
1·8
(–5·0 to 10·5)
–34·4*
(–38·5 to –29·2)
Self-harm 5940·8
(5845·2 to 6051·2)
21·5*
(18·5 to 24·2)
–24·7*
(–26·3 to –23·2)
231·6
(167·0 to 307·3)
–1·7
(–6·9 to 5·4)
–39·0*
(–42·2 to –34·8)
Interpersonal violence ·· ·· ·· 821·9
(610·4 to 1077·7)
2·8
(–4·5 to 12·0)
–33·0*
(–37·4 to –27·3)
Assault with ﬁ rearm 3870·2
(3765·2 to 3974·2)
46·7*
(42·6 to 50·5)
–3·2*
(–5·9 to –0·7)
163·1
(120·0 to 216·6)
21·9*
(14·8 to 29·8)
–21·1*
(–25·4 to –16·5)
Assault with sharp object 6078·6
(5868·9 to 6311·1)
41·9*
(36·4 to 47·2)
–7·0*
(–10·3 to –3·7)
172·3
(124·9 to 233·2)
18·5*
(10·8 to 28·0)
–22·9*
(–27·6 to –17·2)
Assault by other means 10 133·4
(9835·8 to 10 448·3)
21·4*
(18·8 to 23·7)
–17·9*
(–19·3 to –16·6)
486·5
(364·2 to 635·7)
–6·4
(–12·9 to 2·4)
–38·8*
(–42·9 to –33·4)
Forces of nature, war, and legal 
intervention
·· ·· ·· 3933·7
(1860·7 to 7821·0)
–50·7*
(–57·7 to –40·2)
–67·9*
(–72·6 to –61·0)
Exposure to forces of nature 14 335·5
(7133·3 to 28 680·1)
8·2
(–4·6 to 29·0)
–37·4*
(–45·6 to –24·5)
556·8
(280·6 to 1117·0)
–0·7
(–15·1 to 22·3)
–36·7*
(–45·8 to –22·0)
Collective violence and legal 
intervention
43 478·1
(23 580·2 to 77 304·6)
–27·0*
(–32·2 to –17·3)
–46·7*
(–51·2 to –40·8)
3376·9
(1547·3 to 6784·6)
–54·6*
(–60·2 to –46·1)
–70·3*
(–74·2 to –64·5)
All data are reported with 95% uncertainty intervals. YLDs=years lived with disability. *Signiﬁ cant percentage change.
Table 10: Prevalent cases and YLDs for 2013, percentage change, and percentage change of age-standardised rates between 1990 and 2013 for all causes
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next most important cause was cataract followed by other 
vision loss, preterm birth complications, glaucoma, 
macular degeneration, and diabetes.
Figure 3 shows the comparison of the leading causes of 
global YLDs in 1990 and 2013, which provides detailed 
cause breakdowns that were most relevant to prioritising 
speciﬁ c programmes or interventions. The top cause in 
1990 and 2013 was low back pain. The second leading 
cause changed due to the decline in iron-deﬁ ciency 
anaemia and the rise in major depressive disorder. Two 
more top ten causes were musculoskeletal disorders: 
neck pain and the large category of other musculoskeletal 
disorders. Other top ten causes included migraine, age-
related and other hearing loss, COPD, anxiety, and 
diabetes. Causes that increased more than two ranks 
from 1990 to 2013 included diabetes mellitus, osteo-
arthritis, dysthymia, medication overuse headache, and 
Alzheimer’s disease and other dementias. Declines of 
more than two ranks were noted for dermatitis, 
diarrhoeal diseases, acne vulgaris, conduct disorder, and 
war and legal intervention.
Table 10 provides the global estimates of prevalence and 
YLDs for 2013 and change from 1990 to 2013 for each 
cause (the full details at the levels of the sequelae; 
prevalence, YLD, and change between 1990 and 2013 by 
cause and age group; and prevalence, YLD, and change 
between 1990 and 2013 by cause and country are shown 
in the appendix pp 738–811). In the GBD framework, 
individuals should be assigned to a unique sequela such 
that the sum of the YLDs or prevalence by sequela should 
equal the total prevalence and YLDs for a disease or 
injury. Since speciﬁ c sequelae are of substantive interest 
to help target interventions or needs for new interventions, 
and to enhance the transparency of computation, we have 
provided the full list of causes and sequelae. Comparison 
of the percentage change in absolute number of YLDs 
from 1990 to 2013 and the percentage change in the 
age-standardised YLD rate shows where demographic 
change, both population increase and rising mean age, 
had a major eﬀ ect. Age-standardised YLDs and prevalence 
for several infectious diseases showed signiﬁ cant declines 
of greater than 10% including diarrhoeal diseases, 
typhoid, paratyphoid, lower respiratory infections, 
meningitis, encephalitis, diphtheria, whooping cough, 
tetanus, measles, Chagas, African trypanosomiasis, 
cysticercosis, cystic echinococcosis, lymphatic ﬁ lariasis, 
onchocerciasis, trachoma, rabies, ascariasis, trichuriasis, 
and hookworm. By contrast, signiﬁ cant increases in age-
standardised rates of greater than 10% were noted for 
HIV (from 1990 to 2013, but declines since 2005),61 
cutaneous and mucocutaneous leishmaniasis, and 
dengue. Some other disorders such as malaria, 
tuberculosis, upper respiratory infections, varicella, and 
schistosomiasis did not show signiﬁ cant changes in 
either direction of greater than 10%.
Age-standardised YLD rates for all maternal causes 
and sequelae combined declined signiﬁ cantly. Overall 
age-standardised YLDs for neonatal disorders increased 
80·5% from 1990 to 2013 (table 10). Large increases in age-
standardised rates were noted for all neonatal causes. Age-
standardised YLDs and prevalence of nutritional 
deﬁ ciencies decreased as did the absolute numbers of 
cases. Although there was a decline in the age-standardised 
rates for syphilis, they were either non-signiﬁ cant or small 
for chlamydia and gonorrhoea (table 10). The decline was 
signiﬁ cant for hepatitis B and C, but non-signiﬁ cant for 
hepatitis A and E. Of note, the number of individuals with 
hepatitis C infection increased.
Age-standardised YLD rates from all non-communicable 
diseases changed by only 1·4% from 1990 to 2013, but 
YLD numbers increased by 54·2% (table 10). Stagnant 
overall rates masked highly diverse trends for speciﬁ c 
causes. Overall, neoplasm YLDs increased 82·5% and 
age-standardised rates increased signiﬁ cantly by 8·5%. 
However, within the category of neoplasms, signiﬁ cant 
declines were noted for stomach cancer, liver cancer due 
to alcohol use, liver cancer due to other causes, larynx 
cancer, cervical cancer, nasopharynx cancer, gallbladder 
and biliary tract cancer, and bladder cancer. Signiﬁ cant 
increases were noted for liver cancer due to hepatitis C, 
breast cancer, prostate cancer, colon and rectum cancer, 
pancreatic cancer, non-melanoma skin cancer, kidney 
cancer, thyroid cancer, non-Hodgkin lymphoma, and 
other neoplasms. Of note, there was no signiﬁ cant change 
in the trachea, bronchus, and lung cancer age-
standardised rates. YLDs for cardiovascular diseases 
overall increased 89·2%, but age-standardised rates did 
not change signiﬁ cantly. Among cardiovascular causes, 
age-standardised YLD rates declined signiﬁ cantly for 
atrial ﬁ brillation and ﬂ utter and peripheral vascular 
diseases. By contrast, age-standardised rates increased 
signiﬁ cantly by more than 5% for hypertensive heart 
disease and cardiomyopathy and myocarditis.
Numbers of YLDs from chronic respiratory diseases 
increased from 1990 to 2013 by 55·1% but age-standardised 
rates remained stagnant (table 10). Overall cirrhosis age-
standardised prevalence and YLD rates declined, although 
for cirrhosis caused by hepatitis C the change was not 
signiﬁ cant. Among the digestive diseases, gastritis 
and duodenitis, appendicitis, inguinal, femoral, and 
abdominal hernia, gallbladder and biliary diseases, 
and other digestive diseases increased in absolute terms 
but declined in age-standardised rates. By contrast, 
inﬂ ammatory bowel diseases, paralytic ileus and intestinal 
obstruction, and pancreatitis increased in numbers and 
rates. YLDs from neurological disorders, as a group, 
increased 59·6%, but age-standardised rates increased by 
only 5·0%. There was no change in age-standardised rates 
for Alzheimer’s and other dementias but YLD numbers 
increased by 91·8%. The age-standardised rates of 
Parkinson’s disease and primary epilepsy increased but 
not signiﬁ cantly, consistent with the consideration that 
they are largely genetically determined. YLDs from 
multiple sclerosis increased in age-standardised rates and 
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(Figure 4 continues on next page)
Northern Ireland Back pain MDD Neck pain Falls Diabetes Migraine Hearing Anxiety Other MSK COPD
Scotland Back pain Neck pain Diabetes Falls Hearing Migraine Asthma Other MSK MDD Anxiety
Wales Back pain MDD Neck pain Falls Hearing Diabetes Migraine Anxiety Other MSK COPD
Central Europe, eastern Europe, and central Asia Back pain MDD Hearing Migraine Neck pain Diabetes Falls Osteoarthritis Other MSK Med Head
Central Asia Back pain MDD Diabetes Migraine Iron Neck pain Hearing Falls Anxiety Osteoarthritis
Armenia Back pain MDD Diabetes Hearing Migraine Falls Neck pain Iron Osteoarthritis Anxiety
Azerbaijan Back pain MDD Diabetes Migraine Iron Falls Neck pain Hearing Anxiety Osteoarthritis
Georgia Diabetes MDD Hearing Back pain Falls Migraine Neck pain Osteoarthritis COPD Other MSK
Kazakhstan Back pain MDD Diabetes Migraine Hearing Neck pain Iron Falls Anxiety Osteoarthritis
Kyrgyzstan MDD Back pain Migraine Diabetes Iron Neck pain Hearing Falls Anxiety Osteoarthritis
Mongolia MDD Back pain Migraine Diabetes Neck pain Hearing Iron Falls Anxiety Alcohol
Tajikistan MDD Back pain Iron Migraine Diabetes Falls Neck pain Hearing Anxiety Schizophrenia
Turkmenistan MDD Back pain Migraine Diabetes Iron Neck pain Hearing Falls Anxiety Schizophrenia
Uzbekistan MDD Back pain Migraine Diabetes Iron Neck pain Hearing Falls Anxiety Schizophrenia
Central Europe Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis COPD Iron
Albania Back pain Falls MDD Iron Migraine Hearing Diabetes Neck pain Anxiety Osteoarthritis
Bosnia and Herzegovina Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis War COPD
Bulgaria Back pain Falls Diabetes Hearing MDD Neck pain Osteoarthritis Migraine COPD Anxiety
Croatia Back pain Hearing MDD Diabetes Falls Neck pain Migraine Osteoarthritis COPD Anxiety
Czech Republic Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis COPD Anxiety
Hungary Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis COPD Anxiety
Macedonia Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis Iron COPD
Montenegro Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis Iron COPD
Poland Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis COPD Anxiety
Romania Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis Iron COPD
Serbia Back pain MDD Hearing Diabetes Falls Neck pain Migraine Osteoarthritis COPD Iron
Global Back pain MDD Iron Neck pain Hearing Migraine Diabetes COPD Anxiety Other MSK
Developed countries Back pain MDD Neck pain Other MSK Hearing Diabetes Migraine Falls Anxiety COPD
Developing countries Back pain MDD Iron Neck pain Hearing Migraine Diabetes COPD Anxiety Other MSK
High-income countries Back pain Neck pain MDD Other MSK Diabetes Hearing Anxiety Falls Migraine COPD
Australasia Back pain MDD Other MSK Neck pain Migraine Anxiety Asthma COPD Hearing Diabetes
Australia Back pain MDD Other MSK Neck pain Migraine Anxiety COPD Asthma Hearing Diabetes
New Zealand Back pain MDD Neck pain Anxiety Other MSK Asthma COPD Hearing Diabetes Migraine
High-income Asia Pacific Back pain Other MSK Neck pain Diabetes MDD Hearing Iron Migraine Falls Osteoarthritis
Brunei Back pain Neck pain MDD Iron Other MSK Migraine Anxiety Diabetes Schizophrenia Dermatitis
Japan Back pain Other MSK Diabetes Neck pain MDD Hearing Falls Iron Alzheimer Osteoarthritis
Singapore MDD Diabetes Other MSK Neck pain Back pain Iron Hearing Falls Anxiety Schizophrenia
South Korea Back pain Neck pain Other MSK Migraine Diabetes Iron MDD Hearing Anxiety Falls
High-income North America Back pain Other MSK MDD Anxiety COPD Diabetes Neck pain Hearing Falls Migraine
Canada Back pain Other MSK Neck pain MDD Hearing Diabetes Migraine Anxiety Asthma Falls
USA Back pain MDD Other MSK Anxiety COPD Diabetes Neck pain Hearing Falls Migraine
Southern Latin America Back pain MDD Neck pain Anxiety Other MSK COPD Hearing Asthma Diabetes Iron
Argentina Back pain MDD Neck pain Anxiety Other MSK COPD Hearing Iron Diabetes Asthma
Chile Back pain MDD Neck pain Anxiety Other MSK COPD Epilepsy Migraine Hearing Asthma
Uruguay Back pain MDD Neck pain Anxiety Other MSK COPD Hearing Asthma Iron Diabetes
Western Europe Back pain Neck pain Falls MDD Hearing Diabetes Migraine Anxiety Other MSK Alzheimer
Andorra Back pain Neck pain MDD Falls Hearing Migraine Anxiety Other MSK COPD Alzheimer
Austria Neck pain Back pain Migraine Falls MDD Hearing Diabetes Anxiety Other MSK COPD
Belgium Back pain Neck pain Falls MDD Diabetes Migraine COPD Hearing Alzheimer Anxiety
Cyprus Back pain Neck pain MDD Diabetes Migraine Anxiety Falls Hearing Other MSK COPD
Denmark Back pain Neck pain MDD Falls COPD Other MSK Anxiety Alzheimer Hearing Migraine
Finland Back pain Falls Neck pain MDD Diabetes Hearing Migraine Oth unint Alzheimer Asthma
France Back pain MDD Neck pain Falls Anxiety Hearing Migraine Other MSK Diabetes Alzheimer
Germany Back pain Hearing Neck pain Falls Diabetes MDD Anxiety Other MSK Migraine Alzheimer
Greece Back pain Neck pain Falls MDD Hearing Diabetes Other MSK Anxiety COPD Alzheimer
Iceland Back pain Neck pain Diabetes MDD Falls Migraine COPD Anxiety Hearing Other MSK
Ireland MDD Neck pain Back pain Anxiety Migraine Falls Asthma Diabetes Hearing Other MSK
Israel Back pain MDD Neck pain Migraine Falls Hearing Other MSK Diabetes Iron COPD
Italy Back pain Neck pain Migraine Falls Hearing MDD Other MSK Alzheimer Anxiety COPD
Luxembourg Back pain Neck pain Migraine MDD Falls Diabetes Hearing Anxiety Other MSK COPD
Malta Back pain Neck pain Diabetes MDD Falls Migraine Hearing Anxiety Other MSK COPD
Netherlands Back pain Neck pain Anxiety Migraine MDD Diabetes Hearing Other MSK Dermatitis COPD
Norway Back pain Neck pain Anxiety MDD Falls Diabetes Hearing Other MSK Migraine Alzheimer
Portugal Back pain MDD Neck pain Diabetes Hearing Migraine Anxiety Other MSK Asthma Falls
Spain Diabetes Back pain Neck pain MDD Falls Hearing Migraine Other MSK COPD Anxiety
Sweden Back pain Falls MDD Neck pain Hearing COPD Anxiety Migraine Other MSK Asthma
Switzerland Back pain Falls Neck pain COPD MDD Hearing Migraine Anxiety Diabetes Alzheimer
UK Back pain Neck pain Falls MDD Diabetes Hearing Migraine Anxiety Other MSK COPD
England Back pain Neck pain Falls MDD Diabetes Hearing Migraine Anxiety Other MSK COPD
1 2 3 4 5 6 7 8 9 10
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Barbados MDD Diabetes Back pain Hearing Anxiety Asthma Iron COPD Other MSK Neck pain
Belize MDD Iron Anxiety Diabetes Back pain Migraine Hearing Neck pain COPD Other MSK
Cuba Diabetes MDD Hearing Anxiety Back pain Asthma COPD Iron Neck pain Other MSK
Dominica MDD Diabetes Anxiety Back pain Hearing Iron Migraine Neck pain COPD Other MSK
Dominican Republic MDD Back pain Iron Anxiety Diabetes Hearing Migraine Neck pain COPD Other MSK
Grenada MDD Iron Anxiety Back pain Diabetes Hearing Migraine Neck pain COPD Other MSK
Guyana Iron MDD Anxiety Back pain Diabetes Migraine Hearing Neck pain COPD Other MSK
Haiti Iron MDD Anxiety Disaster Back pain Hearing Migraine Neck pain Diabetes COPD
Jamaica MDD Iron Anxiety Back pain Diabetes Hearing Migraine Neck pain COPD Other MSK
Saint Lucia MDD Diabetes Anxiety Back pain Hearing Iron Neck pain COPD Migraine Other MSK
Saint Vincent and the Grenadines MDD Diabetes Anxiety Back pain Iron Hearing Migraine Neck pain COPD Other MSK
Suriname MDD Iron Anxiety Diabetes Back pain Hearing Migraine Neck pain COPD Other MSK
The Bahamas MDD Diabetes Anxiety Back pain Hearing Iron Migraine COPD Neck pain Other MSK
Trinidad and Tobago MDD Diabetes Anxiety Back pain Hearing Iron Other MSK COPD Migraine Neck pain
Central Latin America MDD Back pain Diabetes Anxiety Hearing Iron Other MSK Migraine Neck pain COPD
Colombia MDD Back pain Anxiety Hearing Diabetes Other MSK Asthma Migraine COPD Iron
Costa Rica MDD Back pain Asthma Hearing Anxiety Other MSK Diabetes Neck pain COPD Migraine
El Salvador Back pain MDD Iron Hearing Anxiety Asthma Diabetes Other MSK Neck pain War
Guatemala Iron Back pain MDD Anxiety War Hearing Diabetes Migraine Neck pain COPD
Honduras MDD Back pain Iron Anxiety Hearing Diabetes Asthma Neck pain Migraine COPD
Mexico MDD Back pain Diabetes Hearing Other MSK Anxiety Iron Neck pain Migraine COPD
Nicaragua War MDD Back pain Iron Diabetes Anxiety Hearing Asthma Migraine Neck pain
Panama Back pain MDD Diabetes Hearing Anxiety Asthma Iron Other MSK Neck pain Migraine
Venezuela Back pain MDD Diabetes Hearing Anxiety Other MSK Migraine Neck pain COPD Asthma
Tropical Latin America Back pain MDD Anxiety Diabetes Hearing Other MSK Asthma Neck pain Migraine COPD
Brazil Back pain MDD Anxiety Diabetes Hearing Other MSK Asthma Neck pain Migraine COPD
Paraguay Back pain Anxiety MDD Hearing Other MSK Migraine Diabetes Neck pain Asthma Iron
Southeast Asia, east Asia, and Oceania Back pain Neck pain MDD Hearing Diabetes Iron Schizophrenia Other MSK COPD Migraine
East Asia Back pain Neck pain MDD Diabetes Hearing Other MSK Schizophrenia Iron COPD Anxiety
China Back pain Neck pain MDD Diabetes Hearing Other MSK Schizophrenia Iron COPD Anxiety
North Korea Back pain Neck pain Iron Hearing MDD Schizophrenia Diabetes Other MSK COPD Anxiety
Taiwan Back pain Neck pain Hearing Diabetes Anxiety Other MSK COPD Migraine Schizophrenia MDD
Oceania Back pain Iron MDD Diabetes Hookworm Neck pain Hearing Migraine Anxiety COPD
Federated States of Micronesia Back pain Iron Diabetes MDD Hearing Neck pain Anxiety Migraine COPD Dermatitis
Fiji Back pain Diabetes MDD Hearing Neck pain Iron COPD Other MSK Migraine Anxiety
Kiribati Trichuria Back pain Iron MDD Neck pain Hearing Diabetes Migraine RHD Anxiety
Marshall Islands Back pain Iron Trichuria MDD Hearing Neck pain Diabetes Anxiety COPD Migraine
Papua New Guinea Iron Back pain Hookworm MDD Diabetes Neck pain Hearing Migraine Anxiety Dermatitis
Samoa Back pain Iron Hearing MDD Diabetes Neck pain COPD Dermatitis Anxiety Migraine
Solomon Islands Back pain Iron MDD Hearing Neck pain Diabetes RHD Anxiety Migraine Dermatitis
Tonga Back pain Iron Hearing MDD Diabetes Neck pain COPD Anxiety Migraine Other MSK
Vanuatu Back pain MDD Hearing Neck pain Iron Diabetes Migraine Anxiety COPD
Southeast Asia Back pain Iron Hearing MDD Migraine Diabetes COPD Neck pain Schizophrenia Anxiety
Thalass trait
Cambodia
Indonesia
Laos
Malaysia
Maldives
Myanmar
Philippines
Sri Lanka
War
Back pain
Iron
Back pain
Back pain
Hearing
Back pain
Back pain
Iron
Iron
Back pain
Diabetes
Diabetes
Back pain
Iron
Hearing
Back pain
Migraine
FB trema
Anxiety
Iron
Migraine
Hearing
Iron
Hearing
MDD
Migraine
MDD
MDD
MDD
MDD
Diabetes
Migraine
Hearing
Hearing
COPD
Migraine
Iron
Diabetes
MDD
MDD
COPD
MDD
Migraine
Hearing
COPD
Migraine
Migraine
COPD
Diabetes
COPD
Hearing
COPD
Diabetes
COPD
COPD
Neck pain
Neck pain
Neck pain
Neck pain
Thalass trait
Neck pain
Neck pain
Neck pain
Anxiety
Schizophrenia
Diabetes
Trichuria
Neck pain
Schizophrenia
Anxiety
Asthma
Schizophrenia
Anxiety
Anxiety
Iron
Anxiety
Anxiety
Schizophrenia
Schizophrenia
Slovakia Back pain Falls MDD Hearing Diabetes Neck pain Migraine Osteoarthritis COPD Anxiety
Slovenia Back pain Falls Hearing MDD Diabetes Neck pain Migraine Osteoarthritis COPD Anxiety
Eastern Europe Back pain MDD Hearing Migraine Neck pain Med head Other MSK Diabetes Osteoarthritis Alcohol
Belarus Back pain MDD Hearing Migraine Neck pain Osteoarthritis Med head Other MSK Diabetes Alcohol
Estonia MDD Back pain Hearing Migraine Neck pain Diabetes Osteoarthritis Other MSK Med Head Alcohol
Latvia Back pain Hearing MDD Migraine Neck pain Osteoarthritis Diabetes Other MSK Med Head COPD
Lithuania Back pain MDD Hearing Migraine Neck pain Osteoarthritis Diabetes Other MSK Med Head COPD
Moldova Back pain MDD Hearing Migraine Neck pain Iron Diabetes Osteoarthritis Med Head Other MSK
Russia Back pain MDD Hearing Migraine Neck pain Med head Other MSK Diabetes Osteoarthritis Alcohol
Ukraine Back pain MDD Hearing Migraine Neck pain Osteoarthritis Diabetes Other MSK COPD
Latin America and Caribbean Back pain MDD Anxiety Diabetes Hearing Other MSK Iron Migraine Neck pain Asthma
Andean Latin America MDD Back pain Anxiety Iron Migraine Hearing Neck pain COPD Asthma Other MSK
Bolivia MDD Iron Back pain Anxiety Migraine Hearing Neck pain Other MSK COPD Asthma
Ecuador MDD Back pain Iron Anxiety Hearing Migraine Neck pain COPD Other MSK Asthma
Peru MDD Back pain Anxiety Migraine Iron Hearing Asthma War Neck pain COPD
Caribbean MDD Iron Diabetes Anxiety Back pain Hearing Neck pain Migraine COPD Other MSK
Antigua and Barbuda MDD Anxiety Diabetes Iron Back pain Hearing Migraine Neck pain COPD Other MSK
1 2 3 4 5 6 7 8 9 10
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(Figure 4 continues on next page)
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Thailand
Timor-Leste
Vietnam
South Asia
Afghanistan
Bangladesh
Bhutan
India
Nepal
Pakistan
North Africa and Middle East
Algeria
Bahrain
Egypt
Iran
Iraq
Jordan
Kuwait
Lebanon
Libya
Morocco
Oman
Palestine
Qatar
Saudi Arabia
Sudan
Syria
Tunisia
Turkey
United Arab Emirates
Yemen
Sub-Saharan Africa
Central sub-Saharan Africa
Migraine
Iron
Back pain
Back pain
Iron
Back pain
Back pain
MDD
Back pain
MDD
Back pain
Back pain
Back pain
Back pain
Back pain
Iron
MDD
Diabetes
Diabetes
Back pain
Back pain
Back pain
MDD
Opioids
Diabetes
Iron
MDD
MDD
Back pain
Back pain
Iron
MDD
Iron
Hearing
Back pain
War
MDD
Back pain
Iron
MDD
Back pain
Iron
Iron
MDD
MDD
Diabetes
Iron
MDD
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numbers. It is not clear whether this increase in rates was 
due to improvements in case ascertainment or indicates a 
true increase in disease prevalence. Among the headache 
disorders, only medication overuse headache had a 
signiﬁ cant change in rates of 43·3%.
Overall, the YLDs for mental and substance use disorders 
increased 45·0% from 1990 to 2013, but there was only a 
1·0% increase in the age-standardised rate (table 10). For 
all disorders in this group, including autism, Asperger’s 
syndrome, anorexia nervosa, and bulimia, there were 
increases and decreases in age-standardised rates of less 
than 10%. Diabetes mellitus YLDs increased by 135·7%, 
but age-standardised rates increased only 43·4%. By 
contrast, chronic kidney disease YLDs increased 49·5% 
but rates declined by 2·8%. Patterns in age-standardised 
rates were diﬀ erent between speciﬁ c causes of chronic 
kidney disease with an increase in chronic kidney disease 
due to diabetes but a reduction in chronic kidney disease 
due to hypertension and glomerulonephritis. Among 
urinary diseases, the increase in numbers and age-
standardised rates for urolithiasis was notable. For most 
gynaecological diseases, numbers increased, but the 
changes in age-standardised rates were small; the category 
uterine ﬁ broids was an exception with a reduced rate and 
only a small increase in numbers.
YLDs for the large category of musculoskeletal disorders 
increased by 60·7%, but there was no change in the age-
standardised rate (table 10). The only exception to this 
general pattern was rheumatoid arthritis for which age-
standardised rates declined signiﬁ cantly by 4·6%. YLDs 
due to congenital disorders, as a group, increased 61·4% 
and age-standardised rates by 19·7%. These large 
increases in numbers and age-standardised rates were 
noted for all congenital causes except Klinefelter’s 
syndrome, for which the rate did not increase signiﬁ cantly. 
The reason for the large increases in prevalence and YLDs 
was the improved survival because birth prevalence for 
congenital disorders remained stable or declined (data not 
shown). Although skin diseases, as a group, did not show 
a signiﬁ cant pattern for age-standardised YLDs, some 
causes including cellulitis, bacterial skin diseases, and 
decubitus ulcer declined signiﬁ cantly. Most causes of 
vision and hearing loss included in the sense organ 
category increased in absolute numbers of YLDs but the 
age-standardised rates declined.
Injury age-standardised YLD rates decreased 
substantially from 1990 to 2013. There were reductions of 
more than 30% in age-standardised YLD rates for road 
injuries, drowning, ﬁ re, heat, and hot substances, 
poisoning, venomous animal contact, non-venomous 
animal contact, and self-harm (table 10).
The main disorders that drove changes in rates varied 
with age (appendix pp 776–811). In childhood, most 
infectious diseases and iron-deﬁ ciency anaemia showed 
decreases in YLD rates, whereas neonatal disorders and 
congenital disorders showed increases, largely due to 
lower initial case fatality and better long-term survival, 
and in the case of preterm birth complications an increase 
in the birth prevalence (data not shown). For ages 
15–49 years, large increases from 1990 to 2013 were noted 
in disability associated with diabetes (appendix pp 776–
811), HIV, and medication overuse headache, whereas 
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Figure 4: Top ten causes of years lived with disability by location in 2013
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there were large decreases in the YLD rates of iron-
deﬁ ciency anaemia, falls, and collective violence. In adults 
aged 50–69 years, reductions in YLD rates for all injuries 
(appendix pp 776–811) and increase in diabetes YLD rates 
were notable.
Figure 4 shows the ten leading causes of YLDs for each 
country. Causes are colour coded by their global rank to 
emphasise where they vary substantially in the leading 
set. There was substantial consistency in the top causes. 
Low back pain and major depressive disorder were among 
the top ten causes of YLDs in every country. 40 causes 
were in the top ten list across all countries but only 16 of 
these causes were in the top ten of more than 20 countries. 
Low back pain was the leading cause in 45 of 50 developed 
countries and major depressive disorder was the leading 
cause in three countries, with neck pain and diabetes 
leading in one country each. Across developing country 
regions, there was more variation in leading causes. Low 
back pain or major depressive disorder was the leading 
cause in 94 of 138 developing countries. But other causes 
such as iron-deﬁ ciency anaemia, HIV, and war were 
leading causes in more than one country. Regional 
patterns emerged such as the more prominent role of 
falls in central Europe where they were ranked second in 
11 of 13 countries. The category other musculoskeletal—
which includes disorders such as shoulder problems, 
pathological fractures from osteoporosis, osteomyelitis, 
pyogenic arthritis, and systemic lupus erythematous—
was prominent in high-income Asia and high-income 
North America. Anxiety disorders ranked more highly in 
many Caribbean nations and diabetes was prominent in 
Mexico, Nicaragua, Panama, and Venezuela. In Oceania, 
some soil-based helminths were highly prevalent, 
pushing them into the top ﬁ ve of the YLD rank list. 
Onchocerciasis, predominantly the onchocercal skin 
sequela, was ranked highly in Liberia, Cameroon, and 
South Sudan. The disability from past war and conﬂ ict 
ranked as the top cause of YLDs in Cambodia, Nicaragua, 
and Rwanda, and number two in Vietnam.
The ﬁ gure appendix provides an analysis of the change 
in the YLDs per person from 1990 to 2013 by country and 
region. The countries were ordered by YLDs per person in 
1990. Across countries in 1990, YLDs per person ranged 
from 0·072 to more than double at 0·170. Generally, 
developed countries with higher mean age for the 
population had higher YLDs per person, but there were 
many exceptions to this pattern. Changes in the YLDs per 
person were decomposed into contributing causes for 
YLDs—for convenience these cause groups were chosen to 
represent the major causes of YLDs at the global level. The 
ﬁ gure provides a summary of what causes contributed to 
increases or decreases in YLDs per person for each country.
From 1990 to 2013, 139 of 188 countries had increases in 
the YLDs per person. Although the drivers of increased 
YLDs per person varied by region and country, generally, 
musculoskeletal, mental, substance use, neurological, and 
chronic respiratory disorders played important parts across 
most of the regions and countries. In sub-Saharan Africa, 
increases were largely driven by HIV/AIDS. Declining 
levels of iron-deﬁ ciency anaemia contributed to a decline in 
YLDs per person in many countries. In the subset of 
countries where the overall YLDs per person declined, 
speciﬁ c factors such as long-term disability due to war were 
important factors—most strikingly evident in Lebanon. 
However, declines due to neglected tropical diseases and 
malaria, as well as diarrhoea and lower respiratory 
infections (represented as other communicable diseases in 
the ﬁ gure appendix) also pushed YLD per person lower in 
some countries. Mostly increasing YLDs per person meant 
that by 2013 the range across countries was from 0·076 to 
0·153. It is important to note that the ﬁ gure appendix 
shows YLDs per person and not age-standardised YLD 
rates; therefore, changes in YLD rates were aﬀ ected by 
changes in population age structure and changes in age-
speciﬁ c disease rates.
From 1990 to 2013, YLDs per person rose in most 
countries and YLLs per person declined. Both trends led to 
a shift towards greater disability as a share of the overall 
burden. Figure 5 shows the shift from 1990 to 2013 towards 
greater disability as the ratio of YLDs to YLDs plus YLLs76 
(namely disability-adjusted life years [DALYs]). 30 countries 
as of 2013 had the most DALYs due to YLDs, representing 
a major change from historical patterns of premature 
mortality being the dominant set of health issues. In 1990, 
premature mortality still represented more than half of 
DALYs in every country. By 2013, the lowest YLD to DALY 
ratio outside of sub-Saharan Africa was in Afghanistan, 
but most developing countries outside of sub-Saharan 
Africa had ratios of greater than 35%. In sub-Saharan 
Africa, however, the ratio of YLDs to DALYs ranged from 
10·4% in Mali to 38·9% in Cape Verde.
Discussion
We analysed more than 35 620 epidemiological sources 
from 188 countries spanning the past three decades to 
provide the most up-to-date empirical assessment of the 
leading causes of acute disease incidence, chronic disease 
prevalence, and YLDs for 6 years (1990, 1995, 2000, 2005, 
2010, and 2013) for 188 countries using consistent and 
comparable methods. Importantly, our study provides the 
ﬁ rst comprehensive assessment of the extent, pattern, 
and trend of non-fatal health loss in countries, with 
important implications not only for health policy, but also 
for the provision and ﬁ nancing of health services (panel).
A wide array of disease and injury sequelae aﬀ ects the 
world’s population. Globally, only 4·3% of the population 
had no burden of disease or injury sequelae in 2013, up 
slightly from 4·2% in 1990. There were 59 diseases and 
injuries with a global prevalence of greater than 1%, but 
each caused little disability. These disorders comprised 
various causes of mild to moderate vision impairment, 
hearing loss, soil-transmitted helminths, mild anaemia, 
caries, and many others. For many of these common but 
fairly mild disorders, there are eﬀ ective interventions.89–92 
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Figure 5: Percentage of disability-adjusted life years due to years lived with disability in 1990 (A) and 2013 (B) in 188 countries
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The GBD provides several insights into the health of 
diﬀ erent populations by quantifying the prevalence of a 
wide range of disorders and YLDs that take into account 
the general public’s view of severity.
Of the 240 GBD causes that led to mortality, Naghavi 
and colleagues76 reported that global age-standardised 
death rates were declining by 80%. For YLDs, the 
distribution of causes where age-standardised rates were 
declining, stagnant, or increasing was diﬀ erent. For 
140 causes, distributed across communicable diseases, 
non-communicable diseases, and injuries, age-
standardised rates declined signiﬁ cantly from 1990 to 
2013. For 89 causes, changes in age-standardised rates 
were statistically indistinguishable from zero over the 
same period. For 72 causes, including epidemic disorders 
like HIV and dengue but also cancers, diabetes, and 
COPD, age-standardised rates increased signiﬁ cantly. Of 
301 causes, the percentage change in the age-standardised 
rate for YLDs was higher than the percentage change in 
the age-standardised YLLs for 213 causes. Divergence in 
rates for diseases and injuries between mortality and 
morbidity could be because of reductions in case-fatality 
rates due to treatment or improved background risks 
such as malnutrition. To the extent that mortality is 
declining faster than disease prevalence due to treatment, 
access to care might be a crucial driver of trends in health. 
The mortality–disability temporal disconnect, however, is 
further evidence of the importance of paying attention to 
trends in disease incidence, prevalence, and YLDs and 
not simply focusing on mortality. Diabetes is an important 
example in which age-standardised prevalence rates 
increased 43% while death rates increased only 9%. 
Stagnant or increasing age-standardised rates combined 
with rising mean age of the world’s population implies 
substantial future increases in burden from these causes. 
The documented shift in many developed and developing 
countries to a larger fraction of DALYs due to YLDs is 
another manifestation of this global shift. Despite the 
evidence for this shift, global health policy discussion 
remains focused mostly on premature mortality. For 
example, in the Sustainable Development Goals Open 
Working Group proposal93 with 13 targets for the health 
goal, only one on narcotic drug abuse and harmful use of 
alcohol was focused on a disability.
Although the general pattern of the past 23 years has 
been for infectious disease mortality and morbidity, 
measured through incidence or prevalence, to decline, 
there are some very notable exceptions that stress that 
such trends are not inevitable with rising income per 
person and educational attainment. Compared with 
1990, both HIV and malaria YLDs increased in 2013. 
More careful examination of our estimates for the six 
periods shows that malaria and HIV YLDs have been 
declining since at least 2005. Increases for dengue 
(nearly 450%) and for cutaneous and mucocutaneous 
leishmaniasis have continued throughout the period. 
Increases in dengue have been ascribed to the rise of 
breeding sites for the mosquito vector in urban and 
periurban areas.94 Increases for cutaneous leishmaniasis 
have been related to the expansion of previously 
non-endemic areas as a result of urbanisation and 
deforestation with domestic animals as potential 
reservoirs. Additionally, economic hardship, natural 
disasters, armed conﬂ ict, movement of seasonal workers, 
development of new projects, and bringing non-immune 
labour forces into endemic areas are contributing causes. 
Also, pressure on populations throughout the world is 
pushing migration into areas where the infection is 
endemic, thereby bringing many more humans into 
contact with the natural vectors and resulting in increased 
infection rates.95–98 These counter trends for infectious 
diseases are a reminder that active surveillance of 
infectious diseases at a ﬁ ne-grained geospatial level are 
essential to detect changes that might run against the 
general trend towards lower rates.
The GBD 2010 reported that the burden of 
musculoskeletal disorders was much larger than 
previously appreciated.7,8,19,20,37,38 In this analysis, we show 
that musculoskeletal disorders ranged from 9·6% of 
YLDs to 28·9% of YLDs between 188 countries. Low 
back pain was the leading cause of YLDs in 86 countries 
and the second or third leading cause in 67 countries. 
Although the GBD 2010 analysis brought more 
attention to these disorders, there remains little policy 
discussion of the options available to address and 
prevent these disorders.1,99 From a health service point 
of view, it is important to note that there is a connection 
between the injury analysis of fractures and soft tissue 
injury and musculoskeletal disorders. We estimated 
22 million YLDs from fractures, most of which were 
Panel: Research in context
Systematic review
The GBD 2013 assessment of morbidity is a major 
improvement in the evidence base compared with GBD 2010 
through the inclusion of new data from surveys, disease 
registries, and hospital inpatient and outpatient registrations. 
GBD 2013 also beneﬁ ts from improvements in the Bayesian 
meta-regression tool DisMod-MR. The ﬁ fty-fold increase in 
computational speed allowed consistent estimation of 
prevalence and incidence for each country and time period.
Interpretation
This study provides a comprehensive description of morbidity 
levels and patterns worldwide. Because the study provides a 
complete re-analysis of trends for each cause from 1990 to 
2013, it supersedes the results of the GBD 2010 study. This is 
the ﬁ rst time that country-speciﬁ c results for all 
188 countries with populations of more than 50 000 people 
have been comprehensively published. In all countries, the 
share of disability in total burden is increasing because of 
ageing populations and a slower decline in disability rates 
compared to the decline in mortality.
Articles
www.thelancet.com   Vol 386   August 22, 2015 787
long-term disabilities. Most of the individuals aﬄ  icted 
would present with a musculoskeletal chief complaint 
in surveys and therefore to avoid double counting we 
subtracted the long-term disability from fractures and 
dislocations out of the estimates of the category of other 
musculoskeletal disorders. Musculoskeletal disorders 
combined with fractures and soft tissue injuries 
reached a total of 20·8% of global YLDs in 2013; across 
countries this total ranged from 10·8% in Mali to 
30·0% in South Korea. Our analysis of time trends 
showed that this category of disorders was an important 
driver of rising YLD rates per person. Increases were 
driven by ageing of the population in most countries 
with trends in obesity and physical inactivity likely 
exacerbating the problem.100,101 Musculoskeletal 
disorders were not only an important contributor to the 
burden of disease but were also a crucial component of 
health expenditure in many high-income and middle-
income countries.102–106
Mental and substance abuse disorders accounted for 
21·2% of YLDs, ranging from 15·4% in Germany to 
36·7% in Qatar. Major depressive disorder was a crucial 
contributor in developed and developing countries alike: 
it is the leading cause of YLDs in 56 countries, the second 
leading cause in 56 countries, and the third in 
34 countries. Although major depressive disorder, anxiety 
disorders, schizophrenia, and bipolar disorder are 
leading causes in nearly all countries, there is much 
greater country variation in substance use disorders 
including alcohol. YLDs from alcohol use disorders 
ranged from a high of 2·9% in Russia to a low of 0·3% in 
Iran; YLDs from drug use disorders ranged from a high 
of 13·5% in Qatar to a low of 0·6% in Slovenia. New data 
in the GBD 2013 suggested that Iran and Afghanistan 
had particular problems with opioid dependence. The 
GBD 2013 analysis conﬁ rmed that common mental 
disorders had well established sex patterns in most 
countries: higher rates in women for major depressive 
disorder and anxiety and similar rates for bipolar and 
schizophrenia for men and women. Treatments if widely 
and appropriately deployed could lead to substantial 
reductions in the burden of these disorders; some studies 
suggest that up to half of YLDs could be averted in some 
countries.1,107,108 As new studies accumulate on the role of 
childhood sexual abuse, intimate partner violence, non-
sexual child abuse, and bullying, the possibility of 
prevention programmes is increasing.109–113 Systematic 
quantiﬁ cation of these risks will help establish where 
prevention programmes could be developed and tested.
For the ﬁ rst time in the GBD studies, we provide a 
systematic quantiﬁ cation of the geographical and 
temporal coverage of the input epidemiological data for 
nearly all sequelae. For several diseases with sequelae 
representing diﬀ erent levels of severity such as major 
depressive disorder (mild, moderate, and severe 
sequelae), the data representativeness metrics show 
there are often more data for overall disease prevalence 
than for determining the distribution of severity for a 
cause. Sequelae with the highest DRI tend to be those 
where administrative data such as notiﬁ able disease 
reporting or hospital discharge data can be corrected for 
completeness or selection bias, or both. For some 
sequelae, such as drug use disorders only one study was 
available to ascertain the distribution of cases by level of 
severity. Despite attempts to quantify uncertainty from 
various sources in the estimates (see limitations below), 
it is highly likely that for sequelae with low DRIs 
uncertainty might be larger than estimated. At the global 
level, 12 of the top causes of YLDs had a DRI of less than 
0·25. Priorities for further data collection in a country 
might usefully be informed by comparison of the 
estimated YLDs and the DRI for the country for each 
cause. Examining countries, the fraction of sequelae with 
any data available in a country, shows marked variation 
across countries within a region or within income 
group—eg, Nigeria with a DRI of 47% and Mauritania at 
10% or the UK at 81% and Greece at 52%. Our 
computation of the DRI was based on the data available 
to the GBD through published studies or reports, publicly 
released datasets, and unpublished data. In view of our 
experience in China and Mexico with subnational burden 
of disease estimation, it is likely data coverage could be 
improved through detailed national burden of disease 
studies, which often lead to several unpublished sources. 
Ministries of health and national statistics authorities in 
countries with low coverage should carefully assess 
which high burden disorders with low data availability 
would beneﬁ t from new data collection eﬀ orts.
With each iteration of the GBD, the cause and sequelae 
list has expanded. Expansion involves taking an existing 
cause and splitting it into more detailed component 
causes—eg, eating disorders were broken down into 
anorexia nervosa and bulimia. Residual categories, such 
as other mental disorders, other neurological disorders 
or other musculoskeletal disorders contain many rarer 
causes and some common causes that have very low 
levels of disability. One of the key values of the GBD was 
the comprehensive and systematic nature of the analysis; 
it is likely that in future iterations based on health service 
use data or new epidemiological studies or policy 
demand, the cause and sequelae list will be expanded 
further. The GBD cause list, even in the current expanded 
form, still has only 301 causes compared with the 
11 299 four-digit ICD-10 codes. The GBD cause list 
provided a more manageable public health and health 
service planning focused approach to the complexity of 
disease coding. The sequelae list also had many potential 
applications, such as facilitating the mapping of data 
collected through diﬀ erent studies and typologies into a 
common framework.
For GBD 2013, the study beneﬁ ted from use of a larger 
computational cluster than for GBD 2010 (22 teraﬂ ops 
compared with 8 teraﬂ ops). The optimised recoding of 
DisMod-MR 1.0 to DisMod-MR 2.0, combined with 
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greater computational capacity, allowed us to generate 
country-speciﬁ c posterior estimates for incidence, 
prevalence, remission, and excess mortality for each of 
the six periods. We estimated and reported internal 
validity of diﬀ erent models and conducted cross-
validation studies for ten of the models. We believe 
DisMod-MR 2.0 is a substantial improvement over 
DisMod-MR 1.0, but there is still much opportunity to 
improve these data synthesis programs in the future. In 
particular, work is underway to develop the next iteration 
of DisMod-MR that would allow for variation of incidence, 
remission, excess mortality rates simultaneously over 
age, geography, and time unlike the present approach, in 
which variation in rates over time is captured by 
independent estimation of the available data for six 
diﬀ erent periods. Despite progress in the estimation 
software, a fundamental challenge in epidemiological 
synthesis of sparse and heterogeneous data is 
distinguishing between true variation in the underlying 
rates and study heterogeneity due to variation in, for 
example, case deﬁ nitions, assays, instruments, and 
sampling frames. DisMod-MR 2.0 allows explicit 
modelling of these factors, but true resolution of this 
challenge requires more data to be collected with 
consistent deﬁ nitions and study design.
The comorbidity microsimulation for each 
country–age–sex–year has been used to both quantify 
comorbidity and allocate to contributing causes of each 
disability weight. By weighting each country–age–sex–year 
microsimulation by the true population in each age 
group, we have created a working model of individual 
health for all 7·3 billion individuals in the world 
consistent with the entire GBD non-fatal health outcome 
results. With future iterations of the GBD, we intend to 
incorporate data for risk factors into the global 
microsimulation providing an even more comprehensive 
working model of each country’s population. This global 
and national microsimulation has many potential 
applications from inequality measurement to 
comprehensive forecasting of multiple interventions. For 
example, the GBD microsimulations provide an ideal 
environment for modelling the eﬀ ect of interventions 
that would represent the complex interplay between 
disorders that is often missing in many intervention 
impact assessments. The distribution of functional 
health status across individuals in each country for 
diﬀ erent timepoints can also be used to compute 
measures of individual inequality in functional health. If 
the correlations between socioeconomic indicators 
within each country–age–sex–year group with health 
outcomes and risk factors can be estimated, then the 
microsimulation environment could also be used to look 
at the relation between health and income inequality.
Disability weights through the inclusion of new data 
from national surveys in Italy, Hungary, Sweden, and the 
Netherlands and revisions in lay descriptions for selected 
health states have changed from those used in the GBD 
2010. The severe hearing loss disability weight increased 
from 0·05 to 0·18 with similar increases for profound 
hearing loss and deafness. Through the inclusion of 
incontinence in the lay descriptions for spinal cord lesion 
below the neck, the disability weight increased from 
0·047 to 0·296. These ﬁ ndings draw attention to the 
importance of the exact wording of lay descriptions for 
use in population surveys. We revised lay descriptions in 
the latest round of data collection based on commentary 
in the literature and a careful review of all lay descriptions 
checking for symmetry and consistency. We believe that 
future iterations of the GBD will beneﬁ t from further 
data collection and vigorous scrutiny and debate by the 
scientiﬁ c community of the exact lay descriptions in 
use—the full listing is provided in the appendix 
pp 688–93 and further details are provided in Salomon 
and colleagues.85 In many countries undertaking 
subnational burden of disease studies, there may be 
opportunities to collect further disability weight data 
using the latest iteration of the GBD lay descriptions and 
measurement protocol. Such data would help establish 
whether there was any notable national variation in 
disability weights from the global average and strengthen 
the global empirical database for disability weight 
measurement.
Another important component determining average 
disability weight was the empirical analysis of the 
distribution of severity controlling for comorbidity. The 
number of studies or data sources that allowed for 
teasing apart functional health limitations from a 
particular cause from other comorbid causes were few. 
Very low DRIs for many sequelae in table 1 document 
this limitation. More datasets like the US MEPS that 
include both functional health limitation measurement 
and ICD-coded diagnoses would be extremely helpful in 
strengthening the empirical assessment of severity 
controlling for comorbidity. This must be regarded as 
one of the most important data gaps for the quantiﬁ cation 
of many chronic disorders.
Because the GBD 2013 has re-estimated prevalence and 
YLDs for all disease and injury sequelae for 1990, 1995, 
2000, 2005, 2010, and 2013, we can compare the results of 
GBD 2013 directly with GBD 2010. The leading global 
causes of YLDs estimated for 2010 in this study (low back 
pain, major depressive disorder, iron-deﬁ ciency anaemia, 
neck pain, and age-related and other hearing loss) were 
similar to those reported in GBD 2010 (low back pain, 
major depressive disorder, iron-deﬁ ciency anaemia, neck 
pain, and COPD) for 2010. For 97 diseases or injuries, 
global YLDs from GBD 2013 for 2010 were signiﬁ cantly 
diﬀ erent from the GBD 2010 estimates for 2010. For 
27 diseases and injuries, there were changes in YLDs 
greater than 30% but these changes were not signiﬁ cantly 
diﬀ erent from GBD 2010. Generally, changes stemmed 
from the inclusion of new data, exclusion of studies used 
in GBD 2010 due to changes of inclusion criteria for each 
sequela that emerged through the process of replicating 
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many GBD 2010 systematic reviews, the shift to 
DisMod-MR 2.0, which reduced the eﬀ ect of large sample 
size outlier studies, changes in covariates, changes in 
disability weights, or changes in severity distributions. 
The appendix pp 33–54 provides a more detailed account 
for each of these cases including changes in inclusion 
criteria where relevant. At the level of global YLDs, the 
most notable eﬀ ect of these changes was the inclusion of 
age-related and other hearing loss in the top ten causes of 
global YLDs; this change was almost exclusively due to 
the revision of the hearing loss disability weights. The 
yearly updating cycle for GBD provides a much more 
rapid cycle for incorporating new data and scientiﬁ c 
feedback from GBD collaborators and the broader 
scientiﬁ c community. We expect that with each iteration 
there will be important changes driven by the collection 
and release of new data, but that the number of changes 
driven by uncovering older studies, exclusion of older 
studies on quality grounds, or changes in modelling 
strategy will tend to get smaller with each iteration.
A study of this scope has several limitations, many of 
which were detailed in the GBD 2010 analysis.1 Here we 
focus on selected major limitations that are not speciﬁ c 
to the data sources or analysis of a speciﬁ c sequela. First, 
for comorbidity simulation to work eﬀ ectively, especially 
with the assumption of independence, individuals with a 
disease need to be uniquely mapped to a single sequela. 
For some diseases that have several distinct functional 
impairments such as motor and cognitive dysfunction 
for some neonatal disorders, several combinations are 
possible. In some cases, to map all of the possible 
combinations was not feasible because of increased 
computational load and the lack of epidemiological data 
to accurately describe these combinations. In a very 
small number of cases, we did not follow the principle of 
mapping one individual to a unique sequela including 
schistosomiasis, lymphatic ﬁ lariasis, and onchocerciasis.
Second, a major limitation that might aﬀ ect many 
sequelae is that important unpublished data sources 
might be missing. The collaborations with investigators 
in Mexico, China, and England to generate subnational 
burden of disease estimates for 2013 identiﬁ ed 
unpublished data sources or more detailed age and time 
breakdowns for published studies. Other countries are 
likely to have similar data sources, which after being 
identiﬁ ed could enrich the estimation of the burden of 
disease for a country.
Third, in this analysis of prevalence and YLDs, we 
attempted to capture uncertainty from model estimation 
and available data but 95% uncertainty intervals might be 
too narrow because we cannot capture uncertainty that 
comes from the possibility that countries with data might 
in some way be diﬀ erent for a given sequela from 
countries with data. Further, unlike the GBD analysis of 
causes of death, we do not capture uncertainty that 
comes from model speciﬁ cation. We undertook cross-
validation studies for a few models but the move to using 
out of sample validity testing to then create ensembles of 
good models will require further advances in 
computational speed of DisMod-MR to make this viable.76
Fourth, for GBD 2013 we made a substantial eﬀ ort to 
enhance the transparency in all aspects of the estimation. 
In GBD 2010, in some cases contributors who undertook 
systematic reviews provided results but without study 
references. For GBD 2013, we have included in the Global 
Health Data Exchange 31 950 citations with metadata 
covering essentially all sources used in any aspect of this 
analysis. We have provided more detail about modelling 
strategies and internal validity of model ﬁ ts. In view of the 
complexity of the GBD analysis spanning so many 
sequelae, estimation requires a tremendous investment 
across the network of collaborators measured in 
person-years. Replication of the entire eﬀ ort was possible 
but would have required many resources and negotiated 
access to the few datasets provided to the GBD through 
data use agreements that are not in the public domain. 
With the public release of the Epi Viz tool, everyone will 
be able to examine the speciﬁ c studies and datapoints 
used for each disease sequela and the model ﬁ t. To further 
satisfy the reasonable scientiﬁ c curiosity of academics 
about particular sequelae, the GBD collaborators remain 
committed to answering detailed questions about all 
steps of the analysis and many disease-speciﬁ c 
publications will follow in which much greater detail of 
the modelling assumptions and data for each sequela can 
be provided.
Fifth, when data for a sequela are collected using 
diﬀ erent deﬁ nitions, assays, or instrument items, we 
have cross-walked between these diﬀ erences using ﬁ xed 
eﬀ ects in the meta-regressions. For example, in the 
DisMod-MR 2.0 model for major depressive disorder, 
the coeﬃ  cient for symptom scale measures as opposed 
to a diagnostic interview schedule was 0·83 (95% 
uncertainty interval 0·64–1·04) in log space and 2·30 
(1·90–2·83) after exponentiation. By dividing symptom 
scale prevalence datapoints by 2·3, we predicted the 
corresponding values for the reference case. Another 
example of an important cross-walk was between data 
for opioid dependence from household surveys and the 
more inclusive estimates from triangulation of data 
from treatment centres, needle exchange programmes, 
and the justice system.9 DisMod-MR 2.0 estimated a 
coeﬃ  cient of 0·31 (0·15–0·74) after exponentiation 
indicating the household survey prevalence was an 
underestimate by more than a factor of three. Several 
factors could account for this large diﬀ erence including 
lack of a steady residence, lower response to surveys, 
and fear of reprisals for admitting to illegal behaviours.114 
We used a similar covariate for triangulated data for 
cocaine and amphetamine dependence but did not note 
systematic bias compared with household survey data. 
There is no equivalent approach to address the potential 
bias from non-response to surveys or the eﬀ ect of stigma 
on responses for cannabis and alcohol dependence. In 
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the DisMod-MR 2.0 model of alcohol dependence we 
use several study characteristics such as the type of 
survey and the measurement questionnaire. A review of 
Chinese studies on alcohol dependence showed that 
variation in prevalence between studies was strongly 
related to such study characteristics.115 Of particular 
interest in the Chinese review was the ﬁ nding that large 
surveys often rely on proxy reporting for absent 
household members to improve the response rate and 
that these surveys tend to underestimate the prevalence 
of alcohol dependence. Although there is substantial 
evidence for stigma and alcohol dependence, there was 
no quantiﬁ cation of the magnitude and direction of the 
bias on population prevalence estimates, probably 
because a gold standard measurement that would be 
unaﬀ ected by stigma is diﬃ  cult to deﬁ ne.116–118 Experience 
in the GBD 2013 compared with GBD 2010 shows that 
these ﬁ xed-eﬀ ect coeﬃ  cients for study level 
characteristics can be substantially aﬀ ected by the 
inclusion of new data sources. For large cross-walks, 
new data in one country can alter results in many other 
countries. This sensitivity of statistical cross-walks in 
models with sparse data draws attention to the value of 
standardising case deﬁ nitions, assays, and instruments 
in future data collection. The comprehensive nature of 
GBD provides an opportunity to identify what is the 
reference case approach to measurement with the 
current knowledge for each sequela. We plan to 
summarise our assessment of best practice for each 
sequela in a future publication.
Sixth, in models using DisMod-MR 2.0 or natural 
history models, the associations between incidence, 
remission, excess mortality, prevalence, and cause-
speciﬁ c mortality are modelled simultaneously. However, 
if there are no models for the age pattern and level 
of excess mortality across countries, simultaneous 
estimation does not ensure any correlation in the age-
speciﬁ c rates of prevalence and cause-speciﬁ c mortality 
across countries. In this iteration of the GBD, we have 
devoted much more attention to this estimation challenge 
by incorporating into many models more direct 
information about the credible range of excess mortality 
across age, sex, and country. However, country variation 
in excess mortality has not been as extensively debated in 
the literature about burden of disease estimation as it has 
for incidence, prevalence, or causes of death. More 
attention to these associations and the determinants of 
excess mortality such as access to care will be beneﬁ cial 
in future iterations of the GBD.
Seventh, comorbidity simulation, used for quantifying 
the burden of disease and undertaking intervention 
analysis, has a major limitation, namely that we assume 
that within a country–age–sex–year group prevalence 
values are independent. For some disorders such as 
diabetes and ischaemic heart disease or anxiety disorders, 
depression, and alcohol dependence, we expect 
probabilities are dependent. Empirical assessments119,120 
of comorbidity tend to show that age is the dominant 
driver of comorbidity, ignoring dependent comorbidity, 
for example in the MEPS data, leads to minimal errors in 
estimated burden.1 Incorporating dependent comorbidity 
into the micro-simulation environment is not technically 
challenging; the issue is that there are insuﬃ  cient data to 
generally estimate the age-speciﬁ c correlation matrix of 
all 2337 sequelae. As compelling and albeit incomplete 
evidence on dependence accumulates, we intend to 
incorporate this into the comorbidity simulation 
microsimulations.
Eighth, in the current version of DisMod-MR 2.0, we 
were unable to incorporate estimates of the subnational 
units for China, Mexico, and the UK as a ﬁ fth level in the 
estimation cascade (ﬁ gure 2). Instead, subnational units 
were modelled as though they were independent 
countries. If data were sparse, that meant that subnational 
units might borrow strength from the regional estimate 
rather than the country estimate. In some cases, when 
only national data were available, we used these data for 
each subnational unit after dividing the eﬀ ective sample 
size of each datapoint by the number of subnational 
units to avoid overemphasising the national data used in 
each unit in the overall estimation. A ﬁ fth level of the 
cascade will be added in the next version of DisMod-MR.
Ninth, there was a steady drop in the age-standardised 
rates of YLDs for all injury categories between 1990 and 
2013. For the unintentional injury categories, with the 
exception of falls, the steady drop was partly driven by a 
downward trend in case fatality rates accompanied by a 
drop in incident cases. The larger change aﬀ ecting the 
downward trend in YLD rates was related to the 
diﬀ erence between disability with and without treatment. 
In the absence of robust national data for the injury 
treatment rates, we have assumed access to treatment 
scales according to the indicator health system access.76 
The health system access indicator was based on a 
principal component analysis of coverage of mostly 
maternal and child health interventions and health 
system infrastructure. There have been steady global 
improvements in health system access as captured in 
this indicator reducing the estimated injury YLDs.
Tenth, substantial eﬀ orts have been made in the data 
preparation and analysis to address issues of 
ascertainment bias that might aﬀ ect trends. In another 
example of dealing with ascertainment bias we cross-
walked between diagnostic assays from creatine kinase-
myocardial band enzymes to troponins for the detection 
of acute myocardial infarction. Despite these eﬀ orts, 
there are some upward trends that might still relate to 
residual issues of ascertainment including multiple 
sclerosis and prostate cancer.
Eleventh, in a study with more than half a million YLD 
estimates generated from sometimes sparse and always 
disparate data sources there remain areas where 
additional evidence or a change in the modelling strategy 
could lead to better estimates. Yearly updates of GBD 
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allowed for a continued eﬀ ort to search for new data and 
improve methods, particularly for disorders with sparse 
data or inconsistencies between data sources. We are 
already compiling a list of issues to address in the next 
iteration. For example, with our collaborators in Qatar, 
we are searching for data to verify the high YLD estimate 
for opioid dependence, which in the models is aﬀ ected 
by data from studies in Iran and Afghanistan. In other 
cases, further data for the clinical severity associated with 
paragonimiasis would help determine the relevance of 
the health state used to select the disability weight for 
this sequela. Generally, we will search for additional 
evidence of the severity of all disorders for the next 
iteration of GBD.
Despite the limitations, the implications of our ﬁ ndings 
are substantial. By extending the GBD analysis to report 
the commonly understood measures of morbidity and 
disability in populations, by age, by sex, by country, and 
over time, this study represents an enormous resource 
for national, regional, and global policy debates about 
health priorities, not just to keep people alive well into 
old age, but to also keep them healthy. Without this 
health intelligence, large, preventable causes of health 
loss in populations, particularly mental and behavioural 
disorders and serious musculoskeletal disorders, have 
thus far not received the attention that they deserve in 
national health debates.
The GBD 2013 covers a comprehensive, exhaustive, 
and mutually exclusive set of causes and their sequelae at 
the country level over 23 years. By shifting to a process of 
yearly updating, the GBD provides a rapid mechanism 
for incorporating new data, development of methods, 
and new insights into old data or disease mechanisms. 
By steadily increasing the transparency of input sources, 
documenting in detail the methods used, sharing crucial 
code such as DisMod-MR 2.0, and facilitating online 
exploration of new results using dynamic data 
visualisations, we believe GBD can progressively become 
a means for global health surveillance, not just for 
mortality but also for reducing health loss among 
populations everywhere. As a group of investigators, we 
seek to accommodate within the GBD framework 
epidemiological debate about each cause, and based on 
scientiﬁ c principles, describe the functional health of all 
individuals in the world. Studies such as this provide the 
important comprehensive, comparative, and consistent 
evidence to guide policy and practice, evidence that will 
become progressively more reliable as more data and 
information are identiﬁ ed and included as part of the 
global collaboration.
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